{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "li = [{'ID': '2025-01145', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Direct final rule; withdrawal.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) published in the Federal Register of September 20, 2024, a direct final rule amending the Scope section of our regulation that provides for a regulatory hearing before the Agency. The comment period closed December 4, 2024. FDA is withdrawing the direct final rule because the Agency received significant adverse comment.', 'DATES': 'The direct final rule published at September 20, 2024, 89 FR 77019, is withdrawn effective January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-01145.pdf?1737035129', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-17'}, {'ID': '2025-01028', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled \"Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria.\" The draft guidance document provides blood establishments that collect blood and blood components with FDA\\'s revised recommendations to reduce the risk of transfusion-transmitted malaria (TTM). The guidance recommends selectively testing blood donations from donors at risk for malaria using an FDA-licensed donor screening nucleic acid test (NAT) for Plasmodium species (spp.), the causative agents of malaria. The draft guidance, when finalized, is intended to supersede the document entitled \"Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria,\" dated December 2022.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 17, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-01028.pdf?1736948753', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-16'}, {'ID': '2025-01027', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Director of the Center for Drug Evaluation and Research (Center Director) at the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a new drug application (NDA) submitted by Vanda Pharmaceuticals, Inc. (Vanda), for TRADIPITANT capsules, 85 milligrams (mg), in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Vanda an opportunity to request a hearing on the matter.\", 'DATES': 'Either electronic or written requests for a hearing must be submitted by February 18, 2025; submit data, information, and analyses in support of the hearing and any other comments by March 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-01027.pdf?1736948753', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-16'}, {'ID': '2025-00945', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for information.', 'SUMMARY': \"The Food and Drug Administration (FDA, the Agency, or we) is soliciting comments from the public, particularly veterinarians, related to the use of cannabis-derived products (CDPs) in animals, with an emphasis on cannabidiol (CBD) products and general trends associated with those products, including information about: usage trends (e.g., product selection, indications, etc.), quality standards, benefits of use, potential drug interactions, adverse events and safety problems, and toxicological concerns. This information will enhance the Center for Veterinary Medicine's (CVM's) knowledge of potential safety signals associated with these products, in addition to aiding our understanding of veterinarians' experiences related to the use of CDPs for their animal patients.\", 'DATES': 'Either electronic or written comments on the request for information must be submitted by April 16, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00945.pdf?1736948743', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-16'}, {'ID': '2025-00397', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is proposing a tobacco product standard that would regulate nicotine yield by establishing a maximum nicotine level in cigarettes and certain other combusted tobacco products. FDA is proposing this action to reduce the addictiveness of these products, thus giving people who are addicted and wish to quit the ability to do so more easily. The proposed product standard is anticipated to benefit the population as a whole. For example, it would help to prevent people who experiment with cigarettes and cigars from developing addiction and using combusted tobacco products regularly.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by September 15, 2025. Submit comments (including recommendations) on the collection of information under the Paperwork Reduction Act of 1995 (PRA) by September 15, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00397.pdf?1736948724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-16'}, {'ID': '2025-00778', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) proposes to require front-of-package nutrition labels on most foods that must bear a Nutrition Facts label. This action, if finalized, would require the display of a compact informational box containing certain nutrient information on the principal display panel. The box would provide consumers, including those who have lower nutrition knowledge, with standardized, interpretive nutrition information that can help them quickly and easily identify how foods can be part of a healthy diet. We also propose to amend certain nutrient content claim regulations to align with current nutrition science and avoid within-label inconsistencies.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by May 16, 2025. Submit comments (including recommendations) on the collection of information under the Paperwork Reduction Act of 1995 by May 16, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00778.pdf?1736862341', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-16'}, {'ID': '2025-00743', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of February 14, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00743.pdf?1736862337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-15'}, {'ID': '2025-00750', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ALHEMO (concizumab-mtci), approved on December 20, 2024, manufactured by Novo Nordisk, Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00750.pdf?1736862338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-15'}, {'ID': '2025-00742', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of February 14, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00742.pdf?1736862336', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-15'}, {'ID': '2025-00754', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for information.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is requesting information and data about the manufacturing processes and ingredients used to make certain dairy products referred to as high-protein yogurt, Greek yogurt, or Greek-style yogurt in this document. We are taking this action, in part, because the yogurt standard of identity may not align with certain manufacturing processes and ingredients used to concentrate protein to manufacture these products. We intend to use the information and data to help determine what type(s) of actions, if any, should be taken.', 'DATES': 'Either electronic or written comments on the notice must be submitted by April 15, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00754.pdf?1736862338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-15'}, {'ID': '2025-00757', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for information.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is requesting information on industry practices related to poppy seeds, such as information about growing, harvesting, processing, and distribution of poppy seeds, including industry practices to reduce the opiate alkaloid content of poppy seeds. We are taking this action, in part, because we have received reports of adverse events related to the use of some poppy seed products. We intend to use the information to help determine what type(s) of actions, if any, we should take to help ensure that poppy seed products do not pose a health risk when consumed.', 'DATES': 'Either electronic or written comments on the notice must be submitted by April 15, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00757.pdf?1736862339', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-15'}, {'ID': '2025-00564', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with our generic drug user fee program.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by March 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00564.pdf?1736775925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-14'}, {'ID': '2025-00479', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'This notice informs the public of the annual adjustments to the reimbursement rates for meals served in the Summer Food Service Program. These adjustments address changes in the Consumer Price Index, as required under the Richard B. Russell National School Lunch Act. The 2025 reimbursement rates are presented as a combined set of rates to highlight simplified cost accounting procedures. The 2025 rates are also presented individually, as separate operating and administrative rates of reimbursement, to show the effect of the Consumer Price Index adjustment on each rate. On average, the 2025 rates adjustment represents a 3.6 percent increase in the rates from last year.', 'DATES': 'This adjustment is applicable January 1, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00479.pdf?1736516733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-13'}, {'ID': '2025-00341', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the application for ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor), approved December 20, 2024, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00341.pdf?1736343933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-10'}, {'ID': '2025-00340', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that CRENESSITY (crinecerfont), approved on December 13, 2024, manufactured by Neurocrine Biosciences, Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00340.pdf?1736343933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-10'}, {'ID': '2025-00357', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Antimicrobial Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Antimicrobial Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2026, expiration date.', 'DATES': 'Authority for the Antimicrobial Drugs Advisory Committee will expire on October 7, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00357.pdf?1736343935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-10'}, {'ID': '2025-00310', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is requesting nominations for voting members to serve on the Technical Electronic Product Radiation Safety Standards Committee (TEPRSSC) in the Center for Devices and Radiological Health. Nominations will be accepted for current and upcoming vacancies effective January 1, 2025, with this notice. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.', 'DATES': 'Nominations received on or before March 11, 2025, will be given first consideration for membership on TEPRSSC. Nominations received after March 11, 2025, will be considered for nomination to the committee as later vacancies occur.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00310.pdf?1736343930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-10'}, {'ID': '2025-00342', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, we, or Agency) is soliciting comments from the public regarding the National Antimicrobial Resistance Monitoring System (NARMS) 2026-2030 Strategic Plan. Comments received will help inform the development of a draft 2026-2030 Strategic Plan, to be discussed at a public meeting in spring 2025. Specific questions and information requests are included in this notice to help guide input from interested parties.', 'DATES': 'Submit either electronic or written comments by March 26, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00342.pdf?1736343933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-10'}, {'ID': '2025-00237', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction.\" This draft guidance provides recommendations to industry regarding the development of drugs and biological products regulated within the Center for Drug Evaluation and Research intended for reduction and long-term maintenance of body weight in patients with obesity or overweight. This draft guidance revises and replaces the draft guidance for industry \"Developing Products for Weight Management\" issued in February 2007.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 8, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00237.pdf?1736257533', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-08'}, {'ID': '2025-00213', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Developing Drugs for Optical Imaging.\" The purpose of this guidance is to provide recommendations to sponsors regarding clinical trial design features that support development and approval of optical imaging drugs that are used in conjunction with imaging devices and intended as intraoperative aids for the detection of pathology such as tumors or to enhance the conspicuity of normal anatomical structures.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 8, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00213.pdf?1736257531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-08'}, {'ID': '2025-00125', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; withdrawal.', 'SUMMARY': 'The Food and Drug Administration (FDA) is issuing this notice to withdraw the December 5, 2024, Federal Register notice entitled \"Yong Sheng Jiao; Denial of Hearing; Final Debarment Order\" because the document provided the incorrect bases for debarment and omitted edited language. A corrected notice document is published elsewhere in this Federal Register.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00125.pdf?1736257519', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-08'}, {'ID': '2025-00126', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Yong Sheng Jiao, also known as Yongsheng Jiao and Wilson Jiao (Jiao), and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Jiao for 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Jiao was convicted of a felony under Federal law for conduct relating to the importation into the United States of any drug or controlled substance under the FD&C Act. In determining the appropriateness and period of Jiao's debarment, FDA considered the relevant factors listed in the FD&C Act. Jiao submitted a request for hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.\", 'DATES': 'The order is applicable January 8, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2025-00126.pdf?1736257519', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-08'}, {'ID': '2024-31545', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act.\" This guidance describes FDA\\'s interim regulatory policy concerning compounding by outsourcing facilities using bulk drug substances while FDA develops the list of bulk drug substances that outsourcing facilities can use in compounding under the applicable section of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance finalizes the draft guidance of the same title issued in December 2023 and replaces the final guidance of the same title issued in January 2017.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31545.pdf?1736171123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31537', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Study of Sex Differences in the Clinical Evaluation of Medical Products.\" Clinical trials and non-interventional studies of medical products should be designed to enroll sufficient numbers of females and males to reflect the prevalence of the disease or condition for which the medical product is being investigated to help ensure the generalizability of results and facilitate exploration of potential differences in effects by sex. This guidance provides recommendations for increasing enrollment of females in clinical trials, analyzing and interpreting sex-specific data, and including sex-specific information in regulatory submissions of medical products. When finalized, this guidance will replace the guidance entitled \"Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs\" issued in July 1993.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 7, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31537.pdf?1736171122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31533', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a revised final guidance for industry entitled \"Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act (Edition 5): Guidance for Industry.\" The guidance explains FDA\\'s current thinking on a number of issues related to the labeling of food allergens, including requirements in the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA) and the Food Allergy Safety, Treatment, Education, and Research Act of 2021 (FASTER Act).', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31533.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31534', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled \"Action Levels for Lead in Processed Food Intended for Babies and Young Children.\" The guidance establishes action levels for lead in certain processed foods intended for babies and young children less than 2 years old. The guidance is intended to set achievable action levels that will help further reduce lead in the food supply.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31534.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31546', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act.\" This guidance describes FDA\\'s interim policy concerning compounding by human drug product compounders that are not outsourcing facilities using bulk drug substances while FDA develops the list of bulk drug substances that can be used in compounding under the applicable section of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance finalizes the draft guidance of the same title issued in December 2023 and replaces the final guidance of the same title issued in January 2017.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31546.pdf?1736171123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31525', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry #294 entitled \"Animal Food Ingredient Consultation (AFIC).\" This guidance describes FDA\\'s interim AFIC process and explains one way FDA will work with firms that are developing animal food ingredients now that the Memorandum of Understanding (MOU) with the Association of American Feed Control Officials (AAFCO) expired on October 1, 2024, and while FDA evaluates the animal Food Additive Petition and Generally Recognized as Safe (GRAS) Notification programs. The AFIC process provides an additional way for engagement with FDA regarding ingredients for which firms may otherwise have used the AAFCO ingredient definition process. AFIC will help FDA identify any potential safety concerns associated with such ingredients. The AFIC process also allows for public awareness of and input on such ingredients. In addition, this guidance describes FDA\\'s enforcement policy for certain ingredients assessed using the AFIC process.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31525.pdf?1736171120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31535', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a draft guidance for industry entitled \"Labeling of Plant-Based Alternatives to Animal-Derived Foods.\" This draft guidance, when finalized, will provide our recommendations on best practices for naming and labeling of certain plant-based foods that are marketed and sold as alternatives for animal-derived foods (plant-based alternative foods), especially in the absence of a common or usual name for the product. This draft guidance does not address the naming and labeling of plant-based milk alternatives; FDA is providing recommendations regarding these products in a separate guidance document.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 7, 2025 to ensure that we consider your comment on the draft guidance before we begin work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by March 10, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31535.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31538', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for immediate implementation entitled \"Recommendations To Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).\" FDA is issuing this guidance to provide establishments making donor eligibility determinations with recommendations to reduce the risk of transmission of infections due to sepsis by HCT/Ps. This notice is being issued to respond to a public health safety concern and to address the urgent need for updated recommendations in making a donor eligibility determination when screening a donor for clinical evidence of sepsis and clinical signs to consider.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31538.pdf?1736171122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31531', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #260 entitled \"Type VII Veterinary Master File for Research and Development and Risk Reviews.\" This draft guidance, when finalized, will describe FDA\\'s current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 10, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31531.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31530', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #251 entitled \"Heritable Intentional Genomic Alterations in Animals of Food-Producing Species for Use as Models of Disease.\" This draft guidance, when finalized, will set forth FDA\\'s policy regarding heritable intentional genomic alterations (IGAs) in animals of food- producing species, such as swine and rabbits, that are intended to be marketed for use as models of human or animal disease in biomedical research under contained and controlled conditions. The draft guidance describes the conditions under which we generally may not expect developers of IGAs in animal models of disease to submit an application to FDA\\'s Center for Veterinary Medicine (CVM) or to get our approval before marketing their animals following CVM\\'s prior review of risk factor data.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 10, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31530.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31539', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers.\" This guidance describes FDA\\'s enforcement policy regarding certain firm-initiated communications of scientific information on unapproved use(s) of the firm\\'s approved/ cleared medical products to health care providers (HCPs) engaged in prescribing or administering medical products to individual patients. This guidance finalizes the revised draft guidance of the same title issued in October 2023. The October 2023 revised draft guidance revised and replaced the draft guidance entitled \"Distributing Scientific and Medical Publications on Unapproved New Uses--Recommended Practices,\" issued in March 2014, which itself revised the final guidance entitled \"Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices,\" issued in January 2009. This guidance is not for current implementation, pending the Office of Management and Budget\\'s (OMB\\'s) decision on the collection of information.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025. Submit written comments on the collection of information by February 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31539.pdf?1736171122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31540', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Pulse Oximeters for Medical Purposes--Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations.\" This draft guidance document, when finalized, will provide recommendations regarding non-clinical and clinical performance testing of certain pulse oximeters for medical purposes, including devices with a pulse oximeter function that estimates the amount of oxygen in arterial blood and pulse rate. These recommendations are being proposed based in part on concerns that the accuracy of pulse oximeters can be affected by, among other factors, a person\\'s skin pigmentation. The recommendations are being proposed to inform the performance evaluation for these devices, to support premarket submissions, regardless of submission type, and to promote consistency and facilitate efficient review of these submissions. Among other topics, the draft guidance also proposes recommendations for labeling, which are intended to promote the safe and effective use of pulse oximeters and help users understand the benefits and risks associated with the use of the device. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 10, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31540.pdf?1736171122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31547', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act.\" This guidance updates the previous version of the guidance, of the same title, issued on November 17, 2023, and finalizes the concurrently issued draft guidance entitled \"Select Updates for the 506J Guidance: 506J Device List and Additional Notifications.\" This guidance finalizes a list of device product codes for which a manufacturer of such devices is required to notify FDA in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act) (hereafter referred to as the \"506J Device List\") and clarifies that manufacturers may submit voluntary notifications regarding supply chain issues at any time, unrelated to the declaration or potential declaration of a public health emergency (PHE).', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31547.pdf?1736171123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31543', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Artificial Intelligence Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.\" This draft guidance, when finalized, will provide recommendations regarding the contents of marketing submissions for devices that include artificial intelligence (AI)-enabled device software functions including documentation and information that will support FDA\\'s evaluation of safety and effectiveness. To support the development of appropriate documentation for FDA\\'s assessment of the device, this draft guidance also proposes recommendations for the design, development, and implementation of AI- enabled devices that sponsors may wish to consider using throughout the total product lifecycle (TPLC). This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 7, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31543.pdf?1736171123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31532', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry #187B entitled \"Heritable Intentional Genomic Alterations in Animals: The Approval Process.\" This guidance clarifies FDA\\'s requirements and recommendations for developers of intentional genomic alterations (IGAs) in animals. The guidance is one of two companion documents. \"Heritable Intentional Genomic Alterations in Animals: The Approval Process\" describes how the FDA approval process applies to heritable IGAs in animals. The companion final guidance, GFI #187A entitled \"Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,\" describes FDA\\'s risk-based regulatory approach to the oversight of heritable IGAs in animals.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31532.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31542', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products.\" In accordance with its mission of protecting, promoting, and advancing public health, FDA\\'s Center for Drug Evaluation and Research (CDER), in collaboration with the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), the Center for Veterinary Medicine (CVM), the Oncology Center of Excellence (OCE), the Office of Combination Products (OCP), and the Office of Inspections and Investigations (OII), is issuing this draft guidance to provide recommendations to industry on the use of artificial intelligence (AI) to produce information or data intended to support regulatory decision-making regarding the safety, effectiveness, or quality for drug and biological products.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 7, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by April 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31542.pdf?1736171122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31541', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry entitled \"Validation and Verification of Analytical Testing Methods Used for Tobacco Products.\" The guidance provides information and recommendations related to the validation and verification of analytical test methods, including analytical testing of tobacco product constituents, ingredients, and additives, as well as stability testing of tobacco products. This guidance is intended to help industry produce more consistent and reliable analytical data used to support regulatory submissions for finished tobacco products. This guidance finalizes the draft guidance of the same title issued in December 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31541.pdf?1736171122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31526', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Evaluation of Sex- Specific and Gender-Specific Data in Medical Device Clinical Studies.\" This document provides guidance on the study and evaluation of sex- and/or gender-specific data in clinical investigations or research involving one or more subjects to determine the safety or effectiveness of a device. The purpose of this guidance is to encourage science- driven consideration of sex and/or gender, as appropriate for both the scientific question being addressed and the intended use of the device, when designing medical device clinical studies and reporting data from such studies in accordance with legal requirements. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 7, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31526.pdf?1736171120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31524', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance document entitled \"Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).\" This draft guidance document includes general information on determining eligibility for donors of HCT/Ps. In addition, FDA intends to issue separate guidance documents with recommendations regarding reducing the risk of transmission of specific communicable disease agents and diseases for donors of HCT/Ps. These guidance documents are intended to update an existing guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 6, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31524.pdf?1736171119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31522', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency.\" The draft guidance describes general recommendations for the validation of in vitro diagnostic devices (IVDs) for emerging pathogens during an applicable declaration of public health emergency. This guidance and the associated template include the recommendations that apply to test data and information submitted in a pre-Emergency Use Authorization (EUA), an EUA request, or to a test offered as described in an applicable enforcement discretion policy. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 10, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31522.pdf?1736171119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31544', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for immediate implementation entitled \"Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).\" FDA is issuing this guidance to assist establishments that make donor eligibility determinations for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps), with recommendations for screening donors for evidence of, and risk factors for, infection with Mycobacterium tuberculosis (Mtb), the organism that causes tuberculosis. The guidance also recommends additional steps that HCT/P establishments should take to reduce risk of transmission of Mtb until such time as appropriate FDA-licensed, approved, or cleared donor screening tests are available for use to test donors for Mtb infection. The guidance identifies Mtb as a relevant communicable disease agent or disease (RCDAD) and supplements the recommendations contained in other donor eligibility guidance documents for donors of HCT/Ps. This guidance is being issued to address the urgent public health need to reduce the risk of transmission of Mtb by HCT/Ps.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31544.pdf?1736171123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31527', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway.\" For drugs granted accelerated approval, sponsors conduct confirmatory studies that must be completed postapproval to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. This draft guidance describes FDA\\'s interpretation of the term \"underway\" and discusses policies for implementing this requirement, including factors FDA intends to consider when determining whether a confirmatory trial is underway prior to accelerated approval.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 10, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by March 10, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31527.pdf?1736171120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31536', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) and the Office for Human Research Protections (OHRP) are announcing the availability of a draft guidance for industry, clinical investigators, institutions, and institutional review boards (IRBs) entitled \"Considerations for Including Tissue Biopsies in Clinical Trials.\" This guidance provides recommendations regarding considerations for tissue biopsies that may be conducted in adults and in children as part of clinical trials evaluating investigational medical products and/or that are conducted or supported by the Department of Health and Human Services (HHS).', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 10, 2025. to ensure that the Agency and OHRP consider your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31536.pdf?1736171121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31523', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of three specific draft guidances for industry entitled \"Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps);\" \"Recommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps);\" and \"Recommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).\" These draft guidances are intended to update existing guidances and to assist establishments making donor eligibility determinations in understanding the requirements for determining donor eligibility, including donor screening and testing, for donors of HCT/Ps. These draft guidances are also intended to provide establishments making donor eligibility determinations with recommendations to reduce the risk of transmission of specific communicable disease agents and diseases, specifically, hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV), by HCT/Ps.', 'DATES': 'Submit either electronic or written comments on the draft guidances by February 6, 2025 to ensure that the Agency considers your comment on these draft guidances before it begins work on the final versions of the guidances.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31523.pdf?1736171119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31529', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for FDA staff and interested parties entitled \"Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act.\" This guidance document provides our current thinking on the approach we generally intend to take when we evaluate the public health importance of a food allergen other than one of the major food allergens (i.e., milk, eggs, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybean, and sesame) listed in the Federal Food, Drug, and Cosmetic Act (FD&C Act).', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31529.pdf?1736171120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-07'}, {'ID': '2024-31692', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing its determination that the Food Contact Notifications (FCNs) listed in this notice are no longer effective. Several manufacturers notified FDA in writing that they ceased producing, supplying, or using the listed food contact substances (FCSs) for their intended use in the United States. We are taking this action in accordance with the process set out in our regulations, by which FDA may determine that an FCN is no longer effective.', 'DATES': 'Applicable date: This determination for the FCNs listed in table 1 and table 2 is effective January 6, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31692.pdf?1735911930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-06'}, {'ID': '2024-31703', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is requesting nominations for voting members to serve on the National Mammography Quality Assurance Advisory Committee in the Center for Devices and Radiological Health. Nominations will be accepted for current and upcoming vacancies effective February 1, 2025, with this notice. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.', 'DATES': 'Nominations received on or before March 7, 2025, will be given first consideration for membership on the National Mammography Quality Assurance Advisory Committee. Nominations received after March 7, 2025, will be considered for nomination to the committee as later vacancies occur.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31703.pdf?1735911931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-06'}, {'ID': '2024-31263', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice of Proposed Rulemaking; withdrawal.', 'SUMMARY': 'This document informs the public that FNS is withdrawing the proposed rule titled, \"Provisions to Improve the Supplemental Nutrition Assistance Program\\'s Quality Control System,\" that published in the Federal Register on September 19, 2023, and its correction on December 19, 2023. This rule proposed amendments to Supplemental Nutrition Assistance Program (SNAP) regulations to strengthen and improve the integrity and accuracy of the SNAP quality control (QC) system as requested by the Agriculture Improvement Act of 2018.', 'DATES': 'As of January 6, 2025, the proposed rule published on September 19, 2023, at 88 FR 64756, and its correction on December 19, 2023, at 88 FR 87725, are officially withdrawn.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31263.pdf?1735911916', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-06'}, {'ID': '2024-30578', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice of proposed rulemaking, incorporation by reference.', 'SUMMARY': 'The U.S. Department of Agriculture (the Department) is issuing this proposed rule to formally incorporate by reference the FNS Handbook 310 into SNAP regulations. By doing so, the Department is ensuring that the public receives a notice and comment period prior to implementation of revisions to the Handbook, which is the standard operating procedure manual for conducting quality control (QC) reviews of SNAP cases. The Department also proposes to remove reference to FNS Handbook 311 until it can be incorporated by reference. The Department requests comment on these proposed provisions.', 'DATES': 'Written comments must be received on or before March 4, 2024 to ensure their consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30578.pdf?1735825509', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-03'}, {'ID': '2024-31312', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration\\'s (FDA, Agency, or we) Office of Pediatric Therapeutics, the Center for Drug Evaluation and Research, and the Center for Biologics Evaluation and Research are announcing a public meeting entitled \"Interested Parties Meeting: Implementation of the Best Pharmaceuticals for Children Act and Pediatric Research Equity Act.\" The purpose of the public meeting is to seek input from interested parties, including patient/parent/ caregiver groups, consumer groups, regulated industry, academia, and others. This input will enable FDA to obtain any recommendations or information relevant to the report to Congress that FDA is required to submit concerning pediatric drug and biologic development and labeling, as outlined in section 508 of the Food and Drug Administration Safety and Innovation Act (FDASIA).', 'DATES': 'The public meeting will be held on May 15, 2025, from 9 a.m. to 4:30 p.m. Eastern Time. Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket. Either electronic or written comments on this public meeting must be submitted by June 13, 2025. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31312.pdf?1735825511', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-03'}, {'ID': '2024-31470', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the revocation of the temporary permit issued to M.G. Waldbaum Co., a subsidiary of Michael Foods Egg Co., to market test \"ultrapasteurized liquid whole eggs\" and \"ultrapasteurized liquid whole eggs with citric acid\" because the need for the temporary permit no longer exists.', 'DATES': 'This permit is revoked as of January 2, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31470.pdf?1735652715', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-02'}, {'ID': '2024-31493', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Advanced Manufacturing Technologies Designation Program.\" FDA encourages the early adoption of advanced manufacturing technologies (AMTs) by the pharmaceutical industry, which can improve the reliability and robustness of the manufacturing process and can benefit patients by enhancing product quality and reducing drug development time or increasing or maintaining the supply of drugs that are life-supporting, life-sustaining, of critical importance to providing health care, or in shortage. This guidance provides recommendations to persons and organizations interested in participating in FDA\\'s Advanced Manufacturing Technologies Designation Program, which facilitates the development of drugs manufactured using an AMT that has been designated as such under the program. The guidance finalizes the draft guidance of the same title issued on December 13, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 2, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31493.pdf?1735652717', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2025-01-02'}, {'ID': '2024-31360', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of two abbreviated new drug applications (ANDAs) from the holder of those ANDAs. The basis for the withdrawal is that the ANDA holder has repeatedly failed to file required annual reports for those ANDAs.', 'DATES': 'Approval is withdrawn as of December 31, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31360.pdf?1735566317', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-31'}, {'ID': '2024-31365', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; reopening of the comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the request for information and comments notice entitled \"Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Products,\" published in the Federal Register of July 25, 2024. FDA is reopening the comment period to update comments and to receive any new information.', 'DATES': 'FDA is reopening the comment period on the request for information and comments notice published July 25, 2024 (89 FR 60436). Either electronic or written comments must be submitted by March 3, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31365.pdf?1735566318', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-31'}, {'ID': '2024-31363', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2026, expiration date.', 'DATES': 'Authority for the Dermatologic and Ophthalmic Drugs Advisory Committee will expire on October 7, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31363.pdf?1735566317', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-31'}, {'ID': '2024-31145', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice.', 'SUMMARY': \"FSIS is announcing the 2025 rates it will charge meat, poultry, and egg products establishments, and importers and exporters for providing voluntary, overtime, and holiday inspection and identification, certification, and laboratory services. Additionally, FSIS is announcing a change to the fee FSIS assesses to exporters that choose to apply for export certificates electronically through the export component of the Agency's Public Health Information System. The 2025 basetime, overtime, holiday, and laboratory services rates will be applied on January 12, 2025.\", 'DATES': 'FSIS will charge the rates announced in this notice beginning January 12, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31145.pdf?1735307149', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31262', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMISIRGE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 28, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 30, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31262.pdf?1735307160', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31308', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the collection of information associated with new animal drug applications and veterinary master files.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by February 28, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31308.pdf?1735307168', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31269', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VEOZAH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 28, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 30, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31269.pdf?1735307161', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31270', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of individuals on its advisory committees regardless of their gender identification, religious affiliation, racial and ethnic identification, or disability status, and, therefore, encourages nominations of appropriately qualified candidates from all groups.', 'DATES': 'Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests on an FDA advisory committee or panel may send a letter or email stating that interest to FDA (see ADDRESSES) by February 13, 2025, for vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see ADDRESSES) by February 13, 2025. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31270.pdf?1735307161', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31027', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"M15 General Principles for Model-Informed Drug Development.\" The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance discusses the multidisciplinary principles of model-informed drug development (MIDD). This includes recommendations on MIDD planning, model evaluation, and evidence documentation. The draft guidance also includes a harmonized framework for assessing evidence derived from MIDD. The draft guidance is intended to facilitate multidisciplinary understanding, appropriate use, and harmonized assessment of MIDD and its associated evidence.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 28, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31027.pdf?1735307138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31276', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROCTAVIAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 28, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 30, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31276.pdf?1735307162', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31023', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XTAMPZA ER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 28, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 30, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31023.pdf?1735307138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31022', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NEXOBRID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 28, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 30, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31022.pdf?1735307138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31261', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices.\" This draft guidance provides recommendations to assist sponsors, clinical investigators, and institutional review boards (IRBs) in defining, identifying, and reporting protocol deviations. The guidance provides definitions for protocol deviations and important protocol deviations. In addition, the guidance provides a recommended classification system for sponsors to report protocol deviations to FDA in clinical study reports for drugs, biological products, and devices; for investigators to report protocol deviations to sponsors and to IRBs; and for IRBs to evaluate protocol deviations.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 28, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31261.pdf?1735307160', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31272', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is requesting that any industry organizations interested in participating in the selection of a pool of nonvoting industry representatives to serve as temporary nonvoting members on the Patient Engagement Advisory Committee (the Committee) in the Center for Devices and Radiological Health notify FDA in writing. FDA is also requesting nominations for temporary nonvoting industry representatives to be included in a pool of individuals to serve on the Committee. Nominees recommended to serve as a temporary nonvoting industry representative may either be self- nominated or nominated by an industry organization. This position may be filled by representatives from different medical device areas based on expertise relevant to the topics being considered by the Committee. Nominations will be accepted for upcoming vacancies effective with this notice. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.', 'DATES': 'Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interest must send a letter stating that interest to the FDA by January 29, 2025, (see sections I and II of this document for details). Concurrently, nomination materials for prospective candidates should be sent to FDA by January 29, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31272.pdf?1735307161', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31298', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled \"National Agriculture and Food Defense Strategy Survey\" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31298.pdf?1735307166', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31025', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled \"Shortages Data Collection\" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31025.pdf?1735307138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31026', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"E11A Pediatric Extrapolation.\" The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance provides a comprehensive and systematic approach to pediatric extrapolation during drug development. Notably, the guidance discusses approaches to safety extrapolation and defining extrapolation as a continuum. The guidance also includes approaches to study designs and statistical methodologies, including modeling and simulation, for developing and implementing pediatric extrapolation. The guidance is intended to provide approaches that can increase the efficiency of pediatric drug development and accelerate the availability of safe and effective drugs approved for use in children. The guidance replaces the draft guidance \"E11A Pediatric Exploration\" issued on August 29, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31026.pdf?1735307138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31305', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Combined FDA and Sponsor Oncologic Drugs Advisory Committee (ODAC) Briefing Document.\" This draft guidance provides recommendations to sponsors regarding use and development of a combined version of the ODAC briefing document, as part of the Oncology Center of Excellence\\'s (OCE) Project Point/Counterpoint initiative. This single document includes information that customarily would be contained in separate briefing documents prepared individually by the Sponsor and FDA. Project Point/ Counterpoint is an option for advisory committee meetings for oncology products. Sponsors in non-oncology therapeutic areas who want to discuss whether a combined advisory committee briefing document may be appropriate for their applications should contact the relevant review division. This briefing document format may provide efficiencies by allowing Sponsors and FDA to choose to use a single document that provides the views of the Sponsor and FDA on key issues.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 28, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31305.pdf?1735307167', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31275', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"E6(R3) Good Clinical Practice: Annex 2.\" The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second annex to \"E6(R3) Good Clinical Practice\" published June of 2023. This annex provides additional considerations for the application of good clinical practices to a variety of trial designs and data sources. Specifically, this draft guidance discusses trials with decentralized and pragmatic elements and real-world data sources. This draft guidance highlights the importance of quality by design and focusing efforts and resources on critical aspects of the trials that might impact the safety of participants and the reliability of results. The draft guidance is intended to encourage innovation in trial design and provides flexible, modern, and clear good clinical practices for conducting trials, while avoiding unnecessary complexities.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 28, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31275.pdf?1735307162', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31266', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; announcement of transfer.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the transfer of regulatory responsibility for medical maggots and medicinal leeches to the Center for Biologics Evaluation and Research (CBER). These products are currently regulated by the Center for Devices and Radiological Health (CDRH). FDA is transferring regulatory responsibility of these products to CBER because these products are living organisms that more closely align with products regulated by CBER. This action affects only Center assignment and does not change requirements applicable to these products.', 'DATES': 'FDA is transferring regulatory responsibility to CBER on December 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31266.pdf?1735307160', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31307', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on July 29, 2024. The document announced the withdrawal of approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of August 28, 2024. The document indicated that FDA was withdrawing approval of the ANDAs 073462 for tolmetin sodium capsules, equivalent to (EQ) 400 milligrams (mg) base; 073588 for tolmetin sodium tablets, EQ 200 mg base; 074002 for tolmetin sodium tablets, EQ 600 mg base; 077040 for citalopram hydrobromide tablets, EQ 10 mg base, EQ 20 mg base; EQ 40 mg base; 085787 for trifluoperazine hydrochloride (HCl) concentrate, EQ 10 mg base/milliliters (mL); 086808 for cyproheptadine HCl tablets, 4 mg; 087774 for phenylbutazone capsules, 100 mg; and 088602 for pseudoephedrine HCl; triprolidine HCl tablets, 60 mg/2.5.mg, held by Fosun Pharma USA Inc., 104 Carnegie Center, Suite 204, Princeton, NJ 08540. Additionally, ANDAS 075631 for ketorolac tromethamine injectable, 15 mg/mL and 30 mg/mL; 076427 for milrinone lactate injectable, EQ 1 mg base/mL; 076791 for haloperidol lactate injectable, EQ 5 mg base/mL; 076828 haloperidol lactate injectable, EQ 5 mg base/ mL; 077947 for fluconazole injectable, 200 mg/100 mL (2 mg/mL) and 400 mg/200 mL (2 mg/mL); 078197 for granisetron HCl injectable, EQ 0.1 mg base/mL (EQ 0.1 mg base/mL); 091436 for levofloxacin injectable, EQ 500 mg/20 mL (EQ 25 mg/mL); 207101 for sumatriptan succinate injectable, EQ 6 mg base/0.5 mL (EQ12 mg base/mL); and 215065 for methocarbamol solution, 1gram/10 mL (100 mg/mL), held by Baxter Healthcare Corp., One Baxter Parkway, Deerfield, IL 60015; and the ANDAs 090367 for levofloxacin tablets, 250 mg, 500 mg, 750 mg; and 211959 for clobazam tablets, 10 mg and 20 mg, held by Celltrion USA, Inc., U.S. Agent for Celltrion, Inc., One Evertrust Plaza, Suite 1207, Jersey City, NJ 07302; and the ANDA 212053 for chlorzoxazone tablet, 375 mg and 750 mg, held by i3 Pharmaceuticals LLC, 200 Park Ave., Warminster, PA 18974. Before FDA withdrew the approval of these ANDAs, Fosun Pharma USA Inc.; Baxter Healthcare Corp.; Celltrion USA, Inc., U.S. Agent for Celltrion, Inc.; and i3 Pharmaceuticals LLC, 200 Park Ave., Warminster, PA 18974, informed FDA that they did not want the approval of the ANDAs withdrawn. Because Fosun Pharma USA Inc.; Baxter Healthcare Corp.; Celltrion USA, Inc., U.S. Agent for Celltrion, Inc.; and i3 Pharmaceuticals, LLC, timely requested that approval of their respective ANDAs not be withdrawn, the approvals are still in effect. This notice corrects these errors.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31307.pdf?1735307167', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31264', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a: New collection.', 'DATES': 'Written comments must be received on or before TBD February 28, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31264.pdf?1735307160', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31014', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 29, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31014.pdf?1735307137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31309', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cardiovascular and Renal Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on February 24, 2025, from 9 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31309.pdf?1735307168', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-31260', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will take place virtually on February 20, 2025, from 9 a.m. to 6 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-31260.pdf?1735307159', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-30'}, {'ID': '2024-30776', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA, Agency, or we) is announcing that we have concluded that certain statements set forth in the FDA-approved labeling for buprenorphine-containing transmucosal products for the treatment of opioid dependence (BTODs) related to the recommended maintenance dosage and dosage adjustments during pregnancy can be modified. We believe that certain statements in BTOD labeling can be modified because the labeling for these products may be misinterpreted by some as establishing a maximum dosage when none exists. FDA is concerned that misinterpretation of these labeling statements may be adversely impacting patients' access to BTODs. We encourage sponsors of approved applications for BTODs to submit supplemental new drug applications (NDAs) (labeling supplements) to modify these labeling statements as described in this notice.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30776.pdf?1735220718', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-27'}, {'ID': '2024-29957', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is issuing this final rule updating the definition for the implied nutrient content claim \"healthy\" to be consistent with current nutrition science and Federal dietary guidance, especially the Dietary Guidelines for Americans (Dietary Guidelines), regarding how consumers can maintain healthy dietary practices. This final rule revises the requirements for when the term \"healthy\" can be used as an implied nutrient content claim in the labeling of human food products to help consumers identify foods that are particularly useful as the foundation of a nutritious diet that is consistent with dietary recommendations.', 'DATES': 'This rule is effective February 25, 2025. The compliance date of this final rule is February 25, 2028.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29957.pdf?1734624913', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-27'}, {'ID': '2024-30544', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is proposing to require testing of talc-containing cosmetic products using standardized testing methods for detecting and identifying asbestos that may be present as a contaminant in talc. We are also proposing corresponding adulteration provisions. Asbestos is a potential contaminant in talc, which is used in certain cosmetic products, and is a known human carcinogen. This proposed rule, if finalized, will help protect users of talc-containing cosmetic products from harmful exposure to asbestos given the potential for contamination of these products.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by March 27, 2025. Submit written comments (including recommendations) on information collection issues under the Paperwork Reduction Act of 1995 by January 27, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30544.pdf?1735220714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-27'}, {'ID': '2024-30334', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research's (CDER), Office of Surveillance and Epidemiology (OSE) and Office of New Drugs (OND) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on November 20, 2014.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30334.pdf?1734961514', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-26'}, {'ID': '2024-30784', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for information; extension of comment period.', 'SUMMARY': \"The Food and Drug Administration (FDA or we) is extending the comment period for the request for information, published in the Federal Register of November 8, 2024. In that notice, FDA invited comment relating to the listing requirements of other countries and FDA's approach to facilitating U.S. industry compliance with these requirements through the issuance of export certification for human food products provided in the form of lists (export lists). We are extending the comment period to allow interested persons additional time to submit comments on FDA's approach.\", 'DATES': 'FDA is extending the comment period announced in the notice for request for information published November 8, 2024 (89 FR 88785). Electronic or written comments must be submitted by February 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30784.pdf?1734961538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-26'}, {'ID': '2024-30782', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of a modified system of records.', 'SUMMARY': 'In accordance with the requirements of the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS) is modifying an existing departmentwide system of records, \"Federal Advisory Committee Membership Files,\" System No. 09-90-0059. The modifications include, among other things, adding records about any prospective guest speakers at Federal advisory committee meetings who disclose financial interests and professional relationships related to the matter they will be speaking on, and changing the name of the system of records to \"Federal Advisory Committee/Subgroup Member, Subscriber/Registrant, and Guest Speaker Records.\"', 'DATES': 'In accordance with 5 U.S.C. 552a(e)(4) and (11), the modified system of records is effective December 26, 2024. The new and revised routine uses will be effective January 27, 2025. Submit any comments by January 27, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30782.pdf?1734961538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-26'}, {'ID': '2024-30710', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice; Request for Information.', 'SUMMARY': \"The U.S. Department of Agriculture's (USDA) Food and Nutrition Service (FNS) requests comments from the public to help inform future policymaking, guidance, and technical assistance related to grain-based desserts and high-protein yogurt (which may include Greek and Greek- style yogurt) crediting in the Child Nutrition Programs. FNS welcomes comments from all interested partners, including child nutrition professionals, State agencies, the food industry, the research community, and other individuals and organizations with an interest in the Child Nutrition Programs.\", 'DATES': 'Written comments must be received on or before March 26, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30710.pdf?1734961531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-26'}, {'ID': '2024-30261', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to establish requirements for a nonprescription drug product with an additional condition for nonprescription use (ACNU). A nonprescription drug product with an ACNU is a drug product that could be marketed without a prescription if an applicant implements an additional condition to ensure appropriate self-selection or appropriate actual use, or both, by consumers without the supervision of a practitioner licensed by law to administer such drug. The final rule is intended to increase options for applicants to develop and market safe and effective nonprescription drug products and increase consumer access to appropriate, safe, and effective drug products, which could improve public health.', 'DATES': 'This rule is effective January 27, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30261.pdf?1734961513', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-26'}, {'ID': '2024-30333', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on November 19, 2024.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30333.pdf?1734702323', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-23'}, {'ID': '2024-30577', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice; request for information.', 'SUMMARY': \"This is a Request for Information to inform the U.S. Department of Agriculture's (USDA's) development of the Child Nutrition Programs Tribal Pilot Projects, as authorized in the Consolidated Appropriations Act, 2024. The Act authorized USDA to conduct pilot projects to allow one or more Tribes or Tribal organizations to administer one or more Child Nutrition Programs, assuming the roles and responsibilities typically held by State agencies. USDA will use comments received in response to this Request for Information to inform the application process, and eligibility and selection criteria, for the Child Nutrition Tribal Pilot Projects. USDA invites feedback from Tribes; Tribal organizations, leaders, representatives, and associations; State agencies that administer the Child Nutrition Programs; and others interested in opportunities to promote Tribal sovereignty in the operation of the Child Nutrition Programs. This notice is not a request for proposals and does not commit the Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. All submitted information will remain with the Government and will not be returned.\", 'DATES': 'Written comments must be received on or before March 24, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30577.pdf?1734702337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-23'}, {'ID': '2024-30575', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule; correction.', 'SUMMARY': \"The Food and Nutrition Service is correcting a final rule that appeared in the Federal Register on October 31, 2024. The document makes access and parity improvements in USDA's food distribution programs to support access for eligible populations and streamline requirements for program operators.\", 'DATES': 'Effective December 30. 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30575.pdf?1734702337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-23'}, {'ID': '2024-30484', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice; soliciting nominations.', 'SUMMARY': 'Pursuant to the provisions of the rules and regulations of the USDA and the Federal Advisory Committee Act (FACA), the USDA is soliciting nominations for membership on the National Advisory Committee on Microbiological Criteria for Foods (NACMCF)and announcing potential charges for the 2025-2027 term. USDA seeks to appoint 30 members. Advisory Committee members serve a two-year term beginning September 2025 through September 2027. Members may be reappointed for one additional consecutive term at the discretion of the Secretary of Agriculture.', 'DATES': 'All nomination packages must be received by February 18, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30484.pdf?1734615936', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-20'}, {'ID': '2024-30355', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30355.pdf?1734615919', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-20'}, {'ID': '2024-30230', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30230.pdf?1734529541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-19'}, {'ID': '2024-30224', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, us, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30224.pdf?1734529540', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-19'}, {'ID': '2024-30228', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of the Interstate Shellfish Dealer's Certificate as well as the collection of other records related to participation in the National Shellfish Sanitation Program (NSSP).\", 'DATES': 'Either electronic or written comments on the collection of information must be submitted by February 18, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30228.pdf?1734529541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-19'}, {'ID': '2024-30231', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of the regulation requiring the manufacturer, packer, or distributor of a dietary supplement to notify us that it is marketing a dietary supplement product that bears on its label or in its labeling a statement provided for in the Federal Food, Drug, and Cosmetic Act (FD&C Act).', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by February 18, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30231.pdf?1734529542', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-19'}, {'ID': '2024-30227', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions associated with food additives intended for use in animal food, food additive petitions, investigational food additive files exemptions, and declaration of color additives on animal food labels.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by February 18, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30227.pdf?1734529541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-19'}, {'ID': '2024-30232', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is an extension, without change, of a currently approved collection to collect qualitative customer and stakeholder feedback in an efficient and timely manner.', 'DATES': 'Written comments must be received on or before February 18, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-30232.pdf?1734529543', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-19'}, {'ID': '2024-29962', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the following public workshop entitled \"FY 2025 Generic Drug Science and Research Initiatives Workshop.\" The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives. FDA is seeking this input from a variety of interested parties--industry, academia, patient advocates, professional societies, and other interested parties--as it fulfills its commitment under the Generic Drug User Fee Amendments of 2022 (GDUFA III) to develop an annual list of science and research initiatives specific to generic drugs. FDA will take the information it obtains from the public workshop into account in developing its fiscal year (FY) 2026 Generic Drug User Fee Amendments (GDUFA) science and research initiatives.', 'DATES': 'The public workshop will be held on June 3 and 4, 2025. Either electronic or written comments on this public workshop must be submitted by July 7, 2025. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29962.pdf?1734443166', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-18'}, {'ID': '2024-29964', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOHONOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 18, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 16, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29964.pdf?1734443166', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-18'}, {'ID': '2024-29955', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29955.pdf?1734443165', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-18'}, {'ID': '2024-29954', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29954.pdf?1734443165', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-18'}, {'ID': '2024-29966', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BYLVAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 18, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 16, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29966.pdf?1734443167', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-18'}, {'ID': '2024-29072', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': 'This final rule implements three provisions of the Fiscal Responsibility Act (FRA) of 2023, affecting the program purpose and individuals subject to the able-bodied adults without dependents (ABAWD) time limit for the Supplemental Nutrition Assistance Program (SNAP). These changes do the following: add language about assisting low-income adults in obtaining employment and increasing their earnings to the program purpose; update and define exceptions from the ABAWD time limit; and adjust the number of discretionary exemptions available to State agencies each year. This rule also clarifies procedures for when State agencies must screen for exceptions to the time limit and verification requirements for exceptions.', 'DATES': 'This final rule is effective January 16, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29072.pdf?1734356716', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-17'}, {'ID': '2024-29247', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to B. Braun Medical, Inc., for the Perfusor Space Syringe Infusion Pump System, Infusomat Space Volumetric Infusion Pump System, and Outlook ES. FDA revoked this Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocation, which includes an explanation of the reasons for revocation, is reprinted at the end of this document.', 'DATES': \"The revocation of the Authorization for the B. Braun Medical, Inc.'s Perfusor Space Syringe Infusion Pump System, Infusomat Space Volumetric Infusion Pump System, and Outlook ES is effective as of October 1, 2024.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29247.pdf?1733924744', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-12'}, {'ID': '2024-29231', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Science Board to the Food and Drug Administration by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Science Board to the Food and Drug Administration for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 26, 2026, expiration date.', 'DATES': 'Authority for the Science Board to the Food and Drug Administration will expire on June 26, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29231.pdf?1733924741', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-12'}, {'ID': '2024-29237', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry entitled \"Registration and Listing of Cosmetic Product Facilities and Products.\" The guidance will assist persons submitting cosmetic product facility registrations and product listing submissions to FDA under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This guidance includes three new draft frequently asked questions and answers about cosmetic product facility registrations and product listing submissions, in Appendix B, for comment purposes only. Aside from the three new draft frequently asked questions and answers, this guidance finalizes the draft Appendix B published in an otherwise final guidance on December 19, 2023. This guidance also includes minor changes to the final guidance for clarity.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 12, 2024. However, the portion of this guidance in Appendix B that describes three new frequently asked questions and answers, is being distributed for comment purposes only. To ensure that the Agency considers your comment on this draft section before it begins work on the final version of this section of the guidance, submit either electronic or written comments on this section by January 13, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-29237.pdf?1733924742', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-12'}, {'ID': '2024-28807', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the availability of the guidance for industry entitled \"Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions.\" This guidance describes the electronic submission of certain data and information in standardized formats. This information is used by the Center for Drug Evaluation and Research (CDER) in the planning of, and by FDA\\'s Office of Inspections and Investigations (OII) in the conduct of, BIMO inspections.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28807.pdf?1733492727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-09'}, {'ID': '2024-28811', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (the Committees). The general function of the Committees is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on February 5, 2025, from 8 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28811.pdf?1733492728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-09'}, {'ID': '2024-28392', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Expedited Program for Serious Conditions--Accelerated Approval of Drugs and Biologics.\" Accelerated approval is one of FDA\\'s expedited programs intended to facilitate and expedite development and review of certain drugs and biological products for serious or life-threatening conditions. This guidance provides information on FDA\\'s policies and procedures for the accelerated approval program, including discussions of which products may be candidates for accelerated approval, the standards for granting accelerated approval, and the procedures for withdrawing accelerated approval. When finalized, this draft guidance will replace the accelerated approval-related content in the final guidance for industry entitled \"Expedited Programs for Serious Conditions--Drugs and Biologics\" issued on May 30, 2014 (the 2014 final guidance). Additional programs to expedite product development are covered in the 2014 final guidance as well as other guidances.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 4, 2025. to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28392.pdf?1733406319', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-06'}, {'ID': '2024-28692', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'National Institute of Food and Agriculture', 'ACTION': 'Notice and request for comments.', 'SUMMARY': \"In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, this notice announces the National Institute of Food and Agriculture's (NIFA) intention to extend and revise a previously approved information collection, entitled Organizational Information.\", 'DATES': 'Written comments on this notice must be received by February 4, 2025 to be assured of consideration. Comments received after that date will be considered to the extent practicable.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28692.pdf?1733406351', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-06'}, {'ID': '2024-28433', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28433.pdf?1733319922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-05'}, {'ID': '2024-28363', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule; correction.', 'SUMMARY': 'The Food and Nutrition Service is correcting a final rule that appeared in the Federal Register on November 18, 2024. The document implements statutory requirements and policy improvements to strengthen the employment and training (E&T) program through the collection of information to determine the overall effectiveness of the E&T program in reaching the goal of assisting participants in obtaining the skills necessary to obtain and retain employment.', 'DATES': 'Effective January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28363.pdf?1733319918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-05'}, {'ID': '2024-28452', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Yong Sheng Jiao, also known as Yongsheng Jiao and Wilson Jiao (Jiao), and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Jiao for 5 years from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Jiao was convicted of a felony under Federal law for conduct relating to the importation into the United States of any drug or controlled substance under the FD&C Act. In determining the appropriateness and period of Jiao's debarment, FDA considered the relevant factors listed in the FD&C Act. Jiao submitted a request for hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.\", 'DATES': 'The order is applicable December 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28452.pdf?1733319925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-05'}, {'ID': '2024-28361', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance entitled \"Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions.\" This guidance demonstrates FDA\\'s commitment to developing innovative approaches to the regulation of artificial intelligence (AI)-enabled devices. More specifically, this guidance provides recommendations on the information to include in a Predetermined Change Control Plan (PCCP) in a marketing submission for a device that includes one or more AI-enabled device software functions (AI-DSFs). This guidance recommends that a PCCP describe the planned AI-DSF modifications, the associated methodology to develop, validate, and implement those modifications, and an assessment of the impact of those modifications. FDA reviews the PCCP as part of a marketing submission for a device to ensure the continued safety and effectiveness of the device without necessitating additional marketing submissions for implementing each modification described in the PCCP.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28361.pdf?1733233522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-04'}, {'ID': '2024-28230', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a draft guidance for industry entitled \"Notifying FDA of a Permanent Discontinuance in the Manufacture or an Interruption of the Manufacture of an Infant Formula.\" Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a manufacturer of a critical food (which includes infant formula) must notify FDA of a permanent discontinuance or an interruption of the manufacture of a critical food that is likely to lead to a meaningful disruption in the supply of the food in the United States. The draft guidance, when finalized, is intended to help the infant formula industry comply with this notification requirement as it pertains to infant formula.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 18, 2025 to ensure that we consider your comment on this draft guidance before we begin work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by February 3, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28230.pdf?1733156117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-04'}, {'ID': '2024-28362', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft revised guidance for industry (GFI) #49 entitled \"Evaluating Target Animal Safety and Effectiveness of Antibacterial New Animal Drugs for Bovine Mastitis.\" This draft guidance provides recommendations and considerations for bovine mastitis drug products with antibacterial activity that are administered by intramammary infusion.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 3, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28362.pdf?1733233522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-04'}, {'ID': '2024-28229', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Best Practices for FDA Communication with Interested Parties: Draft Report for Public Comment.\" This draft report and implementation plan respond to the Consolidated Appropriations Act of 2023, which directs FDA to issue a report on FDA\\'s practices for broadly communicating with external interested parties and a plan for implementation of such best practices. In addition, FDA is to conduct a review of the types and methods of public communication that FDA uses to communicate and interact with medical product sponsors and other external interested parties; identify best practices for the efficient development, issuance, and use of such communications; and develop a plan for implementation of best practices for these communications. As directed, FDA is publishing and soliciting feedback on this draft report and implementation plan.', 'DATES': 'Submit either electronic or written comments on the draft report and implementation plan by February 3, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28229.pdf?1733147119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-03'}, {'ID': '2024-28228', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a document entitled \"Food and Drug Administration Report and Plan on Best Practices for Guidance\" (Report and Plan). FDA is publishing this Report and Plan in response to the Consolidated Appropriations Act, 2023, which directs FDA to issue a report identifying best practices for the efficient prioritization, development, issuance, and use of guidance documents and a plan for implementation of such best practices.', 'DATES': 'The announcement of the report and plan is published in the Federal Register on December 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28228.pdf?1733147119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-03'}, {'ID': '2024-27853', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Nutrition Service (FNS) is proposing changes to Supplemental Nutrition Assistance Program (SNAP) regulations in accordance with the Food and Nutrition Act of 2008, which calls for a cost adjustment in the Thrifty Food Plan (TFP) for Hawaii to reflect the cost of food in Hawaii. The proposal would update the method for calculating this cost adjustment to incorporate food prices from throughout the State of Hawaii rather than from Honolulu alone, ensuring that SNAP benefit allotments better reflect food prices faced by participants throughout the State of Hawaii.', 'DATES': 'Written comments must be received on or before February 3, 2025 to be assured of consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27853.pdf?1733147117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-03'}, {'ID': '2024-28061', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during July, August, and September 2024. The animal drug regulations are also being amended to improve their accuracy and readability.', 'DATES': 'This rule is effective December 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28061.pdf?1732887926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-02'}, {'ID': '2024-28206', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that KEBILIDI (eladocagene exuparvovec-tneq), approved on November 13, 2024, manufactured by PTC Therapeutics Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28206.pdf?1732887943', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-02'}, {'ID': '2024-28205', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; reopening of public comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) published in the Federal Register of September 23, 2024, a notice of public meeting scheduled for October 21, 2024, and solicited comments from interested parties. FDA requested that all electronic and written comments be submitted by November 21, 2024. FDA is reopening the public comment period until December 20, 2024, in response to feedback received from interested parties. This action will allow for interested parties additional time to review the meeting transcript and recording to prepare information and comments.', 'DATES': 'The comment period for the notice of public meeting published on September 23, 2024, (89 FR 77521) is reopened. Either electronic or written comments must be received on or before December 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28205.pdf?1732887943', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-02'}, {'ID': '2024-28210', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on January 10, 2025, from 9 a.m. to 4:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28210.pdf?1732887944', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-12-02'}, {'ID': '2024-28033', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development.\" This guidance is intended to help sponsors planning to use circulating cell-free plasma derived tumor DNA (ctDNA) as a biomarker in cancer clinical trials conducted under an investigational new drug application (IND) and/or to support marketing approval of drugs and biological products for treating solid tumor malignancies in the early-stage (curative-intent) setting. This guidance finalizes the draft guidance entitled \"Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development\" issued on May 2, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on November 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28033.pdf?1732715149', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-29'}, {'ID': '2024-28044', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with administrative detention and banned medical devices.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by January 28, 2025', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28044.pdf?1732715150', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-29'}, {'ID': '2024-28036', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of medicated feed mill license reporting.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by January 28, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28036.pdf?1732715149', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-29'}, {'ID': '2024-28034', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on financial disclosure by clinical investigators.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by January 28, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-28034.pdf?1732715149', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-29'}, {'ID': '2024-27797', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2026, expiration date.', 'DATES': 'Authority for the Oncologic Drugs Advisory Committee will expire on September 1, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27797.pdf?1732628729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-27'}, {'ID': '2024-27796', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects.\" This draft guidance makes recommendations on followup testing for Ames-positive active ingredients in circumstances when a sponsor decides to continue development. The guidance recommends a consistent process of followup testing and evaluation that first should be conducted for an Ames-positive active ingredient before proceeding with first-in-human (FIH) trials in healthy human subjects. These recommendations are intended to potentially help address and lower safety concerns before proceeding with FIH trials in healthy human subjects.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 25, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27796.pdf?1732628729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-27'}, {'ID': '2024-27804', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products.\" This draft guidance provides recommendations to sponsors regarding the measurement of ovarian toxicity using clinical measures and biomarkers of ovarian function in relevant cancer clinical trials that enroll premenopausal adults with ovaries. Assessment of ovarian toxicity in cancer trials helps ensure that patients and clinicians have information about the possible long-term impacts of treatment on ovarian function and thus facilitate informed decision- making regarding anti-cancer agents.', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 27, 2025, to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27804.pdf?1732628730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-27'}, {'ID': '2024-27661', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices.\" This guidance provides information regarding FDA recommendations and general principles to be referenced by holders of premarket approval applications (PMAs) and humanitarian device exemptions (HDE) for class III devices sterilized by ethylene oxide (EtO) whose products are affected by the potential, actual, or temporary stop or reduction of operations at a sterilization facility, if they wish to have FDA consider whether the exercise of enforcement discretion relating to the implementation of certain types of sterilization site changes is appropriate. FDA is issuing this guidance to provide an enforcement discretion policy to help proactively address manufacturing limitations or supply chain issues due to disruptions caused by closures or potential closures of sterilization facilities that use EtO as a medical device sterilant during the time in which manufacturers are transitioning to compliance with certain new requirements. FDA believes that the enforcement discretion policy described in this guidance may help address concerns during this time related to potential sterile medical device impacts affecting certain devices sterilized by EtO, help mitigate possible interruptions in sterile device processing, and help maintain adequate supplies of finished sterile medical devices. This guidance has been implemented without prior comment, but it remains subject to comment in accordance with the Agency\\'s good guidance practices.', 'DATES': 'The announcement of the guidance is published in the Federal Register on November 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27661.pdf?1732542336', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-26'}, {'ID': '2024-27655', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by December 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27655.pdf?1732542336', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-26'}, {'ID': '2024-27654', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by December 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27654.pdf?1732542336', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-26'}, {'ID': '2024-27483', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by December 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27483.pdf?1732283124', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-25'}, {'ID': '2024-27114', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Orthopedic Non-Spinal Bone Plates, Screws, and Washers--Premarket Notification (510(k)) Submissions.\" This guidance document provides recommendations for information to include in 510(k) submissions for non-resorbable bone plate, screw, and washer devices. The scope of this guidance includes devices that are indicated for orthopedic bone fixation but does not include devices indicated for spinal, mandibular, maxillofacial, cranial, and orbital fracture fixation.', 'DATES': 'The announcement of the guidance is published in the Federal Register on November 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27114.pdf?1732196718', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-22'}, {'ID': '2024-27085', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review.\" This guidance provides FDA\\'s current thinking regarding the 510(k) Third Party (3P510k) Review Program and review of EUA requests by a third party review organization (3PEUA review). The 3P510k Review Program and 3PEUA review create an alternative process for manufacturers to seek review of 510(k) submissions and EUA requests to assist FDA in reviewing in a timely manner.', 'DATES': 'The announcement of the guidance is published in the Federal Register on November 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27085.pdf?1732110317', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-21'}, {'ID': '2024-27289', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is extending the comment period for the notice of public meeting; request for comments, published in the Federal Register of August 12, 2024. In that notice, FDA announced a public meeting entitled \"Development of an Enhanced Systematic Process for the Food and Drug Administration\\'s Post-Market Assessment of Chemicals in Food.\" FDA hosted the public meeting on September 25, 2024, and is now extending the comment period to allow interested persons additional time to submit comments about approaches to systematic post-market assessment of chemicals in food.', 'DATES': 'FDA is extending the comment period announced in the notice of public meeting; request for comments published August 12, 2024 (89 FR 65633). Either electronic or written comments must be submitted by January 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27289.pdf?1732110346', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-21'}, {'ID': '2024-27093', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Miguel Angel Montalvo Villa from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Montalvo Villa was convicted of multiple felonies under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mr. Montalvo Villa was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of September 19, 2024 (30 days after receipt of the notice), Mr. Montalvo Villa has not responded. Mr. Montalvo Villa's failure to respond and request a hearing constitutes a waiver of Mr. Montalvo Villa's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable November 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27093.pdf?1732023945', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27048', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" that explained the process that would be used to make product-specific guidances available to the public on FDA\\'s website. The draft guidances identified in this notice were developed using the process described in that guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 21, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27048.pdf?1732023938', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27082', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on October 16, 2024. The document announced that NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g), was not withdrawn from sale for reasons of safety or effectiveness. The document incorrectly listed the dosage strength as 100 g. The correct strength is 100 milligrams (mg). This notice corrects that error.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27082.pdf?1732023943', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27090', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that IC-GREEN (indocyanine green), 25 milligrams (mg)/vial, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for IC-GREEN (indocyanine green), 25 mg/vial, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27090.pdf?1732023944', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27094', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Cue Health, Inc., for the Cue COVID-19 Test, and Cue COVID-19 Test for Home and Over The Counter (OTC) Use. FDA revoked the Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.', 'DATES': \"The revocation of the Authorizations for the Cue Health, Inc.'s Cue COVID-19 Test, and Cue COVID-19 Test for Home and Over The Counter (OTC) Use are effective as of October 9, 2024.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27094.pdf?1732023946', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27011', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Office of the Commissioner (OC), Office of Digital Transformation (ODT) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on September 20, 2024.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27011.pdf?1732023929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27103', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that FORTESTA (testosterone) gel, 10 milligrams (mg)/0.5 gram (gm) actuation, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27103.pdf?1732023947', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-27070', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for information.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is requesting information to help fill data gaps that remain regarding per- and polyfluoroalkyl substances (PFAS) in seafood. The purpose of this request is to help increase our understanding of the potential for PFAS exposure from seafood. We intend to use the information submitted in response to this request to help inform future activities to reduce dietary exposure to PFAS that may pose a health concern.', 'DATES': 'Either electronic or written comments on the notice must be submitted by February 18, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-27070.pdf?1732023941', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-20'}, {'ID': '2024-26918', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products.\" The draft guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 18, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26918.pdf?1731937536', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26916', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that HYDROCORTONE (hydrocortisone sodium phosphate) injection, equivalent to (EQ) 50 milligrams (mg) base/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for HYDROCORTONE (hydrocortisone sodium phosphate) injection, EQ 50 mg base/mL, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26916.pdf?1731937535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26912', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Ivette Maria Portela Martinez from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Ms. Portela Martinez was convicted of two felonies under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Ms. Portela Martinez was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of September 14, 2024 (30 days after receipt of the notice), Ms. Portela Martinez has not responded. Ms. Portela Martinez's failure to respond and request a hearing constitutes a waiver of Ms. Portela Martinez's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable November 19, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26912.pdf?1731937535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26917', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Kevin Sheng Hsiang Fang for a period of 5 years from importing articles of food or offering such articles for importation into the United States. FDA bases this order on a finding that Mr. Fang was convicted of a felony count under Federal law for conduct relating to the importation into the United States of an article of food. Mr. Fang was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of July 1, 2024 (30 days after receipt of the notice), Mr. Fang has not responded. Mr. Fang's failure to respond and request a hearing constitutes a waiver of Mr. Fang's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable November 19, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26917.pdf?1731937535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26915', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that JESDUVROQ (daprodustat) tablets, 1 milligram (mg), 2 mg, 4 mg, 6 mg, and 8 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for JESDUVROQ (daprodustat) tablets, 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26915.pdf?1731937535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26913', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 26 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of December 19, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26913.pdf?1731937535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26910', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AGILI-C and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by January 21, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 19, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26910.pdf?1731937534', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26941', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a new information collection for the contract of the study titled Guidance for SNAP Certification and Quality Control Interviews. The purpose of this collection is to help FNS develop new guidance for SNAP eligibility and Quality Control interviews based on principles of human-centered design and cultural competency.', 'DATES': 'Written comments must be received on or before January 21, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26941.pdf?1731937539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-19'}, {'ID': '2024-26801', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with FDA's Prescription Drug User Fee program.\", 'DATES': 'Either electronic or written comments on the collection of information must be submitted by January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26801.pdf?1731678338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-18'}, {'ID': '2024-26809', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': \"The final rule implements the employment and training (E&T) provisions of the Agricultural Act of 2014. This section provided the Department additional oversight authority of State agencies' administration of the Supplemental Nutrition Assistance Program (SNAP) E&T program; required the Department to develop reporting measures and required State agencies to report outcome data to the Department. It also required the Department to monitor and assess State agencies' effectiveness of E&T programs and provided the Department with the authority to require State agencies to make improvements to their programs as necessary. Finally, State agencies are required to submit reports on the impact of certain E&T components, and in certain States, the E&T services provided to able-bodied adults without dependents (ABAWDs). The final rule will strengthen the E&T program through the collection of information to determine the overall effectiveness of the E&T program in reaching the goal of assisting participants in obtaining the skills necessary to obtain and retain employment.\", 'DATES': 'Effective date: This rule will become effective January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26809.pdf?1731678339', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-18'}, {'ID': '2024-26845', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': \"This rule finalizes changes proposed October 3, 2019, by the Department to revise Supplemental Nutrition Assistance Program (SNAP) regulations for calculating standard utility allowances (SUAs) and expand allowable shelter expenses to include basic internet costs. It requires State agencies to submit for FNS approval their SUA methodologies at least every five years, and methodology submissions must incorporate any revisions necessary to demonstrate that the baseline expenditure data and underlying methodology reflect recent trends and changes. This rule also provides State agencies with the flexibility necessary to ensure that they meet households' needs while also aligning SUAs with data on low-income household utility costs in a more consistent manner. This rule also finalizes updates proposed April 20, 2016, regarding the treatment of Low Income Home Energy Assistance Program or other similar energy assistance program payments, in accordance with amendments made to the Food and Nutrition Act of 2008 by the Agricultural Act of 2014. The intent of this final rule is to ensure consistency and integrity of SUAs across the country, which the Department believes is good governance.\", 'DATES': 'Effective date: This final rule is effective January 17, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26845.pdf?1731678345', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-18'}, {'ID': '2024-26682', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics.\" FDA is publishing this draft guidance which, when finalized, will provide recommendations on approaches for the nonclinical safety evaluation of oligonucleotide-based therapeutics (ONTs) to support clinical development and marketing of these products. ONTs present unique challenges and opportunities in the nonclinical evaluation of safety that differ in many regards from those appropriate for small molecule drugs or therapeutic proteins.', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 14, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26682.pdf?1731591948', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-15'}, {'ID': '2024-26399', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public workshop entitled \"Patient- Focused Drug Development: Workshop to Discuss Methodologic and Other Challenges Related to Patient Experience Data.\" The purpose of the public workshop is to discuss methodological challenges related to patient experience data, and other areas of greatest interest or concern to public stakeholders.', 'DATES': 'The public workshop will be held virtually on December 13, 2024, from 10 a.m. to 5 p.m. Eastern Time. Either electronic or written comments on this public meeting must be submitted by February 11, 2025. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26399.pdf?1731505530', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-14'}, {'ID': '2024-26209', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by December 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26209.pdf?1731419122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-13'}, {'ID': '2024-26318', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that NUPLAZID (pimavanserin tartrate) tablet, equivalent (EQ) 17 milligram (mg) base, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for NUPLAZID (pimavanserin tartrate) tablet, EQ 17 mg base, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26318.pdf?1731419139', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-13'}, {'ID': '2024-26297', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing a public workshop titled \"Optimizing the Use of Real-World Evidence in Regulatory Decision-Making for Drugs and Biological Products--Looking Forward.\" The purpose of the public workshop is to provide interested parties with an update on FDA\\'s current activities related to real- world evidence (RWE) and to share accomplishments, ongoing challenges, and future opportunities. The public workshop will discuss potential next steps to promote the continued evolution and consistent application of real-world data (RWD) in drug development. This public workshop will be convened and supported by a cooperative agreement between FDA and the Duke University, Duke-Margolis Institute for Health Policy.', 'DATES': 'The public workshop will be held on December 12, 2024, from 12:30 p.m. to 5 p.m., Eastern Time. Either electronic or written comments on this public workshop must be submitted by January 13, 2025. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26297.pdf?1731419136', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-13'}, {'ID': '2024-25974', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration is amending the regulation setting fees for color additive certification services to increase these fees. This increase will allow FDA to continue to provide, maintain, and equip an adequate color additive certification program as required by the Federal Food, Drug, and Cosmetic Act (FD&C Act).', 'DATES': 'This rule is effective December 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25974.pdf?1730987217', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-08'}, {'ID': '2024-26040', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for information.', 'SUMMARY': \"The Food and Drug Administration (FDA, the Agency, or we) invites comment relating to the listing requirements of other countries and FDA's approach to facilitating U.S. industry compliance with these requirements through the issuance of export certification for human food products provided in the form of lists (export lists).\", 'DATES': 'Submit either electronic or written comments on the request for information by January 7, 2025 to ensure that the Agency considers your comment.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-26040.pdf?1730987234', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-08'}, {'ID': '2024-25910', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the availability on its website of the proposed administrative order (proposed order) (OTC000036) entitled \"Amending Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use.\" This proposed order, if finalized, will amend Final Administrative Order OTC000026, to remove orally administered phenylephrine hydrochloride and phenylephrine bitartrate in an effervescent dosage as nasal decongestant active ingredients because they are not effective.', 'DATES': 'Submit electronic comments on the proposed administrative order by May 7, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25910.pdf?1730987201', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-08'}, {'ID': '2024-25833', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a revision of a currently approved information collection form that organizations fighting hunger and poverty fill out to keep their information up to date for use by the general public.', 'DATES': 'Written comments must be received on or before January 6, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25833.pdf?1730900726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-07'}, {'ID': '2024-25567', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is extending the comment period for a draft guidance for industry entitled \"Voluntary Sodium Reduction Goals: Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods (Edition 2).\" The draft guidance, when finalized, will describe our views on the next voluntary goals (Phase II (3-year)) for sodium reduction in a variety of identified categories of foods that are commercially processed, packaged, or prepared. These goals are intended to address the excessive intake of sodium in the current population to help reduce the burden of diet-related chronic disease, promote improvements in public health, and advance health equity by supporting a healthier food supply. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 13, 2025, to ensure that we consider your comment on the draft guidance before we begin work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25567.pdf?1730465128', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-04'}, {'ID': '2024-25315', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for FDA staff entitled \"Sec. 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products--Decomposition and Histamine (CPG 7108.24) Compliance Policy Guide.\" This compliance policy guide (CPG) is intended to provide FDA staff guidance on adulteration associated with decomposition and/or histamine identified during surveillance sampling and testing of fish and fishery products susceptible to histamine formation.', 'DATES': 'The announcement of the guidance is published in the Federal Register on November 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25315.pdf?1730465115', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-04'}, {'ID': '2024-25458', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Over-The-Counter [OTC] Monograph Drug User Fee Program (OMUFA) for fiscal years (FYs) 2026 through 2030. Under OMUFA, FDA collects user fees to support OTC monograph drug activities. The current legislative authority for OMUFA expires September 30, 2025. At that time, new legislation will be required to reauthorize OMUFA for future fiscal years. Following negotiations with the regulated industry and consultation with interested members of the public, the Federal Food, Drug, and Cosmetic Act (FD&C Act) directs FDA to publish recommendations for the reauthorization of the OMUFA program in the Federal Register, provide for a period of 30 days for the public to provide written comments on such recommendations, and hold a meeting at which the public may present its views on such recommendations. FDA will then consider such public views and comments and revise such recommendations as necessary.', 'DATES': 'The public meeting will be held on November 20, 2024, from 9 a.m. to 12:30 p.m. Submit either electronic or written comments on this public meeting by December 20, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25458.pdf?1730378728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-11-01'}, {'ID': '2024-25391', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of additional revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" that explained the process that would be used to make product-specific guidances available to the public on FDA\\'s website. The draft guidances identified in this notice were developed using the process described in that guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by December 30, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25391.pdf?1730292359', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-31'}, {'ID': '2024-25355', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms\" and the supplemental document entitled \"M13A Bioequivalence for Immediate- Release Solid Oral Dosage Forms: Questions and Answers.\" The guidance and supplemental questions and answers document were prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance describes the scientific and technical aspects of study design and data analysis to support bioequivalence (BE) assessment of orally administered immediate-release solid oral dosage forms of pharmaceutical drugs, such as tablets, capsules, and granules/powders for oral suspension. The supplemental questions and answers document provides clarity to concepts covered in the guidance and rationales behind to facilitate implementation. The guidance is intended to provide globally harmonized scientific recommendations for conducting BE studies during both the development and postapproval phases of immediate-release solid oral dosage forms. The guidance replaces the draft guidance \"M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms\" issued on February 1, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 31, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25355.pdf?1730292354', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-31'}, {'ID': '2024-24966', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': \"This final rule considers public comments submitted in response to the proposed rule revising the Commodity Supplemental Food Program (CSFP), the Food Distribution Program on Indian Reservations (FDPIR), The Emergency Food Assistance Program (TEFAP), and USDA Foods disaster response regulations. This final rule makes access and parity improvements in USDA's food distribution programs to support access for eligible populations and streamline requirements for program operators.\", 'DATES': 'Effective date: This rule is effective December 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24966.pdf?1730292329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-31'}, {'ID': '2024-25122', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; response to objection; confirmation of effective date.', 'SUMMARY': \"The Food and Drug Administration (FDA or we) is responding to the objection that we received from the Environmental Defense Fund, Breast Cancer Prevention Partners, Environmental Protection Network, Environmental Working Group, and Healthy Babies Bright Futures on the final rule that amended the food additive regulations to no longer provide for the use of 25 plasticizers that the petition identified as ortho-phthalates because these food additive uses have been permanently abandoned. After reviewing the objection, FDA has concluded that the objection does not provide a basis for modifying FDA's final rule amending the food additive regulations.\", 'DATES': 'The effective date of May 20, 2022, for the final rule published on May 20, 2022 (87 FR 31080), is confirmed.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25122.pdf?1730205922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-30'}, {'ID': '2024-24820', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during April, May, and June 2024. The animal drug regulations are also being amended to improve their accuracy and readability.', 'DATES': 'This rule is effective October 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24820.pdf?1729860314', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-28'}, {'ID': '2024-25008', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a new collection. The purpose of this information collection is to provide information on the implementation and effectiveness of modernization projects across all 88 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) State agencies to help identify successes, opportunities for improvement, and areas for additional support from FNS to strengthen project implementation.', 'DATES': 'Written comments must be received on or before December 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-25008.pdf?1729860329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-28'}, {'ID': '2024-24841', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination.\" The final guidance provides our current view of insanitary conditions of tattoo ink preparation, packaging, or holding that may render the inks injurious to health because of microbial contamination. This guidance finalizes the draft guidance of the same title issued on June 13, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24841.pdf?1729773931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-25'}, {'ID': '2024-24822', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24822.pdf?1729773927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-25'}, {'ID': '2024-24828', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on December 4, 2024, from 8 a.m. to 3 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24828.pdf?1729773929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-25'}, {'ID': '2024-24868', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a new information collection request in which FNS seeks updated information about the Food Distribution Program on Indian Reservations (FDPIR), including participant characteristics, program operations, and why FDPIR participation has been declining. This study will also include an evaluation of the self-determination demonstration projects (SDDPs), which allow Tribes administering FDPIR to directly purchase food for the FDPIR food packages distributed to their Tribe.', 'DATES': 'Written comments must be received on or before December 24, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24868.pdf?1729773935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-25'}, {'ID': '2024-24866', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a revision of a currently approved collection. This information collection, the FNS-245, Negative Case Action Review Schedule, is designed to collect quality control (QC) data and serve as the data entry form for negative case action QC reviews in the Supplemental Nutrition Assistance Program (SNAP). Revisions to the form, its instructions, and burden hours are within.', 'DATES': 'Written comments must be received on or before December 24, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24866.pdf?1729773934', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-25'}, {'ID': '2024-24715', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry #293 entitled \"FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients.\" This communicates FDA\\'s enforcement policy regarding ingredients listed in chapter six of the 2024 Association of American Feed Control Officials (AAFCO) Official Publication after the Agency\\'s memorandum of understanding with AAFCO expired on October 1, 2024.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 24, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24715.pdf?1729687540', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-24'}, {'ID': '2024-24720', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by November 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24720.pdf?1729687540', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-24'}, {'ID': '2024-24771', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by November 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24771.pdf?1729687547', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-24'}, {'ID': '2024-24713', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The Committee will discuss Considerations for Respiratory Syncytial Virus (RSV) Vaccine Safety in Pediatric Populations and will also hear overviews of the Laboratory of Immunoregulation (LI) and Laboratory of Retroviruses (LR) research programs in the Center for Biologics Evaluation and Research. At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held virtually on December 12, 2024, from 8:30 a.m. to 5:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24713.pdf?1729687539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-24'}, {'ID': '2024-24721', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of our reporting and recordkeeping requirements for antimicrobial animal drug sales and distribution.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by December 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24721.pdf?1729687541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-24'}, {'ID': '2024-24447', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice that appeared in the Federal Register of September 20, 2024. In the notice, FDA requested comments on the draft guidance for industry and FDA staff entitled \"Chemical Analysis for Biocompatibility Assessment of Medical Devices.\" The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the notice published September 20, 2024 (89 FR 77162). Submit either electronic or written comments on the draft guidance by December 19, 2024, to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24447.pdf?1729514742', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-22'}, {'ID': '2024-24442', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Drug Interaction Information in Human Prescription Drug and Biological Product Labeling.\" The draft guidance is intended to assist applicants in developing the DRUG INTERACTIONS section of labeling as described in FDA regulations for the content and format of labeling for human prescription drug and biological products. The purpose of the draft guidance is to provide recommendations on what information to include in, and how to present and organize the information within, the DRUG INTERACTIONS section of labeling for human prescription drug and biological products to enhance communication of clinically significant drug interactions and facilitate the safe and effective use of prescription drugs by healthcare practitioners.', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 21, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24442.pdf?1729514741', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-22'}, {'ID': '2024-24244', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by December 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 21, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24244.pdf?1729255531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-21'}, {'ID': '2024-24287', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GORE TAG THORACIC BRANCH ENDOPROSTHESIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by December 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 21, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24287.pdf?1729255537', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-21'}, {'ID': '2024-24188', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYNDAQEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by December 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 21, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24188.pdf?1729255523', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-21'}, {'ID': '2024-24187', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYNDAMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by December 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 21, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24187.pdf?1729255522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-21'}, {'ID': '2024-24096', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability that appeared in the Federal Register of September 23, 2024. In the notice of availability, FDA requested comments on three draft guidance documents for industry and FDA staff entitled \"The Accreditation Scheme for Conformity Assessment (ASCA) Program; Guidance for Industry, Accreditation Bodies, Testing Laboratories, and FDA Staff\"; \"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment--Standards Specific Information for the ASCA Program; Guidance for Industry, Accreditation Bodies, Testing Laboratories, and FDA Staff\"; and \"Biocompatibility Testing of Medical Devices--Standards Specific Information for the ASCA Program; Guidance for Industry, Accreditation Bodies, Testing Laboratories, and FDA Staff.\" The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the document published September 23, 2024 (89 FR 77526). Either electronic or written comments must be submitted by December 23, 2024, to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24096.pdf?1729169136', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24106', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) 205851 and the new animal drug application (NADA) 141-389 for the designated medical gas Helium, USP held by Linde, Inc., 175 East Park Dr., Tonawanda, NY 14150-7844. Linde, Inc. notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.', 'DATES': 'Approval is withdrawn as of November 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24106.pdf?1729169138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24103', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that TAVIST (clemastine fumarate) tablet, 2.68 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24103.pdf?1729169137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24107', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Postoperative Nausea and Vomiting: Developing Drugs for Prevention.\" This guidance provides recommendations regarding the design of clinical trials for the prevention of postoperative nausea and vomiting in adults, including considerations for eligibility criteria, trial design features, efficacy evaluations, and safety assessments.', 'DATES': 'Submit either electronic or written comments on the draft guidance by December 17, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24107.pdf?1729169138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24111', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Core Patient-Reported Outcomes in Cancer Clinical Trials.\" This final guidance provides recommendations to sponsors regarding the collection of a core set of patient-reported clinical outcomes (herein referred to as core patient-reported outcomes) in cancer clinical trials and related considerations for instrument selection and trial design. This final guidance focuses on patient-reported outcome (PRO) measures and is specific to registration trials for anti-cancer therapies intended to demonstrate an effect on survival, tumor response, or delay in the progression of a malignancy.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24111.pdf?1729169138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24098', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method.\" The draft guidance document provides recommendations on the development of blood collection, processing, and storage systems (e.g., blood bags with anticoagulant and additive solutions, empty bags for platelet pooling) used for the manufacture of blood and blood components intended for transfusion using the buffy coat (BC) method. This guidance is intended for manufacturers of blood collection, processing, and storage systems.', 'DATES': 'Submit either electronic or written comments on the draft guidance by December 17, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24098.pdf?1729169137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24104', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA.\" This guidance provides information and recommendations on the Generic Drug User Fee Amendments (GDUFA) III program enhancements agreed upon by the Agency and industry in \"GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027\" (GDUFA III commitment letter), related to the early assessment of certain Type II drug master files (DMFs) 6 months prior to the submission of certain abbreviated new drug applications (ANDAs) or prior approval supplements (PASs). This guidance describes the process outlined in the GDUFA III commitment letter in greater detail and provides recommendations to DMF holders on how to provide the relevant information to FDA. This guidance finalizes the draft guidance of the same title issued on October 6, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24104.pdf?1729169137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24108', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development; Guidance for Industry.\" This guidance is intended to provide a framework for considering whether and what type of long-term neurologic, sensory, and developmental evaluations could be useful in supporting a determination of safety of an FDA-regulated \"medical product\" (i.e., drug, biological product, or medical device) for use in neonates. Although short-term safety evaluations may be appropriate for adults or other populations, such evaluations may not identify important adverse events in the neonatal population, as medical treatment during the neonatal period coincides with a time of critical growth and physiologic development and latent effects may not be evident until later in life following early-life exposures. Consideration of the potential for long-term neurologic, sensory, and developmental effects in the neonatal population early in a development program is important for establishing safety of a medical product intended for use in neonates. This guidance finalizes the draft guidance of the same title issued on February 13, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24108.pdf?1729169138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24160', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This new collection will provide the U.S. Department of Agriculture, Food and Nutrition Service (FNS) key information from a large representative sample of SNAP households to enable FNS to examine how SNAP households change through time.', 'DATES': 'Written comments must be received on or before December 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24160.pdf?1729169145', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24109', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXXUA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by December 17, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 16, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24109.pdf?1729169138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24095', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WAVEWRITER ALPHA SPINAL CORD STIMULATOR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by December 17, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by April 16, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24095.pdf?1729169136', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-24100', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Direct final rule; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is correcting a final rule entitled \"Regulatory Hearing Before the Food and Drug Administration; General Provisions; Amendments\" that appeared in the Federal Register of September 20, 2024. The final rule inadvertently omitted the effective date for a provision in the regulatory text. This document corrects the error in the DATES portion.', 'DATES': 'Effective February 3, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-24100.pdf?1729169137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-18'}, {'ID': '2024-23954', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled \"Temporary Policies for Compounding Certain Parenteral Drug Products.\" As of October 10, 2024, pursuant to the Public Health Service Act (PHS Act), Department of Health and Human Services (HHS) Secretary Becerra has determined that public health emergencies (PHEs) exist as a result of the consequences of Hurricane Helene in the States of North Carolina, Florida, Georgia, Tennessee, and South Carolina, and as a result of the consequences of Hurricane Milton in the State of Florida. In late September 2024, Hurricane Helene had a devastating impact on one of the largest manufacturers of certain intravenous and peritoneal dialysis solutions in the United States. This guidance describes the FDA\\'s regulatory and enforcement priorities regarding the compounding of certain parenteral drug products by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23954.pdf?1729082726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-17'}, {'ID': '2024-23967', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Requests for Reconsideration at the Division Level Under GDUFA.\" This guidance provides recommendations on the procedures for applicants of abbreviated new drug applications (ANDAs) that wish to pursue a request for reconsideration within the review discipline at the division level or original signatory authority. This guidance reflects the most recent reauthorization of the Generic Drug User Fee Amendments (GDUFA III) and clarifies what matters are appropriate for requests for reconsideration. This guidance finalizes the draft guidance for industry of the same title issued on January 11, 2024.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23967.pdf?1729082727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-17'}, {'ID': '2024-23811', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23811.pdf?1728996324', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-16'}, {'ID': '2024-23706', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry #284 entitled \"Using Relative Supersaturation To Support `Urinary Tract Health\\' Claims for Adult Maintenance Cat Food.\" FDA\\'s Center for Veterinary Medicine (CVM) has evaluated the use of relative supersaturation (RSS) methodology to support urinary tract health claims for certain adult maintenance cat food. RSS is a measurement that estimates the potential for crystal formation and bladder stone growth, which is a common affliction in cats. This guidance provides recommendations for how pet food manufacturers can use RSS methodology to substantiate general structure or function claims that an adult maintenance cat food supports urinary tract health by promoting a healthy mineral content in the urinary tract.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23706.pdf?1728650749', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23651', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application for KISQALI (ribociclib), approved September 17, 2024, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23651.pdf?1728650737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23716', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Endosseous Dental Implants and Endosseous Dental Implant Abutments--Performance Criteria for Safety and Performance Based Pathway.\" The device-specific guidance identified in this notice was developed in accordance with the finalized guidance entitled \"Safety and Performance Based Pathway.\" This guidance has been implemented without prior comment, but it remains subject to comment in accordance with the Agency\\'s good guidance practices.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23716.pdf?1728650751', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23646', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that MIPLYFFA (arimoclomol), approved on September 20, 2024, manufactured by Zevra Denmark AS, meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23646.pdf?1728650736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23646', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that MIPLYFFA (arimoclomol), approved on September 20, 2024, manufactured by Zevra Denmark AS, meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23646.pdf?1728650736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23637', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Janssen Biotech, Inc. (Janssen), for the Janssen COVID-19 Vaccine. FDA revoked the Authorization on June 1, 2023, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.', 'DATES': 'The Authorization is revoked as of June 1, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23637.pdf?1728650734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23712', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that AQNEURSA (levacetylleucine), approved on September 24, 2024, manufactured by IntraBio Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23712.pdf?1728650749', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23701', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; correction.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is correcting a final rule that appeared in the Federal Register on February 2, 2024. In that final rule, FDA amended the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) regulation to harmonize and modernize the device CGMP. FDA is correcting an editorial error that inadvertently omitted a definition in the codified of the final rule. This action is editorial in nature and is intended to ensure the accuracy and clarity of the Agency's regulations.\", 'DATES': 'Effective February 2, 2026.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23701.pdf?1728650748', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-15'}, {'ID': '2024-23629', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application for TREMFYA (guselkumab), approved September 11, 2024, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23629.pdf?1728564343', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-11'}, {'ID': '2024-23544', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the website location where the Agency will post two lists of guidance documents that the Center for Devices and Radiological Health (CDRH) intends to publish in fiscal year (FY) 2025. In addition, FDA has established a docket where interested parties may comment on the priority of topics for guidance, provide comments and/or propose draft language for those topics, suggest topics for new or different guidance documents, comment on the applicability of guidance documents that have issued previously, and provide any other comments that could benefit the CDRH guidance program and its engagement with interested parties. This feedback is critical to the CDRH guidance program to ensure that we meet the needs of interested parties.', 'DATES': 'Either electronic or written comments on the notice must be submitted by December 10, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23544.pdf?1728564330', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-11'}, {'ID': '2024-23061', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'National Institute of Food and Agriculture', 'ACTION': 'Final rule.', 'SUMMARY': 'This amendment to NIFA regulations updates the list of institutions that are granted Hispanic-Serving Agricultural Colleges and Universities (HSACU) certification by the Secretary and are eligible for HSACU programs for the period starting July 1, 2024, and ending July 1, 2025.', 'DATES': 'This rule is effective October 8, 2024 and applicable July 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-23061.pdf?1728305120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-08'}, {'ID': '2024-22570', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on October 31, 2024, from 9 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22570.pdf?1727786728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-02'}, {'ID': '2024-22561', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on November 21, 2024, from 10 a.m. to 4 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22561.pdf?1727786727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-02'}, {'ID': '2024-22575', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with a proposed study entitled \"Promotion of Prescription Drugs Within a Talk Show Format.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by December 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22575.pdf?1727786729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-02'}, {'ID': '2024-22562', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers.\" The guidance provides information for sponsors, clinical investigators, institutional review boards (IRBs), contract research organizations (CROs), and other interested parties on the use of electronic systems, electronic records, and electronic signatures in clinical investigations of foods, medical products, tobacco products, and new animal drugs. The guidance provides recommendations regarding the requirements in our regulations, pursuant to which FDA considers electronic systems, electronic records, and electronic signatures to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper. This guidance finalizes the draft guidance of the same title issued on March 16, 2023, and supersedes the guidance for industry entitled \"Computerized Systems Used in Clinical Investigations\" issued in May 2007.', 'DATES': 'The announcement of the guidance is published in the Federal Register on October 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22562.pdf?1727786727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-02'}, {'ID': '2024-22580', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is publishing this notice to announce the establishment of the Center for Drug Evaluation and Research (CDER) Quantitative Medicine Center of Excellence (QM CoE). Quantitative medicine (QM) is used to inform premarket product review, post-market product assessment, policy development, and policy implementation within several CDER offices. The QM CoE will act as a coordinating body that drives innovation and facilitates integration of QM methodologies and principles across CDER. To realize this purpose, the QM CoE will introduce new activities and coordinate existing activities in key areas, including multidisciplinary education and exchange, development and implementation of applied science policy, knowledge management, and community engagement.', 'DATES': 'The formation of the QM CoE was announced on March 25, 2024. For more details, please visit https://www.fda.gov/about-fda/center-drug- evaluation-and-research-cder/cder-quantitative-medicine-center- excellence-qm-coe.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22580.pdf?1727786730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-02'}, {'ID': '2024-22572', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that AUGMENTIN XR (amoxicillin; clavulanate potassium) Extended-Release Tablets, 1 gram (gm); equivalent to (EQ) 62.5 milligram (mg) base, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for AUGMENTIN XR (amoxicillin; clavulanate potassium) Extended-Release Tablets, 1 gm; EQ 62.5 mg base, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22572.pdf?1727786728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-02'}, {'ID': '2024-22443', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by October 31, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22443.pdf?1727700332', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-10-01'}, {'ID': '2024-22301', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft revised guidance for industry (GFI) #116 (VICH GL23) entitled \"Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2).\" This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). This draft guidance recommends a Standard Battery of Tests that can be used for the evaluation of the genotoxicity of veterinary drug residues in food.', 'DATES': 'Submit either electronic or written comments on the draft guidance by November 29, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22301.pdf?1727441133', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22309', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of four final device-specific guidance documents for the Safety and Performance Based Pathway--specifically, \"Air Powered Dental Handpieces and Air Motors--Performance Criteria for Safety and Performance Based Pathway,\" \"Dental Ceramics--Performance Criteria for Safety and Performance Based Pathway,\" \"Dental Impression Materials--Performance Criteria for Safety and Performance Based Pathway,\" and \"Dental Cements--Performance Criteria for Safety and Performance Based Pathway.\" The device-specific guidances identified in this notice were developed in accordance with the finalized guidance entitled \"Safety and Performance Based Pathway.\"', 'DATES': 'The announcement of the guidances is published in the Federal Register on September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22309.pdf?1727441134', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22292', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of individuals on its advisory committee regardless of their gender identification, religious affiliation, racial and ethnic identification, or disability status and, therefore, encourages nominations of appropriately qualified candidates from all groups.', 'DATES': 'Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests on an FDA advisory committee or panel may send a letter or email stating that interest to FDA (see ADDRESSES) by November 14, 2024, for vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see ADDRESSES) by November 14, 2024.Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22292.pdf?1727441131', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22147', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Center for Veterinary Medicine's (CVM), Office of Management (OM) and Office of New Animal Drug Evaluation (ONADE) have modified their organizational structures. The new organizational structures were approved by the Secretary of Health and Human Services on July 22, 2024.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22147.pdf?1727363711', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22308', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a document entitled \"Amended Environmental Assessment for Production of AquAdvantage Salmon at the Bay Fortune and Rollo Bay Facilities on Prince Edward Island, Canada.\" This amended environmental assessment (EA) has been prepared by FDA in support of the approved new animal drug application (NADA 141-454) concerning AquAdvantage Salmon (AAS), in response to an order by the U.S. District Court, Northern District of California.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22308.pdf?1727441133', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22332', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Clarification of Radiation Control Regulations for Manufacturers of Diagnostic X-Ray Equipment.\" This guidance provides clarification to industry and FDA staff of the Federal regulations that relate to diagnostic x-ray equipment. These regulations pertain to the recordkeeping, reporting, manufacturing, importing, and installation of an \"electronic product\" as defined in FDA regulations. This guidance supersedes FDA\\'s 1989 guidance entitled \"Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment.\"', 'DATES': 'The announcement of the guidance is published in the Federal Register on September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22332.pdf?1727441137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22291', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22291.pdf?1727441131', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-30'}, {'ID': '2024-22096', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Proposed rule; withdrawal.', 'SUMMARY': 'This document informs the public that the Food and Nutrition Service (FNS) of the U.S. Department of Agriculture (USDA) is withdrawing the proposed rule titled Supplemental Nutrition Assistance Program (SNAP): Disaster Supplemental Nutrition Assistance Program (D- SNAP) that published in the Federal Register on May 10, 2016. This rule would have amended the SNAP regulations to establish procedures for planning, requesting and operating D-SNAP. The Department is withdrawing this proposed rule to maintain the flexibility to adapt D- SNAP to unique disaster situations. The importance of this flexibility became apparent as the Department adjusted traditional D-SNAP operations to accommodate the changing circumstances during the public health emergency. The proposed rule would have prevented the Department from enacting many of the successful responses utilized during the public health emergency to best serve households and State agencies in the aftermath of a disaster. After enacting these critical adaptations to D-SNAP design during the public health emergency, receiving feedback from D-SNAP listening sessions, and reviewing the comments received on the proposed rule, the Department is withdrawing the proposed rule to reduce the burden on State agencies and households responding to disasters.', 'DATES': 'As of September 27, 2024, the proposed rule published on May 10, 2016, at 81 FR 28738-28758, is officially withdrawn.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22096.pdf?1727354714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-27'}, {'ID': '2024-22105', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OGSIVEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 25, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-22105.pdf?1727268335', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-26'}, {'ID': '2024-21904', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by October 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21904.pdf?1727181926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21928', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency), the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (collectively, we) are announcing a public workshop entitled \"Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very Low Birth Weight Infants.\" The purpose of the public workshop is to exchange information with the medical and scientific community about the regulatory and scientific issues associated with use of live biotherapeutic products to prevent necrotizing enterocolitis (NEC) in very low birth weight (VLBW) infants.', 'DATES': 'The public workshop will be held on October 25, 2024, from 9 a.m. to 4 p.m. Eastern Time. Either electronic or written comments on this public workshop must be submitted by November 25, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21928.pdf?1727181929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21847', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMLONTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21847.pdf?1727181917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21930', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FRUZAQLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21930.pdf?1727181930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21963', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZAVZPRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21963.pdf?1727181933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21848', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JESDUVROQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21848.pdf?1727181917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21941', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAYBUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21941.pdf?1727181931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21929', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELUCIREM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21929.pdf?1727181929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-25'}, {'ID': '2024-21841', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': \"The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 12, 2018, for the determination of the regulatory review period for the animal drug BRAVECTO. In accordance with the Court's order in Nissan Chemical Corp., et al. v. FDA, et al., No. 22-01598 (D.D.C), this document revises the SUPPLEMENTARY INFORMATION section of that notice by adjusting the start date of the testing phase for BRAVECTO. This notice supersedes the June 11, 2021, Federal Register document revising the February 12, 2018, notice.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21841.pdf?1727095535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-24'}, {'ID': '2024-21844', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OJJAARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21844.pdf?1727095536', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-24'}, {'ID': '2024-21836', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QUVIVIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21836.pdf?1727095534', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-24'}, {'ID': '2024-21680', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is withdrawing approval of four new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that these NDA holders have repeatedly failed to file required annual reports for the identified NDAs.', 'DATES': 'Approval is withdrawn as of September 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21680.pdf?1726836325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21675', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on postmarketing reporting and recordkeeping of adverse experiences for drug and biological products.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by November 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21675.pdf?1726836324', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21671', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with the Agency's Biosimilars User Fee Program.\", 'DATES': 'Either electronic or written comments on the collection of information must be submitted by November 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21671.pdf?1726836323', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21680', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is withdrawing approval of four new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that these NDA holders have repeatedly failed to file required annual reports for the identified NDAs.', 'DATES': 'Approval is withdrawn as of September 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21680.pdf?1726836325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21672', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21672.pdf?1726836323', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21678', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled \"Advancing Smoking Cessation: FDA and NIH Priorities.\" Jointly convened by FDA and the National Institutes of Health (NIH), this public meeting will address the need for novel smoking cessation products to help individuals of all ages, including underserved and vulnerable populations, stop smoking. The overall goal of the meeting is to stimulate novel product development to reduce rates of smoking and related chronic illnesses. The meeting format will include presentations and panel discussions.', 'DATES': 'The public meeting will be held in person with an option for virtual attendance on October 21, 2024, from 9 a.m. to 4:30 p.m. Eastern Time. Submit requests to make oral presentations at the public meeting by 5 p.m. Eastern Time, October 1, 2024. Either electronic or written comments on this public meeting must be submitted by November 21, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21678.pdf?1726836325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21677', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMDEKO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 22, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 24, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21677.pdf?1726836324', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-23'}, {'ID': '2024-21575', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Chemical Analysis for Biocompatibility Assessment of Medical Devices.\" FDA is issuing this draft guidance to describe recommended methodological approaches for chemical analysis for biocompatibility assessment of medical devices. The biocompatibility of medical devices is evaluated based on the duration of exposure and nature of contact with the body. Chemical characterization is one approach that manufacturers can consider when developing a strategy for the overall biocompatibility assessment of a device. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by November 19, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21575.pdf?1726749950', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-20'}, {'ID': '2024-21231', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Direct final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is issuing a direct final rule amending the Scope section of our regulation that provides for a regulatory hearing before the Agency in order to clarify when such hearings are available. We are revising the list of statutory provisions enumerated in the Scope section of the regulation by adding one statutory reference and removing a different statutory reference. The Agency is issuing these amendments directly as a final rule because we believe they are noncontroversial and FDA anticipates no significant adverse comments.', 'DATES': 'This rule is effective February 3, 2025. Either electronic or written comments on the direct final rule or its companion proposed rule must be submitted by December 4, 2024. If FDA receives no significant adverse comments within the specified comment period, the Agency intends to publish a document confirming the effective date of the final rule in the Federal Register within 30 days after the comment period on this direct final rule ends. If timely significant adverse comments are received, the Agency will publish a document in the Federal Register withdrawing this direct final rule within 30 days after the comment period on this direct final rule ends.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21231.pdf?1726749927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-20'}, {'ID': '2024-21232', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is proposing to amend the Scope section of our regulation that provides for a regulatory hearing before the Agency to clarify when such hearings are available. We are proposing to revise the list of statutory provisions enumerated in the Scope section of the regulation by removing one statutory reference and adding a different statutory reference.', 'DATES': 'Either electronic or written comments on the proposed rule or its companion direct final rule must be submitted by December 4, 2024. If FDA receives any timely significant adverse comments on the direct final rule with which this proposed rule is associated, we will publish a document withdrawing the direct final rule within 30 days after the comment period ends, and we will then proceed to respond to comments under this proposed rule using the usual notice and comment procedures.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21232.pdf?1726749928', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-20'}, {'ID': '2024-21559', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is proposing to revoke the regulations entitled \"Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community.\" FDA is proposing this action because the existing regulations have been superseded in part by the \"United States-European Union Amended Sectoral Annex for Pharmaceutical Good Manufacturing Practices (GMPs)\" that entered into force in 2017 (2017 Amended Pharmaceutical Annex), are outdated, do not reflect current Agency practice, and are unnecessary.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by November 19, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21559.pdf?1726749947', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-20'}, {'ID': '2024-21431', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The Committee will meet in open session to discuss three separate topics. At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held virtually on October 10, 2024, from 8 a.m. to 5:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21431.pdf?1726663555', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-19'}, {'ID': '2024-21435', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by October 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21435.pdf?1726663555', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-19'}, {'ID': '2024-21453', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': '60-Day notice and request for comments.', 'SUMMARY': \"In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection for the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) Health Outcomes and Participant Experience (HOPE) Study. This new information collection will provide the U.S. Department of Agriculture, Food and Nutrition Service (FNS) with current information about the population WIC serves, how well WIC services align with participants' needs, and how WIC influences participants' health outcomes. This information will help policymakers and program administrators address service gaps and reduce potential disparities in health outcomes.\", 'DATES': 'Written comments must be received on or before November 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21453.pdf?1726663558', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-19'}, {'ID': '2024-21436', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed revision of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with labeling requirements for prescription drugs.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by November 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21436.pdf?1726663556', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-19'}, {'ID': '2024-21432', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of nine abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of October 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21432.pdf?1726663555', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-19'}, {'ID': '2024-21433', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the fee rate for using a priority review voucher for fiscal year (FY) 2025. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, authorizes FDA to determine and collect priority review user fees for certain applications for review of human drug or biological products when those applications use a tropical disease, rare pediatric disease, or material threat medical countermeasure (MCM) priority review voucher. These vouchers are awarded to the sponsors of tropical disease, rare pediatric disease, or material threat MCM product applications, respectively, that meet the requirements of the FD&C Act, upon FDA approval of such applications. The amount of the fee for using a priority review voucher is determined each fiscal year, based on the difference between the average cost incurred by FDA to review a human drug application designated as priority review in the previous fiscal year, and the average cost incurred in the review of an application that is not subject to priority review in the previous fiscal year. This notice establishes the FY 2025 priority review fee rate applicable to submission of eligible applications for review of human drug or biological products using a rare pediatric disease, material threat MCM, or tropical disease priority review voucher and outlines the payment procedures for such fees.', 'DATES': 'This rate is effective on October 1, 2024, and will remain in effect through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21433.pdf?1726663556', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-19'}, {'ID': '2024-21241', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on October 29, 2024, from 8 a.m. to 5 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21241.pdf?1726577134', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-18'}, {'ID': '2024-21078', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry, investigators, and other interested parties entitled \"Conducting Clinical Trials With Decentralized Elements.\" This guidance provides recommendations regarding the implementation of decentralized elements in clinical trials for drugs, biological products, and devices. Decentralized elements allow trial-related activities to occur remotely at locations convenient for trial participants (e.g., telehealth visits with investigators or visits with local healthcare providers (HCPs)). FDA\\'s regulatory requirements are the same for trials that include decentralized elements and trials that do not include decentralized elements. To help ensure the appropriate oversight trials with decentralized elements, the integrity of trial data, and the safety of trial participants, this guidance covers the responsibilities of sponsors and investigators. This guidance finalizes the draft guidance entitled \"Decentralized Clinical Trials for Drugs, Biological Products, and Devices\" issued on May 3, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on September 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21078.pdf?1726577115', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-18'}, {'ID': '2024-21241', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on October 29, 2024, from 8 a.m. to 5 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21241.pdf?1726577134', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-18'}, {'ID': '2024-20924', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #227 entitled \"Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies.\" This draft guidance provides recommendations to sponsors submitting CMC data submissions to new animal drug applications. This guidance describes the options for soliciting early input from the Center for Veterinary Medicine (CVM) and the process for submission of components of the CMC technical section.', 'DATES': 'Submit either electronic or written comments on the draft guidance by November 18, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20924.pdf?1726490716', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-17'}, {'ID': '2024-20995', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Considerations for Generating Clinical Evidence From Oncology Multiregional Clinical Development Programs.\" This draft guidance provides recommendations to sponsors who are planning global clinical development programs for drugs intended to treat cancer, on improving the evidence obtained from one or more multiregional clinical trials (MRCTs) intended to support a marketing application. This draft guidance expands on principles described in FDA\\'s existing guidance documents related to this topic, by providing additional recommendations for the planning, design, conduct, and analysis of an oncology MRCT that may facilitate FDA\\'s assessment of applicability of the data to the U.S. population with the cancer being investigated and to U.S. medical practice.', 'DATES': 'Submit either electronic or written comments on the draft guidance by November 18, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20995.pdf?1726490717', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-17'}, {'ID': '2024-21074', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Digital Health Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The Committee will discuss total product lifecycle considerations for Generative Artificial Intelligence (AI)-enabled devices. The meeting will be open to the public. FDA is establishing a docket for public comment on this topic.', 'DATES': 'The meeting will be held on November 20-21, 2024, from 9 a.m. to 6 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-21074.pdf?1726490729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-17'}, {'ID': '2024-20897', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research are announcing support for Electronic Common Technical Document (eCTD) Version 4.0 (v4.0)-based electronic submissions.\", 'DATES': 'Support for eCTDv4.0 electronic submissions begins September 16, 2024. FDA will also continue to support eCTDv3.2.2 electronic submissions. Submit either electronic or written comments at any time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20897.pdf?1726231525', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-16'}, {'ID': '2024-20893', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORSERDU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 17, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20893.pdf?1726231525', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-16'}, {'ID': '2024-20894', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZZAYO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 17, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20894.pdf?1726231525', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-16'}, {'ID': '2024-20873', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on June 21, 2024. The document announced the withdrawal of approval of 20 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of July 22, 2024. The document indicated that FDA was withdrawing approval of the ANDA 076648 for nitrofurantoin (monohydrate/macrocrystals) capsules, 75 milligrams (mg) and 25 mg, held by Aurobindo Pharma USA Inc., 279 Princeton-Hightstown Rd., East Windsor, NJ 08520; and the ANDA 090723 for duloxetine hydrochloride capsules, delayed-release pellets, Equivalent to (EQ) 20 mg base, EQ 30 mg base, and EQ 60 mg base, held by Marksans Pharma, Inc., U.S. Agent for Marksans Pharma Ltd., 150 Motor Pkwy., Suite 401, 4th Floor, Rm. 430, Hauppauge, NY 11788. Before FDA withdrew the approval of these ANDAs, Aurobindo Pharma USA Inc., and Marksans Pharma, Inc., U.S. Agent for Marksans Pharma Ltd., informed FDA that they did not want the approval of the ANDAs withdrawn. Because Aurobindo Pharma USA Inc. and Marksans Pharma, Inc., U.S. Agent for Marksans Pharma Ltd., timely requested that approval of their respective ANDAs not be withdrawn, the approvals are still in effect. This notice corrects these errors.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20873.pdf?1726145142', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-13'}, {'ID': '2024-20889', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': \"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.\", 'DATES': 'The meeting will be held on November 7, 2024, from 9 a.m. to 6 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20889.pdf?1726145145', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-13'}, {'ID': '2024-20891', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is seeking public comments on the \"New Drugs Regulatory Program Modernization: Integrated Assessment of Marketing Applications and Integrated Review Documentation.\" The purpose is to seek public comments/feedback on the Integrated Review documentation generated by the Integrated Assessment of Marketing Applications for new drug products developed as part of the New Drugs Regulatory Program Modernization. The Agency hopes to receive public feedback on how this Integrated Review documentation can continue supporting our stakeholders\\' needs.', 'DATES': 'Submit either electronic or written comments on the notice by December 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20891.pdf?1726145145', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-13'}, {'ID': '2024-20665', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the publication of a draft Strategy Document for public comment outlining specific actions FDA will take during fiscal years 2023-2027 to facilitate the use of innovative manufacturing technologies. As part of the Prescription Drug User Fee Act (PDUFA) Reauthorization Performance Goals and Procedures Fiscal Years 2023-2027 (PDUFA VII), FDA committed to advance the use and implementation of innovative manufacturing. In connection with this effort, on June 8, 2023, FDA participated in a public workshop on the use of innovative manufacturing technologies for products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), including barriers to their adoption. FDA also committed to issuing this draft Strategy Document for public comment. The actions described in the draft Strategy Document are based on lessons learned from FDA's experiences with submissions involving advanced manufacturing technologies as well as feedback from the workshop and other public input.\", 'DATES': 'Either electronic or written comments on the draft Strategy Document must be submitted by November 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20665.pdf?1726058736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-12'}, {'ID': '2024-20556', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that OPZELURA (ruxolitinib), approved September 21, 2021, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20556.pdf?1725972342', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-11'}, {'ID': '2024-20553', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding accredited laboratories. There are no changes to the existing information collection. The approval for this information collection will expire on February 28, 2025.', 'DATES': 'Submit comments on or before November 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20553.pdf?1725972342', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-11'}, {'ID': '2024-20552', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOQUEZNA TRIPLE PAK--new drug application (NDA) 215152 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 12, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 10, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20552.pdf?1725972342', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-11'}, {'ID': '2024-20549', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZTALMY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 12, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 10, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20549.pdf?1725972341', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-11'}, {'ID': '2024-20556', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that OPZELURA (ruxolitinib), approved September 21, 2021, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20556.pdf?1725972342', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-11'}, {'ID': '2024-20238', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding records to be kept by official establishments and retail stores that grind raw beef products. There are no changes to the existing information collection. The approval for this information collection will expire on February 28, 2025.', 'DATES': 'Submit comments on or before November 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20238.pdf?1725626737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-09'}, {'ID': '2024-20246', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PLUVICTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 8, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 10, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20246.pdf?1725626738', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-09'}, {'ID': '2024-20062', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cardiovascular and Renal Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on October 10, 2024, from 8:15 a.m. to 5:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20062.pdf?1725540333', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20150', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STEGLUJAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by November 5, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 5, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20150.pdf?1725540346', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20149', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STEGLATRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 5, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 5, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20149.pdf?1725540346', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20115', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YCANTH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 5, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 5, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20115.pdf?1725540341', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20148', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEGLUROMET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by November 5, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by March 5, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20148.pdf?1725540346', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20064', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collections applicable to the Pharmaceutical Distribution Supply Chain, provided for in Subchapter H of Federal Food, Drug, and Cosmetic Act (FD&C Act).', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by November 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20064.pdf?1725540333', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20052', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20052.pdf?1725540331', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-20069', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle.\" This draft guidance explains the principal concepts that sponsors and other interested parties should consider when choosing to collect and submit patient preference information (PPI). The knowledge gleaned from the use of PPI could be used across the total product life cycle, including for review in investigational device exemption (IDE) applications, premarket approval (PMA) applications, humanitarian device exemption (HDE) applications, De Novo classification requests, or premarket notifications (510(k)s). This draft guidance also discusses FDA\\'s inclusion of PPI in its decision summaries and provides recommendations for the inclusion of such information in device labeling for certain devices. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by December 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-20069.pdf?1725540334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-06'}, {'ID': '2024-19862', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collections related to requirements for drug establishment registration and drug listing, including registrant reporting under the Federal Food, Drug, and Cosmetic Act (FD&C Act) with respect to listed drugs and certain guidances.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by November 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19862.pdf?1725453919', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-05'}, {'ID': '2024-19865', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by October 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19865.pdf?1725453920', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-05'}, {'ID': '2024-19870', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with FDA research in obtaining information from pharmacists and other management at outsourcing facilities and related human prescription drug compounding businesses. The research supports a comprehensive analysis of the outsourcing facility sector that informs ongoing FDA work in this area.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by November 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19870.pdf?1725453921', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-05'}, {'ID': '2024-19883', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Control of Nitrosamine Impurities in Human Drugs.\" This guidance recommends steps manufacturers of active pharmaceutical ingredients (APIs) and drug products should take to detect and prevent unacceptable levels of nitrosamine impurities in pharmaceutical products. The guidance describes two general structural classes of nitrosamine impurities: small-molecule nitrosamine impurities (i.e., nitrosamine impurities that do not share structural similarity to the API), and nitrosamine drug substance-related impurities (NDSRIs), which share structural similarity to the API and are generally unique to each API. The potential root causes of small-molecule nitrosamine impurities and NDSRI formation, detection of nitrosamine impurities, and recommendations for risk assessments, testing, and implementation of controls and other appropriate strategies to prevent or reduce the presence of small-molecule nitrosamine impurities and NDSRIs are provided. This guidance revises the final guidance of the same name issued on February 24, 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on September 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19883.pdf?1725453924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-05'}, {'ID': '2024-19856', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendment.', 'SUMMARY': 'The Food and Drug Administration (FDA) is amending the food additive regulations to update the organism Pichia pastoris which has been renamed as Komagataella pastoris. Additionally, the food additive regulation is being updated to include language to clarify that the yeast is non-viable in the market formulation. This action is being taken to improve the accuracy of the regulations.', 'DATES': 'This rule is effective September 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19856.pdf?1725453918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-05'}, {'ID': '2024-19721', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that FLAGYL (metronidazole) tablets, 250 milligrams (mg) and 500 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to these products as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19721.pdf?1725367515', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-04'}, {'ID': '2024-19712', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for Information.', 'SUMMARY': 'The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA or Agency) are announcing a request for information (RFI) for advancing model-informed drug development (MIDD). The purpose of this request is to obtain feedback on how to increase application of established MIDD approaches in regulatory decision making, to identify how emerging MIDD approaches are being incorporated within drug product development, and to identify opportunities to enhance interactions with FDA when discussing MIDD approaches. We intend to use the information submitted in response to this request to identify and prioritize potential focus areas for future policy or guidance development and enhance engagement with interested parties, including interactions as part of the MIDD Paired Meeting Program and other formal meetings with drug developers.', 'DATES': 'Either electronic or written comments on the notice must be submitted by November 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19712.pdf?1725021935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-03'}, {'ID': '2024-19724', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Roche Molecular Systems, Inc, for the cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the cobas Liat System, that includes the cobas SARS-CoV-2 & Influenza A/B Quality Control Kit. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocation, which includes an explanation of the reasons for revocation, is reprinted at the end of this document.', 'DATES': \"The revocation of the Authorization for the Roche Molecular Systems, Inc.'s for the cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the cobas Liat System, that includes the cobas SARS- CoV-2 & Influenza A/B Quality Control Kit is effective as of July 3, 2024.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19724.pdf?1725021937', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-09-03'}, {'ID': '2024-19574', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19574.pdf?1724935533', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-30'}, {'ID': '2024-19481', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration is issuing a final rule to make conforming changes as required by the Further Consolidated Appropriations Act, 2020 (Appropriations Act), which established a new Federal minimum age of sale for tobacco products. These conforming changes include increasing the minimum age of sale for cigarettes, smokeless tobacco, and covered tobacco products from 18 to 21 years of age; increasing the minimum age for age verification by means of photographic identification for cigarettes, smokeless tobacco, and covered tobacco products from under the age of 27 to under the age of 30; increasing the minimum age of individuals who may be present or permitted to enter facilities that maintain vending machines to sell cigarettes, smokeless tobacco, or covered tobacco products from 18 to 21 years of age; and increasing the minimum age of individuals who may be present or permitted to enter facilities that maintain self-service displays that sell cigarettes or smokeless tobacco from 18 to 21 years of age.', 'DATES': 'This rule is effective September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19481.pdf?1724935519', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-30'}, {'ID': '2024-19413', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers.\" This final guidance document is intended to help manufacturers better understand and use the VMSR Program. This guidance describes and clarifies several aspects of the VMSR Program, including the FDA\\'s approach to determining the eligibility of product codes for the program and the conditions for submitting medical device reports (MDRs) for device malfunctions in summary format under the program.', 'DATES': 'The announcement of the guidance is published in the Federal Register on August 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19413.pdf?1724849122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-29'}, {'ID': '2024-19334', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that LIVMARLI (maralixibat), approved on September 29, 2021, manufactured by Mirum Pharmaceuticals, Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19334.pdf?1724762732', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-28'}, {'ID': '2024-19333', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that FENTANYL CITRATE Injections, equivalent to 2.5 milligram (mg) base/50 milliliter (mL) (EQ 0.05 mg base/mL) and EQ 5 mg base/100 mL (EQ 0.05 mg base/mL), were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for FENTANYL CITRATE Injections, EQ 2.5 mg base/50 mL (EQ 0.05 mg base/mL) and EQ 5 mg base/100 mL (EQ 0.05 mg base/mL), if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19333.pdf?1724762732', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-28'}, {'ID': '2024-19323', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Patient Engagement Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.\", 'DATES': 'The meeting will be held on October 30, 2024, from 10 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19323.pdf?1724762730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-28'}, {'ID': '2024-19372', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice of public meeting.', 'SUMMARY': \"This notice is announcing that the National Advisory Committee on Microbiological Criteria for Foods (NACMCF) will hold a public meeting of the full Committee and Subcommittees from September 24, 2024, to September 26, 2024. The Committee will provide updates on FSIS' Genomics charge and the U.S. Food and Drug Administration's (FDA's) Cronobacter spp. in Powdered Infant Formula charge.\", 'DATES': 'The full Committee will hold an in-person and virtual public meeting on Tuesday, September 24, 2024, from 10:00 a.m. to 12:00 p.m. and on Thursday, September 26, 2024, from 4:00 p.m. to 5:00 p.m. The Subcommittees on Genomics and on Cronobacter spp. in Powdered Infant Formula will hold concurrent Subcommittee meetings on Wednesday, September 25, 2024, from 1:00 p.m. to 5 p.m. The Subcommittee meetings are open to members of the public by virtual attendance only. Attendance to all meetings is free but pre-registration by Wednesday, September 18, 2024, is requested.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19372.pdf?1724762738', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-28'}, {'ID': '2024-19233', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined that DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5% (diltiazem hydrochloride (HCl)), 125 milligrams (mg)/125 milliliters (mL) (1 mg/ mL) and 250 mg/250 mL (1 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for diltiazem HCl, 125 mg/125 mL (1 mg/mL) and 250 mg/250 mL (1 mg/mL), if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19233.pdf?1724676331', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-27'}, {'ID': '2024-18971', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for use of a freeze-dried plasma product, octaplasLG Powder, for emergent treatment of hemorrhage or coagulopathy during an emergency involving agents of military combat (e.g., firearms, projectiles, and explosive devices) when plasma is not available for use or when the use of plasma is not practical.', 'DATES': 'The Authorization is effective as of August 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18971.pdf?1724676313', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-27'}, {'ID': '2024-19058', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of withdrawal.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the withdrawal of two Mammography Quality Standards Act (MQSA) Alternative Standards and the amending of one Alternative Standard due to the updated MQSA regulations.', 'DATES': 'The relevant Alternative Standards will be withdrawn or amended as of September 10, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-19058.pdf?1724417123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-26'}, {'ID': '2024-18997', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" that explained the process that would be used to make product-specific guidances available to the public on FDA\\'s website. The draft guidances identified in this notice were developed using the process described in that guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by October 22, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18997.pdf?1724330737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18947', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on the proposed information collection. This is a revision of an existing information collection to conduct demonstration pilot projects to test the redemption of SNAP benefits through mobile payment technologies.', 'DATES': 'Written comments must be received on or before October 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18947.pdf?1724330728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18945', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice of reestablished matching program.', 'SUMMARY': 'In accordance with the Privacy Act of 1974, as amended, USDA FNS is providing notice of a reestablished computer matching program between FNS and the State agencies that administer the Supplemental Nutrition Assistance Program (SNAP). The matching program allows State agencies access to the Electronic Disqualified Recipient System (eDRS), a national database operated by FNS. The system maintains records of SNAP disqualifications imposed by State agencies on individuals who have been found to have committed an intentional program violation (IPV).', 'DATES': 'The deadline for comments on this notice is September 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18945.pdf?1724330728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18970', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on September 26, 2024, from 8 a.m. to 6:15 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18970.pdf?1724330733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18983', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Electronic Submission Template for Medical Device De Novo Requests.\" FDA is issuing this guidance to introduce submitters of De Novo requests to the Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER) to the current resources and associated content developed and made publicly available to support De Novo electronic submissions to FDA. This guidance is intended to represent one of several steps in meeting FDA\\'s commitment to the development of electronic submission templates to serve as guided submission preparation tools for industry to improve submission consistency and enhance efficiency in the review process.', 'DATES': 'The announcement of the guidance is published in the Federal Register on August 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18983.pdf?1724330734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18898', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) refusing to approve a new drug application (NDA) submitted by Intarcia Therapeutics, Inc., an i2o Therapeutics Business Unit, (Intarcia) for ITCA 650 (exenatide in DUROS device). FDA has determined that the approval criteria in the FD&C Act have not been met because Intarcia has failed to demonstrate that ITCA 650 is safe for its intended conditions of use.', 'DATES': 'This notice is applicable August 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18898.pdf?1724330720', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18973', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the issuance of Emergency Use Authorizations (EUAs) (the Authorizations) for certain medical devices related to Coronavirus Disease 2019 (COVID-19). FDA has issued the Authorizations listed in this document under the Federal Food, Drug, and Cosmetic Act (FD&C Act). These Authorizations contain, among other things, conditions on the emergency use of the authorized products. The Authorization follows the February 4, 2020, determination by the Secretary of Health and Human Services (HHS), as amended on March 15, 2023, that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad and that involves the virus that causes COVID-19, and the subsequent declarations on February 4, 2020, March 2, 2020, and March 24, 2020, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19, personal respiratory protective devices, and medical devices, including alternative products used as medical devices, respectively, subject to the terms of any authorization issued under the FD&C Act. These Authorizations, which include an explanation of the reasons for issuance, are listed in this document, and can be accessed on FDA's website from the links indicated.\", 'DATES': 'These Authorizations are effective on their date of issuance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18973.pdf?1724330733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-23'}, {'ID': '2024-18828', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Predetermined Change Control Plans for Medical Devices.\" A predetermined change control plan (PCCP) is the documentation describing what modifications will be made to a device and how the modifications will be assessed. This draft guidance provides FDA\\'s current thinking on a policy for PCCPs and recommendations on the information to include in a PCCP in a marketing submission for a device. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by November 20, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18828.pdf?1724244338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-22'}, {'ID': '2024-18824', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendment.', 'SUMMARY': 'The Food and Drug Administration (FDA) is amending the food additive regulations to update the production organism Lactobacillus bulgaricus that has been scientifically reclassified to Lactobacillus delbrueckii. This action is being taken to improve the accuracy and clarity of the regulations.', 'DATES': 'This rule is effective August 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18824.pdf?1724244337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-22'}, {'ID': '2024-18617', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the committee). The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The committee will discuss considerations related to the use of pertussis controlled human infection models (CHIMs) in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure and will hear an overview of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) research program in the Center for Biologics Evaluation and Research (CBER). At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held virtually on September 20, 2024, from 8:30 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18617.pdf?1724071530', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-20'}, {'ID': '2024-18615', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that PENNSAID (diclofenac sodium) Topical Solution 2%, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18615.pdf?1724071530', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-20'}, {'ID': '2024-18636', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Product- Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA.\" This guidance provides recommendations to industry on product- specific guidance (PSG) meetings between FDA and a prospective applicant preparing to submit to FDA, or an applicant that has submitted to FDA, an abbreviated new drug application (ANDA) under the Federal Food, Drug and Cosmetic Act (FD&C Act). Specifically, this guidance provides information on requesting and conducting PSG meetings with FDA (i.e., pre-submission PSG teleconferences, post-submission PSG teleconferences, pre-submission PSG meetings, and post-submission PSG meetings), as contemplated in the Generic Drug User Fee Amendments (GDUFA) Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027 (GDUFA III commitment letter). This guidance provides procedures that will promote well-managed PSG meetings and help ensure that such meetings are scheduled and conducted in accordance with the time frames set forth in the GDUFA III commitment letter. This guidance finalizes the draft guidance for industry of the same title issued on February 21, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on August 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18636.pdf?1724071532', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-20'}, {'ID': '2024-18261', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a draft guidance for industry entitled \"Voluntary Sodium Reduction Goals: Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods (Edition 2).\" The draft guidance, when finalized, will describe our views on the next voluntary goals (Phase II (3-year)) for sodium reduction in a variety of identified categories of foods that are commercially processed, packaged, or prepared. These goals are intended to address the excessive intake of sodium in the current population to help reduce the burden of diet-related chronic disease, promote improvements in public health, and advance health equity by supporting a healthier food supply.', 'DATES': 'Submit either electronic or written comments on the draft guidance by November 14, 2024 to ensure that we consider your comment on the draft guidance before we begin work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18261.pdf?1723725931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-16'}, {'ID': '2024-18343', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': \"The Food and Drug Administration, with the Department of the Treasury's concurrence, proposes amending its regulations to require that the Submission Tracking Number for Electronic Nicotine Delivery System tobacco products that are being imported or offered for import be submitted in the Automated Commercial Environment or any other electronic data interchange system authorized by U.S. Customs and Border Protection, at the time of entry.\", 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by October 15, 2024. Submit written comments (including recommendations) on the collection of information under the Paperwork Reduction Act of 1995 by October 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18343.pdf?1723725937', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-16'}, {'ID': '2024-18277', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on FDA's Laboratory Accreditation for Analyses of Foods (LAAF).\", 'DATES': 'Either electronic or written comments on the collection of information must be submitted by October 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18277.pdf?1723639540', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-15'}, {'ID': '2024-18268', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Ryan Stabile for a period of 15 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Stabile was convicted of three felony counts under Federal law: one count of conspiracy and two counts of introduction of misbranded drugs with intent to defraud/mislead. The factual basis supporting Mr. Stabile's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Stabile was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of June 7, 2024 (30 days after receipt of the notice), Mr. Stabile had not responded. Mr. Stabile's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable August 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18268.pdf?1723639538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-15'}, {'ID': '2024-18265', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MIEBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by October 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by February 11, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18265.pdf?1723639538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-15'}, {'ID': '2024-18263', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Science Board to the Food and Drug Administration. The Science Board provides advice to the Commissioner of Food and Drugs and other appropriate officials on specific, complex scientific and technical issues important to FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board provides advice to the Agency on keeping pace with technical and scientific developments, including in regulatory science, input into the Agency's research agenda, and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency-sponsored intramural and extramural scientific research programs. The meeting will be open to the public.\", 'DATES': 'The meeting will be held virtually on October 7, 2024, from 9 a.m. to 2 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18263.pdf?1723639538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-15'}, {'ID': '2024-18269', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for ENTEREG (alvimopan) Capsules, 12 milligrams (mg), held by Cubist Pharmaceuticals LLC, 126 East Lincoln Ave., Rahway, NJ 07065 (Cubist). Cubist notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.', 'DATES': 'Approval is withdrawn as of September 16, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18269.pdf?1723639539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-15'}, {'ID': '2024-18045', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is inviting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of eight drug substances. These comments will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drug substances. This notice requesting comments is required by the Controlled Substances Act (CSA).', 'DATES': 'Either electronic or written comments must be submitted by August 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18045.pdf?1723553117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-14'}, {'ID': '2024-18004', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Peripheral and Central Nervous System Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2026, expiration date.', 'DATES': 'Authority for the Peripheral and Central Nervous System Drugs Advisory Committee will expire on June 4, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-18004.pdf?1723466733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-13'}, {'ID': '2024-17924', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting, entitled \"Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub.\" The purpose of the public meeting is to discuss the establishment of a Rare Disease Innovation Hub, which will enhance collaboration and cooperation across the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), as well as other centers and offices across FDA, to advance rare disease therapies. In particular, this meeting will be an opportunity for those in the rare disease community, including patients and caregiver groups, industry organizations, and scientific/academic organizations, to provide input on the priorities of the Rare Disease Innovation Hub and how the Hub can best engage with members of the rare disease community. The public meeting will be facilitated by the Reagan-Udall Foundation for the FDA.', 'DATES': 'The public meeting will be held on October 16, 2024, from 10 a.m. to 1 p.m. Eastern Time. Either electronic or written comments on this public meeting must be submitted by 11:59 p.m. Eastern Time on October 31, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17924.pdf?1723207541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-12'}, {'ID': '2024-17926', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Gastrointestinal Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on September 13, 2024, from 8:30 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17926.pdf?1723207541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-12'}, {'ID': '2024-17793', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; withdrawal.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the withdrawal of a notice that was published in the Federal Register of August 2, 2024.', 'DATES': 'The notice is withdrawn on August 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17793.pdf?1723207518', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-12'}, {'ID': '2024-17791', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the following public meeting entitled \"Development of an Enhanced Systematic Process for FDA\\'s Post-Market Assessment of Chemicals in Food.\" This public meeting will assist in developing the post-market chemicals assessment program we will establish under the new FDA Human Foods Program. The purpose of the public meeting is to hear from interested parties about approaches to systematic post-market assessment of chemicals in food.', 'DATES': 'The public meeting will be held on September 25, 2024, from 12:30 p.m. to 4:30 p.m. Eastern Time. FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2024-N-3609. The docket will close on December 6, 2024. Submit electronic or written comments on this public meeting by December 6, 2024. See \"Participating in the Public Meeting\" in the SUPPLEMENTARY INFORMATION section of this document for registration and other information regarding meeting participation.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17791.pdf?1723207517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-12'}, {'ID': '2024-17752', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee (the Committees). The general function of the Committees is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on November 19, 2024, from 8:30 a.m. to 4:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17752.pdf?1723121153', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-09'}, {'ID': '2024-17661', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17661.pdf?1723121133', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-09'}, {'ID': '2024-17771', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases.\" This guidance is intended to assist sponsors in identifying an optimized dosage(s) for human prescription drugs or biological products for the treatment of oncologic diseases during clinical development prior to submitting an application for approval for a new indication and usage. This guidance does not address selection of the starting dosage for first-in-human trials. In addition, this guidance does not address dosage optimization for radiopharmaceuticals, cellular and gene therapy products, oncolytics, microbiota, or cancer vaccines, nor does it specifically address pediatric drug development. However, some of the principles outlined may be applicable to these therapeutic modalities or to dosage optimization for pediatric patients. This guidance finalizes the draft guidance of the same title \"Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases\" issued on January 23, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on August 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17771.pdf?1723121158', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-09'}, {'ID': '2024-17733', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Bacillus Calmette-Gu[eacute]rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drug and Biological Products for Treatment.\" The purpose of this guidance is to assist sponsors in the development of drug and biological products for the treatment of patients with bacillus Calmette-Gu[eacute]rin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC). This draft guidance reflects proposed revisions to the final guidance entitled \"BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment,\" published in February 2018, and incorporates changes based on review experience as well as the evolving landscape of drug development in bladder cancer, as noted by external experts.', 'DATES': 'Submit either electronic or written comments on the draft guidance by October 8, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17733.pdf?1723121148', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-09'}, {'ID': '2024-17778', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of draft guidance for industry #294 entitled \"Animal Food Ingredient Consultation (AFIC).\" This draft guidance describes FDA\\'s interim AFIC process and explains one way FDA intends to work with firms that are developing animal food ingredients after the Memorandum of Understanding (MOU) with the Association of American Feed Control Officials (AAFCO) expires on October 1, 2024, and while FDA evaluates the animal Food Additive Petition and generally recognized as safe (GRAS) Notification programs. The new AFIC process will provide an additional way for engagement with FDA regarding ingredients for which firms may otherwise have used the AAFCO ingredient definition process. AFIC will help FDA identify any potential safety concerns associated with such ingredients. The AFIC process will also allow for public awareness of and input on such ingredients. In addition, this draft guidance describes FDA\\'s enforcement policy for certain ingredients assessed using the AFIC process.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 9, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17778.pdf?1723121159', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-09'}, {'ID': '2024-17779', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, we, or Agency) is soliciting comments from the public regarding the Food Additive Petition and Generally Recognized as Safe (GRAS) Notification programs to determine if changes are needed to promote their efficiency. Specific questions and information requests are included in this notice to help guide input from stakeholders and other members of the public.', 'DATES': 'Submit either electronic or written comments on the notice by December 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17779.pdf?1723121159', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-09'}, {'ID': '2024-17511', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZLIDHIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by October 7, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by February 4, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17511.pdf?1723034759', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17648', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XOFLUZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by October 7, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by February 4, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17648.pdf?1723034814', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17646', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with a proposed study entitled \"Healthcare Provider Survey of Topics Related to Prescription Drug Promotion.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by October 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17646.pdf?1723034814', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17510', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VANFLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by October 7, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by February 4, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17510.pdf?1723034746', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17643', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALZENNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by October 7, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by February 4, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17643.pdf?1723034812', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17515', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of two abbreviated new drug applications (ANDAs) and is announcing an opportunity for the ANDA holder to request a hearing on this proposal. The basis for the proposal is that the ANDA holder has repeatedly failed to file required annual reports for those ANDAs.\", 'DATES': 'The ANDA holder may submit a request for a hearing by September 9, 2024. Submit all data, information, and analyses upon which the request for a hearing relies October 7, 2024. Submit electronic or written comments by October 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17515.pdf?1723034760', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17639', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INPEFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by October 7, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by February 4, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17639.pdf?1723034810', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17641', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by September 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17641.pdf?1723034811', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17642', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Antimicrobial Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on September 9, 2024, from 9 a.m. to 4 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17642.pdf?1723034811', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17640', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is announcing the Fiscal Year 2025 CDER Office of Pharmaceutical Quality (OPQ) Experiential Learning Site Visit Program (ELSVP). The purpose of this document is to invite pharmaceutical companies interested in participating in this program to submit a site visit proposal to CDER's OPQ.\", 'DATES': 'Starting October 1, 2024, FDA will accept requests to participate in the ELSVP program.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17640.pdf?1723034811', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17649', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17649.pdf?1723034815', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17518', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the renewal of the Blood Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Blood Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 13, 2026, expiration date.', 'DATES': 'Authority for the Blood Products Advisory Committee will expire on May 13, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17518.pdf?1723034761', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17645', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; reopening the comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is reopening the comment period for the proposed administrative order (proposed order) entitled \"Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use\", announced in the Federal Register of June 14, 2024. We are taking this action due to technical difficulties with the OTC Monographs@FDA portal. Because comments cannot be submitted to the OTC Monographs@FDA portal at this time, submit comments on proposed order (OTC000035) to the Federal eRulemaking portal (Docket No. FDA- 2024-N-2422).', 'DATES': 'FDA is reopening the comment period on proposed order (OTC000035) announced in the Federal Register of June 14, 2024 (89 FR 50593). Electronic comments or written comments must be submitted by September 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17645.pdf?1723034813', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-17650', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that CIPRO (ciprofloxacin hydrochloride (HCl)) tablet, equivalent to (EQ) 100 milligrams (mg) base, was withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve abbreviated new drug applications (ANDAs) for ciprofloxacin HCl tablet, EQ 100 mg base.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17650.pdf?1723034815', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-08'}, {'ID': '2024-16365', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled \"Enhancing Diversity in Therapeutics Development for Pediatric Patients.\" The aim of the public workshop is to explore strategies to increase the enrollment of historically underrepresented populations in pediatric clinical trials and to help improve the strength and generalizability of the evidence for the intended use population.', 'DATES': 'The public workshop will be held on September 6, 2024, from 9 a.m. to 5 p.m. Eastern Time. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16365.pdf?1722948312', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-07'}, {'ID': '2024-16963', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Proposed rule and Proposed Determination.', 'SUMMARY': 'FSIS is announcing its proposed determination that raw chicken carcasses, chicken parts, comminuted chicken, and comminuted turkey products contaminated with certain Salmonella levels and serotypes are adulterated within the meaning of the Poultry Products Inspection Act (PPIA). The proposed determination would establish final product standards based on these Salmonella levels and serotypes and would prevent raw chicken carcasses, chicken parts, comminuted chicken, and comminuted turkey products that contain Salmonella at the levels and serotypes that would render them adulterated from entering commerce. FSIS is also proposing to revise the regulations that require that all poultry slaughter establishments develop, implement, and maintain written procedures to prevent contamination by enteric pathogens throughout the entire slaughter and dressing operation to clarify that these procedures must include a microbial monitoring program (MMP) that incorporates statistical process control (SPC) monitoring methods, to require sampling at rehang instead of pre-chill, and to require that all establishments conduct paired sampling at rehang and post-chill.', 'DATES': 'Comments on this proposal must be received on or before October 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16963.pdf?1722948312', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-07'}, {'ID': '2024-17341', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a new information collection request in which FNS seeks a description of Commodity Supplemental Food Program (CSFP) participant characteristics and program operations. CSFP provides free groceries to approximately 700,000 low-income seniors each month and is administered by 60 State agencies, approximately 250 local agencies, and approximately 9,000 distribution sites.', 'DATES': 'Written comments must be received on or before October 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17341.pdf?1722861930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-06'}, {'ID': '2024-17248', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Anesthetic and Analgesic Drug Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Anesthetic and Analgesic Drug Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 1, 2026, expiration date.', 'DATES': 'Authority for the Anesthetic and Analgesic Drug Products Advisory Committee will expire on May 1, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17248.pdf?1722602734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-05'}, {'ID': '2024-17243', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Drug Safety and Risk Management Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Drug Safety and Risk Management Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 31, 2026, expiration date.', 'DATES': 'Authority for the Drug Safety and Risk Management Advisory Committee will expire on May 31, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17243.pdf?1722602733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-05'}, {'ID': '2024-17102', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish a notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled \"Risk/Safety Considerations and Motivations for Purchase and Use of Kratom and Psychedelics Alone and in Combination With Other Substances.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by October 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17102.pdf?1722516337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-02'}, {'ID': '2024-17103', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the final guidance for industry entitled \"M12 Drug Interaction Studies\" and the supplemental document entitled \"M12 Drug Interaction Studies: Questions and Answers.\" The guidance and supplemental questions and answers document were prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance provides general recommendations on evaluating the enzyme and transporter-mediated pharmacokinetic drug-drug interaction potential for investigational drugs. The supplemental questions and answers document provides clarity to some concepts related to evaluation of drug interactions covered in the guidance. The guidance is intended to harmonize the regional recommendations for designing, conducting, and interpreting in vitro and clinical evaluations of drug-drug interactions while developing investigational drugs. The guidance replaces the draft guidance \"M12 Drug Interaction Studies\" issued on August 29, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on August 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17103.pdf?1722516337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-02'}, {'ID': '2024-17089', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2026, expiration date.', 'DATES': 'Authority for the Psychopharmacologic Drugs Advisory Committee will expire on June 4, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-17089.pdf?1722516334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-08-02'}, {'ID': '2024-16830', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on generic clearance for quantitative testing for the development of FDA communications, which collects individual generic quantitative information (e.g., surveys, experimental studies) to test communications or educational messages on FDA-regulated food and cosmetic products, dietary supplements, and animal food and feed while they are being developed or are in review.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16830.pdf?1722343528', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16832', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on a collection of information used to conduct a voluntary consumer survey entitled, \"FDA Food Safety and Nutrition Survey.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16832.pdf?1722343529', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16831', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by August 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16831.pdf?1722343529', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16877', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the fiscal year (FY) 2025 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).', 'DATES': 'These fees apply to the period from October 1, 2024, and will remain in effect through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16877.pdf?1722343535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16883', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2025. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2025, which apply from October 1, 2024, through September 30, 2025, and provides information on how the fees for FY 2025 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16883.pdf?1722343537', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16884', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for biosimilar user fees for fiscal year (FY) 2025. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological product approved in a biosimilar biological product application. BsUFA III directs FDA to establish, before the beginning of each fiscal year, the amount of initial and annual biosimilar biological product development (BPD) fees, the reactivation fee, and the biosimilar biological product application and program fees for such year. These fees apply to the period from October 1, 2024, through September 30, 2025.', 'DATES': \"(1) no later than 7 calendar days after FDA grants the sponsor's request for a BPD meeting for that product or (2) upon the date of submission by the sponsor of an IND describing an investigation that FDA determines is intended to support a biosimilar biological product application for that product. The sponsor will be assessed an annual BPD fee beginning in the next fiscal year after payment of the reactivation fee.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16884.pdf?1722343537', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16896', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2025 rates for GDUFA III fees. These fees are effective on October 1, 2024, and will remain in effect through September 30, 2025.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16896.pdf?1722343539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16878', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the over-the-counter (OTC) monograph order request (OMOR) fee rates under the OTC monograph drug user fee program (OMUFA) for fiscal year (FY) 2025. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to assess and collect user fees from qualifying manufacturers of OTC monograph drugs and submitters of OMORs. This notice publishes the OMOR fee rates under OMUFA for FY 2025. FDA plans to publish the FY 2025 OMUFA facility fee rates, i.e., monograph drug facility (MDF) and contract manufacturing organization (CMO) facility fee rates, in a subsequent Federal Register notice (and anticipates its issuance will generally align with the timing of OMUFA facility fee rate publication for prior fiscal years).', 'DATES': 'These OTC OMORs fees are effective on October 1, 2024, and will remain in effect through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16878.pdf?1722343536', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16894', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the fee rates and payment procedures for fiscal year (FY) 2025 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2025.', 'DATES': 'The application fee rates apply to applications submitted on or after October 1, 2024, and will remain in effect through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16894.pdf?1722343539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16885', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or the Agency) is announcing the fee rates and payment procedures for fiscal year (FY) 2025 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (JINAD's), and for certain submissions related to JINAD files. This notice establishes the fee rates for FY 2025.\", 'DATES': 'The application fee rates are effective for all abbreviated applications for a generic new animal drug submitted on or after October 1, 2024, and will remain in effect through September 30, 2025. The fee rates for requests to establish a JINAD file, and for certain submissions to JINAD files established prior to October 1, 2023, are effective on October 1, 2024, and will remain in effect through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16885.pdf?1722343537', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16876', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the fiscal year (FY) 2025 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2025 rates for the small business establishment fee ($6,488), the non-small business establishment fee ($21,534), and the reinspection fee ($19,465) for outsourcing facilities; provides information on how the fees for FY 2025 were determined; and describes the payment procedures outsourcing facilities should follow.', 'DATES': 'These fee rates are effective October 1, 2024, and will remain in effect through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16876.pdf?1722343535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16875', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for prescription drug user fees for fiscal year (FY) 2025. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Prescription Drug User Fee Amendments of 2022 (PDUFA VII), authorizes FDA to collect application fees for certain applications for the review of human drug and biological products and prescription drug program fees for certain approved products. This notice establishes the fee rates for FY 2025.', 'DATES': 'These fees apply to the period from October 1, 2024, through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16875.pdf?1722343535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16880', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2025 annual fee rate for recognized accreditation bodies and accredited certification bodies, and the initial and renewal fee rate for accreditation bodies applying to be recognized in the third-party certification program that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). We are also announcing the fee rate for certification bodies that are applying to be directly accredited by FDA.', 'DATES': 'The fees apply to the period from October 1, 2024, through September 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16880.pdf?1722343536', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16891', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the fiscal year (FY) 2025 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2024, and will remain in effect through September 30, 2025.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16891.pdf?1722343538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-31'}, {'ID': '2024-16667', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmacy Compounding Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 25, 2026, expiration date.', 'DATES': 'Authority for the Pharmacy Compounding Advisory Committee will expire on April 25, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16667.pdf?1722257121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-30'}, {'ID': '2024-16617', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by August 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16617.pdf?1721997930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-29'}, {'ID': '2024-16629', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2026, expiration date.', 'DATES': 'Authority for the Pulmonary-Allergy Drugs Advisory Committee will expire on May 30, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16629.pdf?1721997933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-29'}, {'ID': '2024-16627', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of August 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16627.pdf?1721997933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-29'}, {'ID': '2024-16618', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC). The general function of the committee is to provide advice and recommendations to the FDA on pediatric regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held virtually on September 18, 2024, from 10 a.m. to 4 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16618.pdf?1721997931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-29'}, {'ID': '2024-16616', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by August 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16616.pdf?1721997930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-29'}, {'ID': '2024-16405', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for information and comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to obtain information and comments that will assist the Agency in assessing how best to advance the development of new biosimilar biological products (biosimilars or biosimilar products), as part of the Biosimilar User Fee Amendments of 2022 (BsUFA III). As FDA continues to advance the development of biosimilars, we are seeking input from industry on whether biosimilar product development would be best served by focusing on product class-specific guidance documents that address common development issues that apply to a broad class of products, or by developing product-specific guidance documents, similar to the approach taken in the Generic Drug User Fee Amendments (GDUFA) program.', 'DATES': 'Submit either electronic or written comments, data, or information by October 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16405.pdf?1721825138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16345', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Mesa Biotech Inc., (a legal entity of Thermo Fisher Scientific), for the Accula SARS-CoV-2 Test. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocation, which includes an explanation of the reasons for revocation, is reprinted at the end of this document.', 'DATES': \"The revocation of the Authorization for the Mesa Biotech Inc.'s Accula SARS-CoV-2 Test is effective as of May 22, 2024.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16345.pdf?1721825129', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16338', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products.\" FDA is issuing this guidance as part of its Real-World Evidence (RWE) program and to satisfy, in part, the mandate under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to issue guidance about the use of RWE in regulatory decision making. This guidance is intended to provide sponsors and other interested parties with considerations when proposing to use electronic health records (EHRs) or medical claims data in clinical studies to support a regulatory decision for effectiveness or safety. This guidance finalizes the draft guidance of the same title issued on September 30, 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on July 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16338.pdf?1721825128', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16358', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the issuance of Emergency Use Authorizations (EUAs) (the Authorizations) for certain medical devices related to Coronavirus Disease 2019 (COVID-19). FDA has issued the Authorizations listed in this document under the Federal Food, Drug, and Cosmetic Act (FD&C Act). These Authorizations contain, among other things, conditions on the emergency use of the authorized products. The Authorization follows the February 4, 2020, determination by the Secretary of Health and Human Services (HHS), as amended on March 15, 2023, that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad and that involves the virus that causes COVID-19, and the subsequent declarations on February 4, 2020, March 2, 2020, and March 24, 2020, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19, personal respiratory protective devices, and medical devices, including alternative products used as medical devices, respectively, subject to the terms of any authorization issued under the FD&C Act. These Authorizations, which include an explanation of the reasons for issuance, are listed in this document, and can be accessed on FDA's website from the links indicated.\", 'DATES': 'These Authorizations are effective on their date of issuance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16358.pdf?1721825130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16403', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Providing Over-the-Counter Monograph Submissions in Electronic Format.\" This guidance is intended to assist submitters by describing the electronic over-the-counter (OTC) monograph submissions requirement in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and providing recommendations and other information on how to send such OTC monograph submissions to FDA in electronic format. This guidance finalizes the draft guidance of the same title issued on September 28, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on July 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16403.pdf?1721825137', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16408', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry (GFI) #100 (VICH GL 18(R2)) entitled \"Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2).\" This guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). The objective of this guidance is to recommend acceptable amounts for residual solvents in pharmaceuticals for the safety of the target animal as well as for the safety of residues in products derived from treated food- producing animals. This revision updates the listings and classification of solvents.', 'DATES': 'The announcement of the guidance is published in the Federal Register on July 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16408.pdf?1721825138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16356', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for information and comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is establishing a public docket to collect information and comments on evaluating and mitigating the immunogenicity risk of host cell proteins (HCPs). For the purpose of this request, FDA is specifically interested in comments on suitable methods to detect, identify, and quantify HCPs, on achievable residual amounts of HCPs for recombinant peptide products, and on the use of in vitro, in silico immunogenicity assessment (IVISIA) of HCPs in a recombinant peptide (rPeptide) product. For the purpose of this request, a \"follow-on\" peptide product refers to the applications currently evaluated through the 505(b)(2) pathway. Although follow-on recombinant peptide products can rely on FDA\\'s findings of safety and effectiveness for a listed drug that is a peptide product, differences in recombinant expression systems used during the peptide production could result in quality attribute differences, including in the HCP profile, which in turn, could contribute to differences in immunogenicity risks between a follow-on recombinant peptide product and the listed drug. The public comments collected will help FDA develop recommendations on how HCP control and characterization can support comparative immunogenicity risk assessment between a recombinant follow-on peptide and the listed product.', 'DATES': 'Although you can submit comments and information at any time, to ensure that the Agency considers your comment in our development of recommendations, submit either electronic or written information and comments by September 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16356.pdf?1721825130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-25'}, {'ID': '2024-16100', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the procedure by which both domestic and foreign bottled water manufacturers that sell bottled water in the United States maintain records of microbiological testing and corrective measures, in addition to existing recordkeeping requirements.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16100.pdf?1721652319', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-23'}, {'ID': '2024-16089', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice announcing a request for comments that appeared in the Federal Register of June 26, 2024. In the notice, FDA requested comments on its \"Information Technology (IT) Strategy\" and \"Customer Experience (CX) Strategy.\" The Agency is taking this action to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the notice published June 26, 2024 (89 FR 53425). Submit either electronic or written comments by August 30, 2024, to ensure that the Agency considers your comment on this request for comments before finalizing the strategies.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16089.pdf?1721652318', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-23'}, {'ID': '2024-16128', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers.\" This draft guidance provides answers to commonly asked questions from applicants and other interested parties regarding postapproval manufacturing changes made to biosimilar and interchangeable biosimilar products licensed under the Public Health Service Act (PHS Act).', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 23, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16128.pdf?1721652324', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-23'}, {'ID': '2024-16096', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled \"Electronic Records: Electronic Signatures\" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16096.pdf?1721652319', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-23'}, {'ID': '2024-16101', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by August 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16101.pdf?1721652319', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-23'}, {'ID': '2024-16046', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for immediate implementation entitled \"Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma; Guidance for Industry.\" The purpose of this guidance is to provide FDA\\'s recommendations to blood establishments for the submission of a Biologics License Application (BLA) for the manufacture of COVID-19 convalescent plasma intended for transfusion in patients with immunosuppressive disease or receiving immunosuppressive treatment in either the outpatient or inpatient setting. The guidance also provides FDA\\'s recommendations for investigational new drug applications (INDs) for investigational COVID- 19 convalescent plasma for transfusion.', 'DATES': 'The announcement of the guidance is published in the Federal Register on July 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16046.pdf?1721393124', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-22'}, {'ID': '2024-15998', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15998.pdf?1721393117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-22'}, {'ID': '2024-16013', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding petitions for rulemaking. There are no changes to the existing information collection. The approval for this information collection will expire on December 31, 2024.', 'DATES': 'Submit comments on or before September 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-16013.pdf?1721393119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-22'}, {'ID': '2024-15988', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the collections of information related to Diversity Action Plans for Clinical Studies.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15988.pdf?1721393115', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-22'}, {'ID': '2024-15942', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment.\" The draft guidance was prepared by the Division of Gastroenterology in the Center for Drug Evaluation and Research at FDA to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease. The draft guidance provides FDA\\'s recommendations about the necessary attributes of clinical studies for drugs being developed for the treatment of pediatric ulcerative colitis or pediatric Crohn\\'s disease, including study population, study design, efficacy considerations, and safety assessments.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 17, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15942.pdf?1721306729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-19'}, {'ID': '2024-15812', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies.\" This guidance describes FDA\\'s recommendations regarding clinical pharmacology considerations for conducting human radiolabeled mass balance studies, including deciding whether and when to conduct the study, designing the study, and reporting results.', 'DATES': 'The announcement of the guidance is published in the Federal Register on July 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15812.pdf?1721220334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-18'}, {'ID': '2024-15695', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application (Supplement-5) for VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc), approved June 21, 2024, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15695.pdf?1721133934', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-17'}, {'ID': '2024-15696', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the draft guidance for industry \"Platform Technology Designation Program for Drug Development\" that appeared in the Federal Register of May 29, 2024. In the notice of availability for the draft guidance, FDA requested comments on the proposed collection of information. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the draft guidance for industry \"Platform Technology Designation Program for Drug Development\" published May 29, 2024, 89 FR 46406. Either electronic or written comments must be submitted by August 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15696.pdf?1721133934', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-17'}, {'ID': '2024-15511', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a revision of a currently approved collection (OMB Number 0584-0646) for the 2027 Farm to School Census.', 'DATES': 'Written comments must be received on or before September 16, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15511.pdf?1721047522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-16'}, {'ID': '2024-15569', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on substantial equivalence reports for tobacco products.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 16, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15569.pdf?1721047530', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-16'}, {'ID': '2024-15570', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on premarket tobacco product applications and recordkeeping requirements.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 16, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15570.pdf?1721047530', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-16'}, {'ID': '2024-15351', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA or the Agency) Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products (OTP) is announcing the Cellular and Gene Therapies Interactive Site Tours Program (the Interactive Site Tours Program). This program is intended to give CBER regulatory project managers and/or reviewers an opportunity to tour biotechnology manufacturing facilities developing cellular and gene therapy products, and to exchange regulatory experiences with their industry counterparts. With this program, CBER intends to enhance review efficiency and quality by providing CBER staff with a better understanding of the biotechnology manufacturing industry and its operations. The purpose of this notice is to invite companies developing cellular and gene therapy products interested in participating in this program to contact OTP for more information.\", 'DATES': 'Companies may send proposed agendas to the Agency by August 14, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15351.pdf?1720788324', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-15'}, {'ID': '2024-15371', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for EXKIVITY (mobocertinib succinate) capsule, equivalent to (EQ) 40 milligrams (mg) base, held by Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave., Lexington, MA 02421 (Takeda). Takeda has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.', 'DATES': 'Approval is withdrawn as of July 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15371.pdf?1720788325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-15'}, {'ID': '2024-15337', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of two draft guidances entitled \"Dental Composite Resin Devices--Premarket Notification (510(k)) Submissions\" and \"Dental Curing Lights--Premarket Notification (510(k)) Submissions.\" These draft guidance documents provide recommendations for device description, performance testing, and labeling to include in 510(k) submissions for dental composite resin devices and dental curing lights. When final, these guidances will supersede the guidances \"Dental Composite Resin Devices--Premarket Notification [510(k)] Submissions\" dated October 26, 2005 and \"Dental Curing Lights-- Premarket Notification [510(k)] Submissions\" dated March 27, 2006. The recommendations in these draft guidances are intended to promote consistency and facilitate efficient review of these submissions. These draft guidances are not final nor are they for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 10, 2024 to ensure that the Agency considers your comment on the draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15337.pdf?1720701933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-12'}, {'ID': '2024-15239', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPEVIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by September 9, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 7, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15239.pdf?1720615534', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-11'}, {'ID': '2024-15130', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Clinical Considerations for Studies of Devices Intended To Treat Opioid Use Disorder.\" Design of clinical studies for devices intended to treat opioid use disorder (OUD) is challenging. To help spur innovative options to combat the opioid overdose crisis and treat OUD, this guidance provides recommendations on the design of pivotal clinical studies for devices intended to treat OUD (OUD device studies). Through these recommendations, FDA intends to aid sponsors in developing OUD device studies that provide scientific evidence used to determine whether there is a reasonable assurance of safety and effectiveness for treating OUD.', 'DATES': 'The announcement of the guidance is published in the Federal Register on July 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15130.pdf?1720615523', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-11'}, {'ID': '2024-15237', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing notice that an applicant for a biologics license application (BLA) for a biosimilar or interchangeable biosimilar product submitted under the Public Health Service Act (PHS Act) (a \"subsection (k) applicant\") notified FDA that an action for patent infringement was filed in connection with the applicant\\'s BLA. Under the PHS Act, within 30 days after the subsection (k) applicant is served with a complaint in an action for patent infringement described under the PHS Act, the subsection (k) applicant shall provide the Secretary of Health and Human Services (HHS) with notice and copy of such complaint. FDA is required to publish notice of the complaint in the Federal Register.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15237.pdf?1720615534', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-11'}, {'ID': '2024-15136', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the termination of the Allergenic Products Advisory Committee, Center for Biologics Evaluation and Research. This document announces the reasons for termination and removes the Allergenic Products Advisory Committee from the Agency's list of standing advisory committees.\", 'DATES': 'This rule is effective July 10, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15136.pdf?1720529131', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-10'}, {'ID': '2024-15125', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop titled \"Artificial Intelligence (AI) in Drug & Biological Product Development.\" Convened and supported by a cooperative agreement between FDA and the Clinical Trials Transformation Initiative (CTTI), the purpose of the public workshop is to bring drug developers and AI experts together to discuss guiding principles for the responsible use of AI in the development of safe and effective drugs and biological products. The workshop format will include presentations and panel discussions.', 'DATES': 'The public workshop will be held virtually and in-person on August 6, 2024, from 10 a.m. to 5:30 p.m. Eastern Time. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15125.pdf?1720529130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-10'}, {'ID': '2024-15127', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Genetic Metabolic Diseases Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on August 2, 2024, from 9 a.m. to 6 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15127.pdf?1720529131', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-10'}, {'ID': '2024-15173', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'This notice announces the annual adjustments to the national average payment rates for meals and snacks served in child care centers, outside-school-hours care centers, at-risk afterschool care centers, and adult day care centers; the food service payment rates for meals and snacks served in day care homes; and the administrative reimbursement rates for sponsoring organizations of day care homes, to reflect changes in the Consumer Price Index. Further adjustments are made to these rates to reflect the higher costs of providing meals in Alaska, Guam, Hawaii, Puerto Rico, and Virgin Islands. The adjustments contained in this notice are made on an annual basis each July, as required by the laws and regulations governing the Child and Adult Care Food Program.', 'DATES': 'These rates are in effect from July 1, 2024 through June 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15173.pdf?1720529138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-10'}, {'ID': '2024-15175', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'This Notice announces the annual adjustments to the national average payments, the amount of money the Federal Government provides States for lunches, afterschool snacks, and breakfasts served to children participating in the National School Lunch and School Breakfast Programs; to the maximum reimbursement rates, the maximum per lunch rate from Federal funds that a State can provide a school food authority for lunches served to children participating in the National School Lunch Program; and to the rate of reimbursement for a half-pint of milk served to non-needy children in a school or institution that participates in the Special Milk Program for Children. The annual payments and rates adjustments for the National School Lunch and School Breakfast Programs reflect changes in the Food Away From Home series of the Consumer Price Index for All Urban Consumers. The annual rate adjustment for the Special Milk Program reflects changes in the Producer Price Index for Fluid Milk Products. Further adjustments are made to these rates to reflect higher costs of providing meals in Alaska, Guam, Hawaii, Puerto Rico, and Virgin Islands. The payments and rates are prescribed on an annual basis each July.', 'DATES': 'These rates are in effect from July 1, 2024, through June 30, 2025.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15175.pdf?1720529138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-10'}, {'ID': '2024-14995', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with reclassification of medical devices.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by September 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14995.pdf?1720442728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-09'}, {'ID': '2024-15031', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'This notice announces the national average value of donated foods or, where applicable, cash in lieu of donated foods, to be provided in school year 2025 (July 1, 2024 through June 30, 2025) for each lunch served by schools participating in the National School Lunch Program (NSLP), and for each lunch and supper served by institutions participating in the Child and Adult Care Food Program (CACFP).', 'DATES': 'Implementation date: July 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15031.pdf?1720442733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-09'}, {'ID': '2024-15008', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for applications.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency), in collaboration with the Clinical Trials Transformation Initiative (CTTI), is requesting applications from patient advocates interested in participating on the Patient Engagement Collaborative (PEC). The PEC is an ongoing, collaborative forum coordinated through the FDA's Patient Affairs Staff, Office of Clinical Policy and Programs (OCPP), Office of the Commissioner at FDA, and is hosted by CTTI. Through the PEC, the patient community and FDA staff are able to discuss an array of topics related to increasing meaningful patient engagement with diverse populations in medical product development and regulatory discussions at FDA. The activities of the PEC may include, but are not limited to, providing diverse perspectives on topics such as systematic patient engagement, transparency, and communication; providing considerations for implementing new strategies to enhance patient engagement at FDA; and proposing new models of collaboration in which patient, caregiver, and patient advocate perspectives can inform medical product development and regulatory discussions.\", 'DATES': 'Applications can be submitted starting at 11:59 p.m. Eastern Time on July 9, 2024. This announcement is open to receive a maximum of 75 applications. Applications will be accepted until 11:59 p.m. Eastern Time on August 8, 2024 or until 75 applications are received, whichever happens first.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15008.pdf?1720442730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-09'}, {'ID': '2024-15003', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA staff entitled \"Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products.\" This document provides guidance to industry and FDA staff on the purpose and content of a use- related risk analysis (URRA) and how a URRA, along with other information, can be used to determine human factors (HF) data needs during product development and to support a marketing application.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 9, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15003.pdf?1720442729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-09'}, {'ID': '2024-15011', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by August 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15011.pdf?1720442730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-09'}, {'ID': '2024-15009', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled \"Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers.\" This revised draft guidance, when finalized, will describe FDA\\'s current thinking on common questions firms may have when voluntarily addressing misinformation about or related to their approved/cleared medical products. This guidance revises and replaces the draft guidance for industry entitled \"Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices\" issued in June 2014. This revised draft guidance is not final nor is it in effect at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 9, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by September 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-15009.pdf?1720442730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-09'}, {'ID': '2024-14714', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in response to an outbreak of Mpox. FDA has issued the Authorization for Labcorp Monkeypox PCR (Polymerase Chain Reaction) Test Home Collection Kit as requested by Laboratory Corporation of America. The Authorization contains, among other things, conditions on the emergency use of the authorized product. The Authorization follows the August 9, 2022, determination by the Secretary of Health and Human Services (HHS) that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves monkeypox virus. On the basis of such determination, the Secretary of HHS declared, on September 7, 2022, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, pursuant to the FD&C Act, subject to terms of any authorization issued under that section. The Authorization, which includes an explanation of the reasons for issuance, and can be accessed on FDA's website from the link indicated.\", 'DATES': 'The Authorization is effective as of March 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14714.pdf?1720010722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14717', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines.\" The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance outlines general principles on planning, designing, and analyzing observational (noninterventional) pharmacoepidemiological studies that utilize fit-for-purpose data for safety assessment of medicines (drugs, vaccines, and other biological products). The draft guidance includes recommendations and high-level best practices for the conduct of these studies. The draft guidance is intended to streamline the development and regulatory assessment of postmarketing pharmacoepidemiological safety studies that include Real-World Data. This guidance also seeks to improve the ability of the study protocol and/or results to be accepted across health authorities and support decision making in response to study results.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 3, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14717.pdf?1720010722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14719', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in response to an outbreak of Mpox. FDA has issued an Authorization for an in vitro diagnostic device, Non-variola Orthopoxvirus Real-time PCR Primer and Probe Set as requested by the Centers for Disease Control and Prevention (CDC). The Authorization contains, among other things, conditions on the emergency use of the authorized product. The Authorization follows the August 9, 2022, determination by the Secretary of Health and Human Services (HHS) that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves monkeypox virus. On the basis of such determination, the Secretary of HHS declared, on September 7, 2022, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, pursuant to the FD&C Act, subject to terms of any authorization issued under that section. The Authorization, which includes an explanation of the reasons for issuance, and can be accessed on FDA's website from the link indicated in Section III. Authorization.\", 'DATES': 'The Authorization is effective as of March 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14719.pdf?1720010723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14732', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAXXIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 2, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14732.pdf?1720010724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14723', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYSTIGGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 2, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14723.pdf?1720010723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14720', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VABYSMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 2, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14720.pdf?1720010723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14729', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENJAYMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 2, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14729.pdf?1720010724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14716', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMJUDO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 2, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14716.pdf?1720010722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14728', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUNSUMIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by January 2, 2025. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14728.pdf?1720010724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-05'}, {'ID': '2024-14300', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is amending our regulations to revoke the authorization for the use of brominated vegetable oil (BVO) in food. This action is being taken because there is no longer a reasonable certainty of no harm from the continued use of BVO in food. Specifically, the final rule revokes the authorization for the use of BVO as a food ingredient intended to stabilize flavoring oils in fruit-flavored beverages. There are no authorizations for other uses of BVO in food.', 'DATES': 'The rule is effective August 2, 2024. For the applicable compliance date, see section VII \"Effective/Compliance Dates\" in the SUPPLEMENTARY INFORMATION section of this document.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14300.pdf?1719924314', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-03'}, {'ID': '2024-14538', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENPOZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14538.pdf?1719837926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14577', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEZSPIRE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14577.pdf?1719837932', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14532', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYVGART and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14532.pdf?1719837924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14540', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KIMMTRAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14540.pdf?1719837926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14541', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYNYZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14541.pdf?1719837926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14535', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECVAYLI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14535.pdf?1719837926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14536', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELFABRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by September 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 30, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14536.pdf?1719837926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-02'}, {'ID': '2024-14409', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products.\" This guidance addresses key aspects of drug delivery performance information for devices, and combination products that include device constituent parts, intended for delivery of a human drug, including a biological product (herein referred to as drug delivery devices). The guidance describes FDA\\'s recommendations related to the device design outputs that are essential for establishing and assessing drug delivery performance. FDA is providing recommendations for development and organization of device drug-delivery performance information to improve the consistency of this information in applications and submissions. The guidance is intended to facilitate and streamline development of drug delivery devices.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 30, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14409.pdf?1719578728', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-07-01'}, {'ID': '2024-14329', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on collections of information associated with our Produce Regulatory Program Standards (PRPS).', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by August 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14329.pdf?1719492344', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-28'}, {'ID': '2024-14284', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.\" FDA is issuing this draft guidance as mandated under the Food and Drug Omnibus Reform Act of 2022 (FDORA) which requires that FDA update or issue guidance relating to the format and content of Diversity Action Plans required by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by FDORA. This guidance describes the format and content of Diversity Action Plans, including the timing and process for submitting such plans by application or notification type. In addition, this draft guidance describes the criteria and process by which FDA will evaluate sponsors\\' requests for waivers from the FD&C Act. Because FDA is required by statute to specify the form and manner for the submission of Diversity Action Plans in guidance, insofar as this draft guidance specifies the form and manner for submission of Diversity Action Plans, when this guidance is finalized, it will have binding effect.', 'DATES': 'Submit either electronic or written comments on the draft guidance by September 26, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-14284.pdf?1719492337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-28'}, {'ID': '2024-13941', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for comment.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting comments on its \"Information Technology (IT) Strategy\" and \"Customer Experience (CX) Strategy.\" In accordance with the Agency\\'s User Fee Program commitments and Omnibus Bill requirements, FDA must annually update and publish its IT Strategy by September 30. The initial strategy, released in September 2023, outlines the future direction of FDA\\'s data and technology capabilities. A key objective of FDA\\'s IT Strategy is to modernize enterprise services and capabilities to improve customer experience. The FDA CX Strategy was created to guide this effort. This comprehensive enterprise plan introduces the Agency\\'s CX framework and considers the perspective of interested parties such as the public, employees, and industry.', 'DATES': 'Submit either electronic or written comments on the IT Strategy by July 31, 2024, to ensure that the Agency considers your comments for future iterations of the IT Strategy.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13941.pdf?1719319520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-26'}, {'ID': '2024-13921', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry #283 entitled \"Priority Zoonotic Animal Drug Designation and Review Process.\" This guidance is intended to assist sponsors pursuing Priority Zoonotic Animal Drug (PZAD) designation for a new animal drug. This guidance is intended to provide the eligibility criteria for PZAD designation, the process for requesting PZAD designation, and enhancements in the FDA review process for PZADs.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13921.pdf?1719319517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-26'}, {'ID': '2024-13922', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #276 entitled \"Effectiveness of Anthelmintics: Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs.\" The guidance provides recommendations for the effectiveness evaluation of drugs indicated for the prevention of heartworm disease caused by Dirofilaria immitis in dogs. These recommendations should be read in conjunction with related Agency Veterinary International Conference on Harmonization (VICH) guidance documents and are intended to provide additional detail to elements of study design and interpretation under the recommendations laid out in the VICH guidances.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13922.pdf?1719319517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-26'}, {'ID': '2024-13961', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13961.pdf?1719319523', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-26'}, {'ID': '2024-13872', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Laboratory Developed Tests: Small Entity Compliance Guide.\" The laboratory developed tests (LDT) final rule amended FDA\\'s regulations to make explicit that in vitro diagnostic products (IVDs) are devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act) including when the manufacturer of the IVD is a laboratory. This small entity compliance guide (SECG) is intended to help small entities comply with applicable medical device regulations, consistent with the LDT final rule, including the phasing out of FDA\\'s general enforcement discretion approach for LDTs so that IVDs manufactured by a laboratory will generally fall under the same enforcement approach as other IVDs.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13872.pdf?1719233120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-25'}, {'ID': '2024-13842', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice of availability.', 'SUMMARY': 'FSIS is announcing the availability of its updated guideline for the prevention of violative residues in meat and poultry slaughter establishments.', 'DATES': 'Comments on the guideline must be received on or before August 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13842.pdf?1719233116', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-25'}, {'ID': '2024-13803', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that INVEGA (paliperidone) extended-release tablet, 1.5 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13803.pdf?1718973931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-24'}, {'ID': '2024-13778', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #288 entitled \"Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use.\" This draft guidance describes the FDA Center for Veterinary Medicine\\'s (CVM) recommendations for the information that should be included in Chemistry, Manufacturing, and Controls (CMC) submissions to New Animal Drug Applications (NADAs), Conditional New Animal Drug Applications (CNADAs), Investigational New Animal Drug (INAD) files, and Veterinary Master Files (VMFs) specific to recombinant protein-based intermediates, drug substances, and drug products. Recombinant proteins are produced with recombinant deoxyribonucleic acid (DNA) technology. The production of recombinant proteins has unique characteristics; therefore, the recommended information related to manufacture, characterization, and stability may differ from other FDA guidances specific to synthetic chemical substances.', 'DATES': 'Submit either electronic or written comments on the draft guidance by August 23, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13778.pdf?1718973928', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-24'}, {'ID': '2024-13796', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #292 entitled \"Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles.\" This draft guidance provides recommendations to sponsors submitting chemistry, manufacturing, and controls (CMC) information for Type A medicated articles. Type A medicated articles contain new animal drugs and provide for administration of these drugs in animal feed.', 'DATES': 'Submit either electronic or written comments on the draft guidance by August 23, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13796.pdf?1718973930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-24'}, {'ID': '2024-13776', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled \"Best Practices for Meeting Management.\" This workshop is being conducted to fulfill a commitment to hold a public meeting to discuss best practices for meeting management in the seventh authorization of the Prescription Drug User Fee Act (PDUFA VII). The purpose of the public workshop is to discuss issues related to submission of meeting requests, efficient time management, finalizing meeting agenda, development and submission of meeting background packages, and lessons learned from the Coronavirus Disease 2019 (COVID-19) pandemic including the use of virtual meeting platforms. The public workshop will also discuss and share experience and metrics related to specific PDUFA meeting activities associated with the Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) meetings in fiscal years (FYs) 2021 through 2023. This will include Type D and Initial Targeted Engagement for Regulatory Advice on CBER/ CDER Products (INTERACT) meetings, which began with PDUFA VII in FY 2023. Learnings from the public meeting could inform FDA\\'s internal process improvement efforts and, as appropriate, be reflected in an update to the \"Best Practices for Communication Between IND [Investigational New Drug Application] Sponsors and FDA During Drug Development\" guidance.', 'DATES': 'The public workshop will be held in person and virtually on July 22, 2024, from 9 a.m. to 2 p.m., Eastern Time. Either electronic or written comments on this public workshop must be submitted by August 22, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13776.pdf?1718973927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-24'}, {'ID': '2024-13777', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled \"Modifications to the List of Recognized Standards, Recognition List Number: 062\" (Recognition List Number: 062), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.', 'DATES': 'Submit either electronic or written comments on the notice at any time. These modifications to the list of recognized standards are applicable June 24, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13777.pdf?1718973928', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-24'}, {'ID': '2024-13631', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding partner collaboration in response to illness outbreaks associated with FSIS-regulated food products. This information collection continues to inform FSIS partner outreach efforts to effectively investigate and prevent foodborne illnesses. There are no changes to the existing information collection. The approval for this information collection will expire on November 30, 2024.', 'DATES': 'Submit comments on or before August 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13631.pdf?1718887537', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13672', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or the Agency) is requesting that any industry organizations interested in participating in the selection of nonvoting industry representatives to serve on its public advisory committees for the Center for Drug Evaluation and Research (CDER) notify FDA in writing. FDA is also requesting nominations for nonvoting industry representatives to serve on CDER's public advisory committees. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for current vacancies effective with this notice.\", 'DATES': 'Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to FDA by July 22, 2024 (see sections I and II of this document for further details). Concurrently, nomination materials for prospective candidates should be sent to FDA by July 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13672.pdf?1718887544', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13644', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection titled Generic Clearance for the Collection of Quantitative Data on Tobacco Products and Communications.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by August 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13644.pdf?1718887539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13678', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendment.', 'SUMMARY': \"The Food and Drug Administration (FDA or the Agency) is amending the regulations for medicated feed mill applications and for veterinary feed directive drugs to update addresses and simplify notification procedures. These technical amendments are being made to improve the accuracy of the Agency's regulations and are non- substantive.\", 'DATES': 'This rule is effective June 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13678.pdf?1718887544', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13690', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry (GFI) #279 entitled \"Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting.\" This final guidance describes an approach to satisfy the requirements for the completion of the Bioequivalence technical section for generic Type A medicated articles (TAMAs) containing poorly soluble, locally acting, active pharmaceutical ingredients (APIs) that have little to no systemic absorption, and for which blood level studies are not considered appropriate to demonstrate product bioequivalence. The suggested approach described in this guidance uses a combination of in vitro and in vivo data to support a determination of bioequivalence to address the unique challenges associated with demonstrating bioequivalence of TAMAs containing poorly soluble, locally acting APIs that have little to no systemic absorption.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13690.pdf?1718887546', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13660', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 20 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of July 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13660.pdf?1718887542', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13674', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled, \"Circumstances That Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection.\" The FDA Reauthorization Act of 2017 (FDARA) amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) so that, as is the case with a drug, a device is deemed to be adulterated if the owner, operator, or agent of the factory, warehouse, or establishment at which the device is manufactured, processed, packed, or held delays, denies, or limits an FDA inspection. This final guidance describes, for both drugs and now devices, the types of behaviors (actions, inactions, and circumstances) that FDA considers to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection. This guidance finalizes the draft guidance of the same title issued on December 16, 2022, and supersedes the October 2014 final guidance entitled, \"Circumstances That Constitute Delaying, Limiting, or Refusing a Drug Inspection.\"', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13674.pdf?1718887544', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13638', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13638.pdf?1718887538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13429', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Considerations in Demonstrating Interchangeability With a Reference Product: Update.\" This draft guidance describes considerations regarding a switching study or studies intended to support a demonstration that a proposed therapeutic protein product is interchangeable with a reference product for the purposes of submitting a marketing application or supplement under the Public Health Service Act (PHS Act). After considering any comments received in the docket for this draft guidance, we intend to revise the final guidance for industry entitled \"Considerations in Demonstrating Interchangeability With a Reference Product\" issued on May 14, 2019, to amend sections in that document regarding the subject addressed in this draft guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by August 20, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13429.pdf?1718887516', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13643', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13643.pdf?1718887539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13658', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on March 29, 2024. The document announced the withdrawal of approval of 30 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of April 29, 2024. The document indicated that FDA was withdrawing approval of the following ANDAs after receiving withdrawal requests from Target Health LLC, U.S. Agent for CASI Pharmaceuticals, Inc., 450 Commerce Blvd., Carlstadt, NJ 07072: ANDA 076280, Tizanidine Hydrochloride (HCl) Tablets, Equivalent to (EQ) 2 milligrams (mg) base and EQ 4 mg base; ANDA 077021, Cilostazol Tablets, 100 mg; ANDA 077310, Cilostazol Tablets, 50 mg; ANDA 077517, Ondansetron HCl Tablets, EQ 4 mg base, EQ 8 mg base, and EQ 24 mg base; ANDA 206672, Entecavir Tablets, 0.5 mg and 1 mg; and ANDA 209550, Tenofovir Disoproxil Fumarate Tablets, 300 mg. Before FDA withdrew the approval of these ANDAs, Target Health LLC, informed FDA that it did not want the approval of the ANDAs withdrawn. Because Target Health LLC, timely requested that approvals of ANDAs 076280, 077021, 077310, 077517, 206672, and 209550 not be withdrawn, the approvals are still in effect. This notice corrects that error.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13658.pdf?1718887541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13655', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry (GFI) #278 entitled \"Human User Safety in New and Abbreviated New Animal Drug Applications.\" This guidance is intended for sponsors interested in pursuing the approval, or conditional approval, of new animal drugs (including new generic animal drugs). This guidance addresses general principles of human user safety (HUS) assessment for new animal drugs, sources of data, mitigation strategies for proposed new animal drugs, potential recommendations to address HUS concerns, and how HUS information should be submitted to the Center of Veterinary Medicine (CVM).', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 21, 2024].', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13655.pdf?1718890517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-21'}, {'ID': '2024-13458', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': \"Notice of the intent to renew the USDA's National Advisory Committee on Meat and Poultry Inspection charter.\", 'SUMMARY': 'The USDA intends to renew the National Advisory Committee on Meat and Poultry Inspection (NACMPI) charter. The purpose of the Committee is to provide advice to the Secretary of Agriculture concerning State and Federal programs with respect to meat and poultry inspection, food safety, and other matters that fall within the scope of the Federal Meat Inspection Act (FMIA) and the Poultry Products Inspection Act (PPIA).', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13458.pdf?1718714724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-20'}, {'ID': '2024-13391', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Facility Readiness: Goal Date Decisions Under GDUFA.\" This guidance provides information to applicants on how FDA will use information related to a facility\\'s readiness for inspection as certified on Form FDA 356h to set a goal date for an original abbreviated new drug application (ANDA). This guidance incorporates a program enhancement agreed upon by the Agency and industry as part of the negotiations relating to reauthorization of the Generic Drug User Fee Amendments (GDUFA) and as described in \"GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027\" (GDUFA III commitment letter). This guidance finalizes the draft guidance of the same title issued on October 7, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13391.pdf?1718628328', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-18'}, {'ID': '2024-13388', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13388.pdf?1718628327', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-18'}, {'ID': '2024-13303', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following educational conference (public meeting) entitled \"First Annual Animal Drug User Fee Educational Conference.\" This is the first of five annual educational conferences FDA will host as described in the \"Animal Drug User Fee Act Reauthorization Performance Goals and Procedures Fiscal Years 2024 Through 2028.\" The purpose of this series of conferences is to provide educational sessions for stakeholders who are interested in the new animal drug approval process.', 'DATES': 'The first educational conference will be held on July 17, 2024, from 9 a.m. to 5 p.m. Eastern Time. See the SUPPLEMENTARY INFORMATION section for registration date and information. You may submit comments at any time for this series of educational conferences. We request that you submit either electronic or written comments by 90 days after each annual educational conference to ensure that the Agency considers your comment on a topic discussed at that conference.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13303.pdf?1718628316', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-18'}, {'ID': '2024-13386', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, us, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13386.pdf?1718628327', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-18'}, {'ID': '2024-13190', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule revising the requirements concerning current good manufacturing practice (CGMP), postmarketing safety reporting, and labeling that apply to certain medical gases. This final rule also establishes regulations regarding certification of designated medical gases. This final rule satisfies the medical gas rulemaking requirements of the Consolidated Appropriations Act, 2017.', 'DATES': 'This rule is effective December 18, 2025, except for the amendments to Sec. Sec. 4.2 (amendatory instruction 2), 4.3 (amendatory instruction 3), and 4.4 (amendatory instruction 4) (21 CFR 4.2, 4.3, and 4.4), which are effective February 2, 2026. The incorporation by reference of certain material listed in this rule has been approved by the Director of the Federal Register as of February 2, 2026.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13190.pdf?1718628314', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-18'}, {'ID': '2024-13299', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13299.pdf?1718369130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-17'}, {'ID': '2024-13271', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics,\" which provides recommendations for the development of oligonucleotide therapeutics. Specifically, this guidance addresses FDA\\'s current thinking regarding clinical pharmacology considerations and recommendations for oligonucleotide therapeutic development programs, including characterizing the potential for QT interval prolongation, performing immunogenicity risk assessment, characterizing the impact of hepatic and renal impairment, and assessing the potential for drug-drug interactions. This guidance finalizes the draft guidance of the same name issued on June 27, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13271.pdf?1718369126', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-17'}, {'ID': '2024-13237', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Diabetic Foot Infections: Developing Drugs for Treatment.\" The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of diabetic foot infections (DFI) without concomitant bone and joint involvement. This guidance finalizes and replaces the draft guidance of the same title issued on October 17, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on June 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13237.pdf?1718369121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-17'}, {'ID': '2024-13224', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is correcting a notice that appeared in the Federal Register on May 23, 2024. The document announced the availability of a draft revised guidance for industry (GFI) #115 (VICH GL22) entitled \"Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (Revision 1).\" The document erroneously included incorrect contact information. This document corrects that error.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13224.pdf?1718369119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-17'}, {'ID': '2024-13228', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the availability on its website of the proposed administrative order (proposed order) entitled \"Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use.\"', 'DATES': 'Submit electronic comments on the administrative order by July 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-13228.pdf?1718282740', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-14'}, {'ID': '2024-12999', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of individuals on its advisory committee regardless of their gender identification, religious affiliation, racial and ethnic identification, or disability status and, therefore, encourages nominations of appropriately qualified candidates from all groups.', 'DATES': 'Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests on an FDA advisory committee or panel may send a letter or email stating that interest to FDA (see ADDRESSES) by July 29, 2024, for vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see ADDRESSES) by July 29, 2024. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12999.pdf?1718196336', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-13'}, {'ID': '2024-12974', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Richard B. Smith III for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Smith was convicted of two felony counts under Federal law, only one of which serves as the basis of this debarment: receiving misbranded drugs in interstate commerce and delivering for pay. The factual basis supporting Mr. Smith's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Smith was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of November 29, 2023 (30 days after receipt of the notice), Mr. Smith had not responded. Mr. Smith's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is effective June 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12974.pdf?1718196332', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-13'}, {'ID': '2024-12975', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Jonathan R. Shaver from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Shaver was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Mr. Shaver was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of February 16, 2024 (30 days after receipt of the notice), Mr. Shaver has not responded. Mr. Shaver's failure to respond and request a hearing constitutes a waiver of Mr. Shaver's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable June 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12975.pdf?1718196332', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-13'}, {'ID': '2024-12783', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with Agency guidance documents pertaining to pharmacies, outsourcing facilities, and other entities with regard to human drug compounding, repackaging, and related activities.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by August 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12783.pdf?1718109922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-12'}, {'ID': '2024-12857', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for information and comments; reopening of the comment period.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is publishing this request for information to better understand the status of trading partners' interoperable systems and processes for enhanced drug distribution security as required by the Food, Drug and Cosmetic Act (FD&C Act). FDA is reopening the comment period for the notice, published in the Federal Register of November 20, 2023, establishing a public docket and requesting information and comments, to allow interested persons additional time to comment.\", 'DATES': 'FDA is reopening the comment period on the notice published November 20, 2023 (88 FR 80726). Either electronic or written comments must be submitted by September 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12857.pdf?1718109933', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-12'}, {'ID': '2024-12784', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an amendment of the notice of meeting of the Tobacco Products Scientific Advisory Committee (TPSAC). This meeting was announced in the Federal Register of May 6, 2024. The amendment is being made to reflect a change in the ADDRESSES portion of the document and to reflect a change in the Procedure portion. There are no other changes.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12784.pdf?1718109922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-12'}, {'ID': '2024-12770', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Center for Drug Evaluation and Research (CDER) within the Food and Drug Administration (FDA or we) is announcing a meeting program, the Emerging Drug Safety Technology Meeting (EDSTM) program. These meetings will be administered by staff in the newly established CDER Emerging Drug Safety Technology Program (EDSTP). EDSTMs provide applicants with an approved application and/or other relevant parties supporting industry's pharmacovigilance (PV) activities (e.g., academia, contract research organizations (CROs), pharmacovigilance vendors, software developers) who meet the eligibility and selection criteria for participation with an opportunity to meet with CDER staff to discuss their research, development, and use of Artificial Intelligence (AI) and other emerging technologies in PV. The goals of the meeting program in its initial phase are to facilitate mutual learning and discussion of the pharmaceutical industry's application of these technologies to PV, including efforts to validate and verify relevant models. While the EDSTP is specifically focused on the use of AI in PV for postmarket activities, it is part of CDER's multifaceted approach to enhance mutual learning of where and how specific innovations, such as AI, can best be used across the drug product life cycle.\", 'DATES': 'Applicants and other relevant parties may submit meeting requests under the program beginning June 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12770.pdf?1718023535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-11'}, {'ID': '2024-12528', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 23, 2026, expiration date.', 'DATES': 'Authority for the Obstetrics, Reproductive and Urologic Drugs Advisory Committee will expire on March 23, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12528.pdf?1717677940', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-07'}, {'ID': '2024-12525', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Arthritis Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Arthritis Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the April 5, 2026, expiration date.', 'DATES': 'Authority for the Arthritis Advisory Committee will expire on April 5, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12525.pdf?1717677939', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-07'}, {'ID': '2024-12536', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12536.pdf?1717677941', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-07'}, {'ID': '2024-12564', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Director of the Center for Drug Evaluation and Research (Center Director) at the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a supplemental new drug application (sNDA) submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Vanda an opportunity to request a hearing on the matter.\", 'DATES': 'Either electronic or written requests for a hearing must be submitted by July 8, 2024; submit data, information, and analyses in support of the hearing and any other comments by August 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12564.pdf?1717677946', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-07'}, {'ID': '2024-12532', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on July 25, 2024, from 9 a.m. to 2:15 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12532.pdf?1717677940', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-07'}, {'ID': '2024-12533', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of ethyl cellulose as a matrix scaffolding for tracers, and the ethyl cellulose shall not exceed 80 percent of the tracer. This action is in response to a food additive petition filed by Micro-Tracers, Inc.', 'DATES': 'This rule is effective June 7, 2024. See section V, Objections and Hearing Requests, for further information on the filing of objections. Either electronic or written objections and requests for a hearing on the final rule must be submitted by July 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12533.pdf?1717677940', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-07'}, {'ID': '2024-12356', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Marina Sievert for a period of 10 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Ms. Sievert was convicted of one felony count under Federal law for mail fraud and one felony count under Federal law for introduction of an unapproved new drug into interstate commerce. The factual basis supporting Ms. Sievert's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Ms. Sievert was given notice of the proposed debarment and was given an opportunity to request a hearing to show why she should not be debarred. As of March 10, 2024 (30 days after receipt of the notice), Ms. Sievert had not responded. Ms. Sievert's failure to respond and request a hearing constitutes a waiver of her right to a hearing concerning this matter.\", 'DATES': 'This order is applicable June 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12356.pdf?1717591517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-06'}, {'ID': '2024-12359', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12359.pdf?1717591517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-06'}, {'ID': '2024-12357', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by July 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12357.pdf?1717591517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-06'}, {'ID': '2024-12319', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Processes and Practices Applicable to Bioresearch Monitoring Inspections.\" The draft guidance is being issued to comply with the Food and Drug Omnibus Reform Act of 2022, which directs the Agency to issue guidance describing the processes and practices applicable to inspections of sites and facilities inspected under FDA\\'s Bioresearch Monitoring inspection program, to the extent not specified in existing publicly available FDA guides and manuals. The draft guidance is intended to cover the following: the types of records and information required to be provided, best practices for communication between FDA and industry in advance of or during an inspection or request for records or other information, and other inspections-related conduct.', 'DATES': 'Submit either electronic or written comments on the draft guidance by August 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12319.pdf?1717505121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-05'}, {'ID': '2024-12338', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection requirements associated with current good manufacturing practice, hazard analysis, and risk-based preventive controls for human and animal food.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by August 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12338.pdf?1717505123', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-05'}, {'ID': '2024-12354', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center for Biologics Evaluation and Research Submissions.\" The draft guidance document and BIMO Technical Conformance Guide provide specifications for the electronic submission of certain data and information in standardized formats. This information is used by FDA\\'s Center for Biologics Evaluation and Research (CBER) in the planning of, and by FDA\\'s Office of Regulatory Affairs (ORA) in the conduct of, BIMO inspections. The draft guidance addresses major (i.e., pivotal) studies used to support safety and efficacy claims in biologics license applications (BLAs) and new drug applications (NDAs) regulated by CBER, as well as certain supplemental applications containing new clinical study reports. This draft guidance, when finalized, will provide additional information regarding the format to be used for electronic submission of BLA and NDA content for the planning and conduct of CBER BIMO inspections, using the electronic Common Technical Document.', 'DATES': 'Submit either electronic or written comments on the draft guidance by August 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12354.pdf?1717505124', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-05'}, {'ID': '2024-12346', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions related to Medical Device Recall Authority.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by August 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12346.pdf?1717505124', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-05'}, {'ID': '2024-12065', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of July 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12065.pdf?1717159522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-03'}, {'ID': '2024-11893', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA), Office of the Commissioner, Headquarters organizations, and Centers have modified their organizational structure', 'DATES': 'This organization was approved by the Secretary of Health and Human Services on March 5, 2024, and became effective on May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11893.pdf?1717082112', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-03'}, {'ID': '2024-12066', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Michael Terry Little for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Little was convicted of one felony count under Federal law for introduction of unapproved new drugs in interstate commerce. The factual basis supporting Mr. Little's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Little was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 13, 2024 (30 days after receipt of the notice), Mr. Little had not responded. Mr. Little's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable June 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12066.pdf?1717159523', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-03'}, {'ID': '2024-12064', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Shanif Abdul Punjani for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Punjani was convicted of one felony count under Federal law for Conspiracy to Defraud the United States. The factual basis supporting Mr. Punjani's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Punjani was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 6, 2024 (30 days after receipt of the notice), Mr. Punjani had not responded. Mr. Punjani's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable June 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-12064.pdf?1717159522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-06-03'}, {'ID': '2024-11564', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is issuing a regulation to implement our authority to destroy a device valued at $2,500 or less (or such higher amount as the Secretary of the Treasury may set by regulation) that has been refused admission into the United States by providing to the owner or consignee notice and an opportunity to appear and introduce testimony prior to the destruction. We are finalizing the change to our internal procedures for administrative destruction of drugs and devices. The notice of proposed rule making (NPRM) published in the Federal Register (October 7, 2022).', 'DATES': 'This rule is effective July 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11564.pdf?1717073115', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-31'}, {'ID': '2024-11811', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the termination of the Science Advisory Board to the National Center for Toxicological Research (NCTR). This document announces the reasons for termination and removes the Science Advisory Board to the NCTR from the Agency's list of standing advisory committees.\", 'DATES': 'This rule is effective May 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11811.pdf?1716986718', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-30'}, {'ID': '2024-11686', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Platform Technology Designation Program for Drug Development.\" The purpose of this draft guidance is to provide details about the implementation of the Platform Technology Designation Program established by the PREVENT Pandemics Act. This draft guidance outlines eligibility factors for receiving a platform technology designation, potential benefits of receiving a designation, how to leverage data from designated platform technologies, how to discuss the planned designation request as part of a milestone meeting, the recommended content of a designation request submission, and the review timelines for a designation request. This draft guidance, when finalized, will represent the current thinking of FDA.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 29, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by July 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11686.pdf?1716900318', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-29'}, {'ID': '2024-11727', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Maria Anzures-Camarena from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Ms. Anzures- Camarena was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Ms. Anzures-Camarena was given notice of the proposed debarment and an opportunity to request a hearing to show why she should not be debarred. As of March 6, 2024, (30 days after receipt of the notice), Ms. Anzures-Camarena has not responded. Ms. Anzures-Camarena's failure to respond and request a hearing constitutes a waiver of her right to a hearing concerning this matter.\", 'DATES': 'This order is applicable May 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11727.pdf?1716900324', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-29'}, {'ID': '2024-11721', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of three new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of June 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11721.pdf?1716900323', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-29'}, {'ID': '2024-11743', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions related to the De Novo Classification Process.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by July 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11743.pdf?1716900326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-29'}, {'ID': '2024-11640', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for use during the COVID-19 pandemic. FDA has issued an Authorization for the drug product PEMGARDA (pemivibart) as requested by Invivyd, Inc. (Invivyd). The Authorization contains, among other things, conditions on the emergency use of the authorized product. The Authorization follows the February 4, 2020, determination by the Secretary of Health and Human Services (HHS), as amended on March 15, 2023, that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect national security or the health and security of U.S. citizens living abroad and that involves a novel (new) coronavirus. The virus, named SARS-CoV-2, causes the illness COVID-19. On the basis of such determination, the Secretary of HHS declared on March 27, 2020, that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to the FD&C Act, subject to the terms of any authorization issued under that section. The Authorization, which includes an explanation of the reasons for issuance, is reprinted in this document.', 'DATES': 'The Authorization is effective as of March 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11640.pdf?1716554733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-28'}, {'ID': '2024-11609', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of four new drug applications (NDAs) and is announcing an opportunity for the NDA holders to request a hearing on this proposal. The basis for the proposal is that the NDA holders have repeatedly failed to file required annual reports for those NDAs.\", 'DATES': 'The NDA holders may submit a request for a hearing by June 27, 2024. Submit all data, information, and analyses upon which the request for a hearing relies July 29, 2024. Submit electronic or written comments by July 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11609.pdf?1716554727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-28'}, {'ID': '2024-11546', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Andrew S. Feldman, on behalf of Jessica Palacio (Palacio), and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Palacio from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Palacio was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product under the FD&C Act. FDA provided notice to Palacio of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. Palacio submitted a request for hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.', 'DATES': 'The order is applicable May 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11546.pdf?1716554717', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-28'}, {'ID': '2024-11639', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the reopening notice entitled \"Color Additive Certification; Increase in Fees for Certification Services; Reopening of the Comment Period\" that appeared in the Federal Register of April 26, 2024. We are taking this action in response to a request for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the notice \"Color Additive Certification; Increase in Fees for Certification Services; Reopening of the Comment Period\" published in the Federal Register of April 26, 2024 (89 FR 32384). Either electronic or written comments must be submitted by June 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11639.pdf?1716554731', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-28'}, {'ID': '2024-11643', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a material threat medical countermeasure (MCM) product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that PAXLOVID (nirmatrelvir co-packaged with ritonavir) tablets, approved on May 25, 2023, manufactured by Pfizer, Inc., meets the criteria for a material threat MCM priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11643.pdf?1716554732', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-28'}, {'ID': '2024-11455', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on the proposed information collection. This is a revision of a currently approved collection. The purpose of this information collection request is to continue the use of the electronic form FNS- 674, titled \"User Access Request Form.\" This form will continue to allow access to current FNS systems, modified access or to remove user access.', 'DATES': 'Written comments must be received on or before July 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11455.pdf?1716468325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-24'}, {'ID': '2024-11313', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft revised guidance for industry (GFI) #115 (VICH GL22) entitled \"Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (Revision 1).\" This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). In order to establish the safety of veterinary drug residues in human food, a number of toxicological evaluations are required, including the assessment of any effects on reproduction. The objective of this guidance is to ensure international harmonization of reproduction testing that is appropriate for the evaluation of effects on reproduction from long-term, low-dose exposures; these effects may be encountered from the presence of veterinary drug residues in food.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 22, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11313.pdf?1716381921', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-23'}, {'ID': '2024-11310', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice of availability and response to comments.', 'SUMMARY': 'On December 21, 2020, FSIS published and requested comments on a guideline addressing the donation of meat and poultry products from official establishments to non-profit organizations. FSIS is announcing updates to this guideline and responding to comments received on the previous version of the guideline.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11310.pdf?1716381921', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-23'}, {'ID': '2024-11237', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the collection of information concerning class II special controls for an automated blood cell separator device operating by centrifugal or filtration separation principle.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by July 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11237.pdf?1716295526', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11216', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Vaccines and Related Biological Products Advisory Committee. This meeting was announced in the Federal Register of March 4, 2024. The amendment is being made to reflect a change in the meeting date in the SUMMARY and DATES portions of the document from May 16, 2024, to June 5, 2024. There are no other changes.', 'DATES': 'The meeting will be held virtually on June 5, 2024, from 8:30 a.m. to 4:30 p.m. EST. This notice is issued under the Federal Advisory Committee Act 5 U.S.C. 1001 et seq. and 21 CFR part 14, relating to the advisory committees.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11216.pdf?1716295523', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11234', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collections associated with the \"Yale-Mayo Clinic Centers of Excellence in Regulatory Science and Innovation (CERSI) B12 Pediatric Device Survey.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by July 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11234.pdf?1716295525', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11222', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice of public meeting.', 'SUMMARY': \"In accordance with the Federal Advisory Committee Act, FSIS is announcing that the National Advisory Committee on Microbiological Criteria for Foods (NACMCF) will hold a virtual public meeting on June 24, 2024. The Committee will provide updates on FSIS' Genomics charge and the U.S. Food and Drug Administration's (FDA's) Cronobacter spp. in Powdered Infant Formula charge.\", 'DATES': 'The full Committee will hold a virtual public plenary meeting on Monday, June 24, 2024, from 1:00 p.m. to 3:00 p.m. EST. Attendance is free but pre-registration by Wednesday, June 19, 2024, is requested.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11222.pdf?1716295524', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11228', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the following public workshop entitled \"Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products.\" The purpose of the public workshop is to discuss transplacental transfer of drug and biological products with immunosuppressive properties and the potential clinical impact on the developing fetus and newborn infant, understand the gaps in knowledge, and consider innovative approaches to improve collection of relevant data.', 'DATES': 'The public workshop will be held on July 11, 2024, from 9 a.m. to 5 p.m. Eastern Time and on July 12, 2024, from 9 a.m. to 1 p.m. Eastern Time. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11228.pdf?1716295524', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11178', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is requesting that any industry organizations interested in participating in the selection of nonvoting industry representatives to serve on certain panels of the Medical Devices Advisory Committee (MDAC or the Committee) in the Center for Devices and Radiological Health (CDRH) notify FDA in writing. FDA is also requesting nominations for nonvoting industry representatives to serve on certain device panels of the MDAC in the CDRH. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for current and upcoming vacancies effective with this notice.', 'DATES': 'Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to the FDA by June 21, 2024 (see sections I and II of this document for further details). Concurrently, nomination materials for prospective candidates should be sent to FDA by June 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11178.pdf?1716295517', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11180', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11180.pdf?1716295518', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11205', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Proposed rule; extension of comment period.', 'SUMMARY': 'The U.S. Department of Agriculture (USDA) Food and Nutrition Service is extending the public comment period on the proposed rule, \"Supplemental Nutrition Assistance Program: Program Purpose and Work Requirement Provisions of the Fiscal Responsibility Act of 2023,\" which was published in the Federal Register on April 30, 2024. This action extends the public comment period from May 30, 2024, to June 14, 2024, to give the public additional time to review the proposed rule.', 'DATES': 'The comment period for the proposed rule published April 30, 2024, at 89 FR 34340, is extended. To be assured of consideration, comments on this proposed rule must be received by the Food and Nutrition Service on or before June 14, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11205.pdf?1716295522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-11229', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the proposed rule entitled \"Labeling Requirements for Approved or Conditionally Approved New Animal Drugs\" published in the Federal Register of March 12, 2024, by 60 days. The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the proposed rule published March 12, 2024 (89 FR 18262), by 60 days. Either electronic or written comments must be submitted by August 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-11229.pdf?1716295524', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-22'}, {'ID': '2024-10936', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of withdrawal.', 'SUMMARY': \"The Food and Drug Administration (FDA, Agency, or we) is announcing the withdrawal of the Center for Veterinary Medicine's (CVM's) Program Policy and Procedures Manual Guide (PPM) 1240.3605 Regulating Animal Foods with Drug Claims. This 1998 document presented guidance to CVM staff for the regulation of animal food that may have intended uses that result in the products also being drugs. FDA is withdrawing PPM 1240.3605 after determining that it no longer reflects Agency current thinking.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10936.pdf?1715949918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-20'}, {'ID': '2024-10910', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Bio-Rad Laboratories Inc., for the Bio-Rad SARS-CoV-2 ddPCR Kit, and Fast Track Diagnostics Luxembourg S.[aacute].r.l. (A Siemens Healthineers Company), for the FTD SARS-CoV- 2. FDA revoked the Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holders. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.', 'DATES': \"The revocation of the Authorization for the Bio-Rad Laboratories Inc.'s Bio-Rad SARS-CoV-2 ddPCR Kit is effective as of March 27, 2024. The revocation of the Authorization for the Fast Track Diagnostics Luxembourg S.[aacute].r.l.'s (A Siemens Healthineers Company), FTD SARS-CoV-2 is effective as of April 18, 2024.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10910.pdf?1715863534', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-17'}, {'ID': '2024-10918', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice.', 'SUMMARY': 'FSIS is announcing the dollar limitations on the amount of meat and meat products and poultry and poultry products that a retail store can sell to hotels, restaurants, and similar institutions without disqualifying itself for exemption from Federal inspection requirements.', 'DATES': 'Applicable June 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10918.pdf?1715863535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-17'}, {'ID': '2024-10896', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" that explained the process that would be used to make product-specific guidances available to the public on FDA\\'s website. The draft guidances identified in this notice were developed using the process described in that guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 16, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10896.pdf?1715863532', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-17'}, {'ID': '2024-10717', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the issuance of Emergency Use Authorizations (EUAs) (the Authorizations) for certain medical devices related to Coronavirus Disease 2019 (COVID-19). FDA has issued the Authorizations listed in this document under the Federal Food, Drug, and Cosmetic Act (FD&C Act). These Authorizations contain, among other things, conditions on the emergency use of the authorized products. The Authorization follows the February 4, 2020, determination by the Secretary of Health and Human Services (HHS), as amended on March 15, 2023, that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad and that involves the virus that causes COVID-19, and the subsequent declarations on February 4, 2020, March 2, 2020, and March 24, 2020, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19, personal respiratory protective devices, and medical devices, including alternative products used as medical devices, respectively, subject to the terms of any authorization issued under the FD&C Act. These Authorizations, which include an explanation of the reasons for issuance, are listed in this document, and can be accessed on FDA's website from the links indicated.\", 'DATES': 'These Authorizations are effective on their date of issuance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10717.pdf?1715777126', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-16'}, {'ID': '2024-10714', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for TRUSELTIQ (infigratinib phosphate) Capsules, 25 milligrams (mg) and 100 mg, held by Helsinn Healthcare SA, C/O Helsinn Therapeutics (U.S.), Inc. (Helsinn), 200 Wood Ave. South, Suite 100, Iselin, NJ 08830. Helsinn has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.', 'DATES': 'Approval is withdrawn as of May 16, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10714.pdf?1715777125', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-16'}, {'ID': '2024-10715', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that XOLREMDI (mavorixafor), approved on April 26, 2024, manufactured by X4 Pharmaceuticals, Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10715.pdf?1715777125', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-16'}, {'ID': '2024-10602', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendment.', 'SUMMARY': \"The Food and Drug Administration (FDA, the Agency, or we) is amending the animal drug regulations for labeling of new animal drugs included on FDA's Index of Legally Marketed Unapproved New Animal Drugs for Minor Species (indexed products) to reflect the 2018 statutory changes to the Federal Food, Drug, and Cosmetic Act (FD&C Act). This amendment is intended to ensure accuracy and clarity in the Agency's regulations. This amendment is nonsubstantive.\", 'DATES': 'This rule is effective May 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10602.pdf?1715690724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-15'}, {'ID': '2024-10583', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that OJEMDA (tovorafenib), approved on April 23, 2024, manufactured by Day One Biopharmaceuticals, Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10583.pdf?1715690721', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-15'}, {'ID': '2024-10584', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Gina Acosta from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Ms. Acosta was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Ms. Acosta was given notice of the proposed debarment and an opportunity to request a hearing to show why she should not be debarred. As of March 6, 2024 (30 days after receipt of the notice), Ms. Acosta has not responded. Ms. Acosta's failure to respond and request a hearing constitutes a waiver of Ms. Acosta's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable May 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10584.pdf?1715690721', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-15'}, {'ID': '2024-10606', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with export certificate applications for FDA-regulated human food and cosmetic products.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by July 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10606.pdf?1715690724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-15'}, {'ID': '2024-10586', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during January, February, and March 2024. The animal drug regulations are also being amended to improve their accuracy and readability.', 'DATES': 'This rule is effective May 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10586.pdf?1715690721', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-15'}, {'ID': '2024-10361', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JEMPERLI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by July 12, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10361.pdf?1715345132', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-13'}, {'ID': '2024-10055', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity to provide public comment on a modified risk tobacco product application (MRTPA). The application is for renewal of an existing modified risk tobacco product (MRTP) order for the IQOS 3.0 System Holder and Charger, a Heated Tobacco Product (HTP), submitted by Philip Morris Products S.A.', 'DATES': 'Electronic or written comments on the application may be submitted beginning May 10, 2024. FDA will establish a closing date for the comment period as described in section I.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10055.pdf?1715258714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-10'}, {'ID': '2024-10230', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Remanufacturing of Medical Devices.\" This final guidance is intended to help clarify whether activities performed on devices are likely \"remanufacturing.\" This final guidance also clarifies existing regulatory requirements for remanufacturers and includes recommendations for information that should be included in labeling to help assure the continued quality, safety, and effectiveness of devices that are intended to be serviced over their useful life.', 'DATES': 'The announcement of the guidance is published in the Federal Register on May 10, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10230.pdf?1715258723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-10'}, {'ID': '2024-10204', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a revision of currently approved information collection requirements associated with initiating collection actions against individuals/households (I/HH) who have received an overissuance in SNAP.', 'DATES': 'Written comments must be received on or before July 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10204.pdf?1715258719', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-10'}, {'ID': '2024-10054', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity to provide public comment on modified risk tobacco product applications (MRTPAs). The applications are for the renewal of existing MRTP orders for IQOS 2.4 System Holder and Charger, Marlboro Amber HeatSticks, Marlboro Green Menthol HeatSticks and Marlboro Blue Menthol HeatSticks, Heated Tobacco Products (HTPs) and HTP Consumables, submitted by Philip Morris Products S.A.', 'DATES': 'Submit either electronic or written comments on the application beginning May 10, 2024. FDA will establish a closing date for the comment period as described in section I.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10054.pdf?1715258714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-10'}, {'ID': '2024-10051', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on June 10, 2024, from 9 a.m. to 5 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10051.pdf?1715086329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-08'}, {'ID': '2024-10053', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on June 4, 2024, from 8:30 a.m. to 4:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-10053.pdf?1715086217', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-08'}, {'ID': '2024-09381', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Center for Devices and Radiological Health's (CDRH), Office of Communication and Education (OCE) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on December 21, 2023, and it became effective on January 22, 2024.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09381.pdf?1714999689', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-07'}, {'ID': '2024-09382', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Center for Devices and Radiological Health's (CDRH), Office of Product Evaluation and Quality (OPEQ) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on December 21, 2023, and it became effective on January 22, 2024.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09382.pdf?1714999630', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-07'}, {'ID': '2024-09917', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Adam Paul Runsdorf from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Runsdorf was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Mr. Runsdorf was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of February 25, 2024 (30 days after receipt of the notice), Mr. Runsdorf has not responded. Mr. Runsdorf's failure to respond and request a hearing constitutes a waiver of Mr. Runsdorf's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable May 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09917.pdf?1715000051', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-07'}, {'ID': '2024-09914', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of June 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09914.pdf?1715000171', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-07'}, {'ID': '2024-09928', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"REMS Logic Model: A Framework to Link Program Design With Assessment.\" The guidance describes FDA\\'s risk evaluation and mitigation strategy (REMS) logic model. The REMS logic model is a framework that FDA recommends, which provides applicants with a systematic, structured approach to the design, implementation, and evaluation of a REMS. The aim of applying the REMS logic model is to develop clear goals, objectives, and strategies that align with the intended outcomes and to help applicants of new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs) incorporate REMS assessment planning into the design of a REMS. The principles in this guidance apply to designing a REMS, developing a REMS assessment, and modifying a REMS.', 'DATES': 'Submit either electronic or written comments on the draft guidance by August 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09928.pdf?1715000171', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-07'}, {'ID': '2024-08933', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency.\" This draft guidance, when finalized, will describe the factors FDA intends to assess when deciding to issue an enforcement policy regarding test manufacturers\\' offering of certain unapproved tests and unapproved uses of approved tests during a declared emergency. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08933.pdf?1714398254', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-06'}, {'ID': '2024-09777', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #290 (VICH GL61) entitled \"Pharmaceutical Development.\" This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). This draft guidance describes the suggested contents for the Pharmaceutical Development section, which provides an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management to the development of a product and its manufacturing process.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09777.pdf?1714740330', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-06'}, {'ID': '2024-08934', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564.\" In the context of emergent situations involving chemical, biological, radiological, or nuclear (CBRN) threats, there may be a public health need for certain in vitro diagnostic devices (IVDs) to be available for immediate response purposes. When finalized, this guidance will describe the Agency\\'s enforcement policy for certain laboratory manufacturers offering certain unauthorized IVDs for immediate response to CBRN agents in the absence of a declaration applicable to IVDs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 5, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08934.pdf?1714398254', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-06'}, {'ID': '2024-09786', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Tobacco Products Scientific Advisory Committee (TPSAC). The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.\", 'DATES': 'The meeting will be held on June 26, 2024, from 9 a.m. to 4:30 p.m. EST.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09786.pdf?1714740331', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-06'}, {'ID': '2024-08935', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration is issuing a final rule to amend its regulations to make explicit that in vitro diagnostic products (IVDs) are devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act) including when the manufacturer of the IVD is a laboratory. In conjunction with this amendment, the Food and Drug Administration is phasing out its general enforcement discretion approach for laboratory developed tests (LDTs) so that IVDs manufactured by a laboratory will generally fall under the same enforcement approach as other IVDs. This phaseout policy includes enforcement discretion policies for specific categories of IVDs manufactured by a laboratory, including currently marketed IVDs offered as LDTs and LDTs for unmet needs. This phaseout policy is intended to better protect the public health by helping to assure the safety and effectiveness of IVDs offered as LDTs, while also accounting for other important public health considerations such as patient access and reliance.', 'DATES': 'This rule is effective July 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08935.pdf?1714398256', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-06'}, {'ID': '2024-09153', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration is issuing a final rule to amend the agricultural water provisions of the produce safety regulation. This rule replaces the microbial criteria and testing requirements for pre-harvest agricultural water for covered produce (other than sprouts) with a regulatory approach that incorporates recent science and Food and Drug Administration outbreak investigation findings to achieve improved public health protections as compared to the earlier requirements. The rule requires systems-based assessments, with required testing in certain circumstances, that focus on key risk factors for contamination by pre-harvest agricultural water and will enable farms to implement effective preventive measures. The rule requires farms to take timely action based on risk and includes a new requirement for expedited mitigation for certain hazards. The requirements are adaptable to future scientific advancements and provide sufficient flexibility to be practicable for all sizes and types of farms to implement across the wide variety of agricultural water systems, uses, and practices. These revisions to the produce safety regulation will more comprehensively address a known route of microbial contamination that can lead to preventable foodborne illness that is a significant public health problem.', 'DATES': 'This rule is effective July 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09153.pdf?1714662913', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-06'}, {'ID': '2024-09678', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': \"In accordance with the Paperwork Reduction Act of 1995, this notice announces FNS' plans to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB) and invites the general public and other public agencies to comment on the proposed ICR before FNS submits it to OMB. The proposed information collection is a revision of an approved information collection. The approved information collection (OMB Control Number 0584-0607) permitted the School Meals Operations (SMO) study to collect survey and administrative data about school year (SY) 2019-2020 through SY 2022- 2023 from a census of State agencies, and survey data about SY 2020- 2021 and SY 2022-2023 from a nationally representative sample of school food authorities. With the revision, FNS will seek approval for the SMO study to collect survey and administrative data about SY 2023-2024 from a census of State agencies. The SMO study will not collect survey data about SY 2023-2024 from school food authorities.\", 'DATES': 'Written comments must be received on or before July 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09678.pdf?1714653935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-03'}, {'ID': '2024-09279', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry (GFI) #187B entitled \"Heritable Intentional Genomic Alterations in Animals: The Approval Process.\" This draft guidance is intended to clarify FDA\\'s requirements and recommendations for developers of intentional genomic alterations (IGA) in animals. The draft guidance is being issued as one of two companion documents. \"Heritable Intentional Genomic Alterations in Animals: The Approval Process\" describes how the FDA approval process applies to heritable IGAs in animals. FDA is issuing GFI #187B as a draft guidance to solicit comments that will enable the Agency to update, and make as efficient as possible, the approval process for IGAs in animals. In addition, FDA requests comments on questions that it intends to address in the final version of this guidance document. The companion final guidance, GFI #187A entitled \"Heritable Intentional Genomic Alterations in Animals: Risk- Based Approach,\" describes FDA\\'s risk-based regulatory approach to the oversight of heritable IGAs in animals. This means that, for people or companies developing certain types of IGAs in animals, FDA may not expect them to submit an application or get approval before marketing their product.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 31, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09279.pdf?1714567520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-02'}, {'ID': '2024-09528', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Angela Maria Giron, M.D. from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Dr. Giron was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Dr. Giron was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of February 16, 2024 (30 days after receipt of the notice), Dr. Giron has not responded. Dr. Giron's failure to respond and request a hearing constitutes a waiver of Dr. Giron's right to a hearing concerning this matter.\", 'DATES': 'This order is applicable May 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09528.pdf?1714567531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-02'}, {'ID': '2024-09278', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #187A entitled \"Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach.\" This guidance is intended to clarify FDA\\'s requirements and recommendations with respect to heritable intentional genomic alterations (IGAs) in animals. The guidance is being issued as one of two companion documents. This guidance, entitled \"Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,\" describes FDA\\'s risk-based regulatory approach to the oversight of heritable IGAs in animals. This means that for people or companies developing certain types of IGAs in animals, FDA may not expect them to submit an application or get approval before marketing their product. For other types of IGAs in animals that do go through the approval process, the companion draft guidance document, GFI #187B entitled \"Heritable Intentional Genomic Alterations in Animals: The Approval Process\" describes how the approval process applies to heritable IGAs in animals.', 'DATES': 'The announcement of the guidance is published in the Federal Register on May 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09278.pdf?1714567520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-02'}, {'ID': '2024-09526', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on reporting and recordkeeping requirements of our regulations concerning new animal drugs for investigational use.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by July 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09526.pdf?1714567531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-02'}, {'ID': '2024-09532', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is requesting nominations for a nonvoting representative of the interests of the tobacco growers to serve on the Tobacco Products Scientific Advisory Committee (TPSAC), in the Center for Tobacco Products. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore encourages nominations of appropriately qualified candidates from these groups. A nominee may either be self-nominated or nominated by an organization. In addition, FDA is requesting that any industry organizations interested in participating in the selection of a nonvoting representative of the interests of the tobacco growers industry to serve on the TPSAC, notify FDA in writing. Nominations will be accepted for either the representative to serve on TPSAC or for the selection group effective with this notice.', 'DATES': 'Nomination materials for prospective candidates should be sent to FDA by June 3, 2024. Concurrently, any industry organization interested in participating in the selection of an appropriate nonvoting member to represent the interests of the tobacco growers industry must send a letter stating that interest to FDA by June 3, 2024 (see sections I and II of this document for further details).', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09532.pdf?1714567532', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-05-02'}, {'ID': '2024-09287', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products; Draft Guidance for Industry.\" Allogeneic cells of human origin may be expanded in culture to manufacture medical products consisting of live cells, inactivated cells, cell lysates, or other cell-based materials such as cell-derived particles. The draft guidance document provides sponsors of allogeneic cell-based medical products recommendations for determining the appropriate cell safety testing to support an investigational new drug application (IND) or a biologics license application (BLA). Cell safety testing should be based on a risk analysis that considers the expansion potential of the cells, the reagents that are used to expand the cells in culture, and the number of individuals the cell-based medical product is capable of treating.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 29, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09287.pdf?1714398274', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-30'}, {'ID': '2024-09286', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Considerations for the Use of Human- and Animal-Derived Materials and Components in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products; Draft Guidance for Industry.\" The draft guidance document provides manufacturers of cellular and gene therapy (CGT) and tissue- engineered medical products (TEMPs) with recommendations regarding assuring the safety, quality, and identity of materials of human and animal origin used in the manufacture of these products. In addition, recommendations are provided regarding the chemistry, manufacturing, and control (CMC) information submitted in an investigational new drug application (IND) relating to the use of human- and animal-derived materials.', 'DATES': 'Submit either electronic or written comments on the draft guidance by July 29, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09286.pdf?1714398274', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-30'}, {'ID': '2024-09177', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by May 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09177.pdf?1714398258', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-30'}, {'ID': '2024-09014', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following virtual public meeting entitled \"Listening Session: Optimizing FDA\\'s Use of and Processes for Advisory Committees.\" The purpose of the listening session is to solicit feedback on the Agency\\'s use of and processes for its advisory committee system.', 'DATES': 'The virtual listening session will be held on June 13, 2024, from 9 a.m. to 4 p.m. Eastern Daylight Time (EDT) or until after the last public commenter has spoken, whichever occurs first. Submit requests to make oral presentations at the listening session by 3 p.m. EDT, May 13, 2024. Electronic or written comments on this listening session must be submitted to the docket by August 13, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09014.pdf?1714398256', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-30'}, {'ID': '2024-08338', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Proposed rule.', 'SUMMARY': 'This proposed rule would amend the Supplemental Nutrition Assistance Program (SNAP) regulations to incorporate three provisions of the Fiscal Responsibility Act of 2023 by adding to the program purpose language assisting low-income adults in obtaining employment and increasing their earnings; updating and defining the exceptions from the able-bodied adults without dependents (ABAWD) time limit; and adjusting the number of discretionary exemptions available to State agencies each year. This proposed rule would also amend the regulations to clarify procedures for how and when State agencies must screen for exceptions to the time limit and clarify the verification requirements.', 'DATES': 'Written comments must be received on or before May 30, 2024 to be assured of consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08338.pdf?1714398252', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-30'}, {'ID': '2024-09156', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Content and Format of Composition Statements in NDAs and ANDAs and Corresponding Statement of Ingredients in Labeling.\" This guidance is intended to assist new drug application (NDA) and abbreviated new drug application (ANDA) applicants in submitting an accurate and complete composition statement in their applications and corresponding statement of ingredients in the labeling, when applicable. This guidance describes best practices for writing the composition statement and corresponding statement of ingredients in labeling. This guidance recommends how applicants can provide complete information with the goal of minimizing the number of assessment cycles and communications that are necessary for approval, as well as ensuring product labels are written clearly.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 28, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09156.pdf?1714135544', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-29'}, {'ID': '2024-09050', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that FLUDARABINE PHOSPHATE Injection, 50 milligrams (mg)/2 milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09050.pdf?1714135522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-29'}, {'ID': '2024-09158', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on May 24, 2024, from 9 a.m. to 4 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09158.pdf?1714135544', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-29'}, {'ID': '2024-09073', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendment.', 'SUMMARY': 'The Food and Drug Administration (FDA) is amending the food additive regulations to update the production organism Corynebacterium lilium that has been scientifically reclassified to Corynebacterium glutamicum. This action is being taken to improve the accuracy and clarity of the regulations.', 'DATES': 'This rule is effective April 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09073.pdf?1714135525', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-29'}, {'ID': '2024-09137', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry (GFI) #120 entitled \"Veterinary Feed Directive Regulation Questions and Answers.\" This revised guidance document will aid industry in complying with the requirements of the veterinary feed directive (VFD) regulation.', 'DATES': 'The announcement of the guidance is published in the Federal Register on April 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09137.pdf?1714135539', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-29'}, {'ID': '2024-09139', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #287 entitled \"Raw Data for Safety and Effectiveness Studies.\" This guidance provides information to animal drug sponsors (sponsors) on the use of raw data in the Center for Veterinary Medicine\\'s (CVM\\'s) review of safety and effectiveness studies submitted in support of new animal drug applications. This guidance also describes our recommendations for submitting raw data.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 28, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09139.pdf?1714135541', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-29'}, {'ID': '2024-08953', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled \"Electronic Records: Electronic Signatures\" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08953.pdf?1714049135', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-09028', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled \"Pregnancy Exposure Registry Enrollment Project: A Survey of Healthcare Providers To Advance Pregnancy Safety Data Collection and Improve Health Communications.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by June 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09028.pdf?1714049145', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-09023', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by May 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09023.pdf?1714049144', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-08956', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is establishing a public docket entitled \"Promoting Effective Drug Development: Identifying Opportunities and Priorities for the Food and Drug Administration\\'s Office of Clinical Pharmacology.\" The purpose of this docket is to solicit input from interested parties on specific and actionable policy topics that could be prioritized, developed, and implemented by the staff of the Center for Drug Evaluation and Research\\'s (CDER\\'s) Office of Clinical Pharmacology (OCP) to support effective drug development programs.', 'DATES': 'Although you can comment at any time, to ensure that the Agency considers your comment, submit either electronic or written comments by June 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08956.pdf?1714049136', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-08952', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; reopening of the comment period.', 'SUMMARY': 'The Food and Drug Administration is reopening the comment period for the draft guidance for industry entitled \"Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination and Removal of a Foreign Manufacturer\\'s Goods From Detention Without Physical Examination; Draft Guidance for Industry; Availability\" that published in the Federal Register of February 12, 2024. We are taking this action in response to a request to extend the comment period to allow additional time for interested parties to submit comments.', 'DATES': 'FDA is reopening the comment period for the draft guidance for industry announced in the Federal Register on February 12, 2024 (89 FR 9852). Submit either electronic or written comments on the draft guidance by June 25, 2024, to ensure that we consider your comments before we begin work on the final guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08952.pdf?1714049135', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-09039', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, institutional review boards (IRBs), and clinical investigators entitled \"Cancer Clinical Trial Eligibility Criteria: Laboratory Values.\" This draft guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this draft guidance includes recommendations for selecting appropriate laboratory values as trial eligibility criteria to avoid unjustified exclusions of diverse trial participants.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 25, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09039.pdf?1714049147', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-09038', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, institutional review boards (IRBs), and clinical investigators entitled \"Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications.\" This draft guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation Research (CBER) for the treatment of cancer. Specifically, this draft guidance includes recommendations regarding the appropriate use of washout periods and concomitant medication exclusions.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 25, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09038.pdf?1714049147', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-08968', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on electronic user fee payment request forms.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by June 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08968.pdf?1714049138', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-09037', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, institutional review boards (IRBs), and clinical investigators entitled \"Cancer Clinical Trial Eligibility Criteria: Performance Status.\" This draft guidance is one in a series of guidances that provide recommendations regarding eligibility criteria for clinical trials of investigational drugs regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) for the treatment of cancer. Specifically, this draft guidance includes recommendations regarding expanding eligibility criteria to include patients with a wider range of performance status.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 25, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-09037.pdf?1714049147', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-08950', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule; reopening of the comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is reopening the comment period for the proposed rule, \"Color Additive Certification; Increase in Fees for Certification Services,\" which published in the Federal Register of November 2, 2022. We are taking this action to add supporting information to the administrative record and to adjust the record to reflect the same cost and benefits figures that were published in the preliminary regulatory impact analysis. We are reopening the comment period for 30 days specifically to invite public comments on the new information being added to the administrative record.', 'DATES': 'FDA is reopening the comment period on the proposed rule \"Color Additive Certification; Increase in Fees for Certification Services,\" which published in the Federal Register on November 2, 2022 (87 FR 66116). Either electronic or written comments must be submitted by May 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08950.pdf?1714049134', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-26'}, {'ID': '2024-08886', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled \"Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers.\" FDA is issuing this revised draft guidance to address questions that manufacturers, packers, distributors, and their representatives (firms) may have when developing FDA-regulated promotional labeling and advertisements (promotional communications) for prescription reference products, biosimilar products, and interchangeable biosimilar products licensed under the Public Health Service Act (PHS Act). In conjunction with the enactment of the Biosimilar User Fee Amendments of 2022 (BsUFA III), FDA agreed to publish a draft guidance on promotional labeling and advertising considerations for interchangeable biosimilar products, as described in the document titled \"Biosimilar Biological Product Reauthorization Performance Goals and Procedures Fiscal Years 2023 through 2027.\" The revised draft guidance is consistent with this commitment and replaces the draft guidance for industry entitled \"Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products: Questions and Answers\" issued on February 4, 2020.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 24, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08886.pdf?1713962748', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-25'}, {'ID': '2024-08098', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': 'This rulemaking finalizes long-term school nutrition requirements based on the goals of the Dietary Guidelines for Americans, 2020-2025, robust stakeholder input, and lessons learned from prior rulemakings. Notably, this rulemaking gradually phases in added sugars limits for the school lunch and breakfast programs and in the Child and Adult Care Food Program, updates total sugars limits for breakfast cereals and yogurt to added sugars limits. As a reflection of feedback from stakeholders, this final rule implements a single sodium reduction in the school lunch and breakfast programs and commits to studying the potential associations between sodium reduction and student participation in the school lunch and breakfast programs. This rulemaking addresses a variety of other school meal requirements, including establishing long-term milk and whole grain requirements. Finally, this rule includes provisions that strengthen Buy American requirements. While this rulemaking takes effect school year 2024-2025, the Department is gradually phasing in required changes over time. Program operators are not required to make any changes to their menus as a result of this rulemaking until school year 2025-2026 at the earliest.', 'DATES': 'This final rule is effective July 1, 2024. Phased-in implementation dates for required changes are addressed in the SUPPLEMENTARY INFORMATION section of this rule.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08098.pdf?1713962726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-25'}, {'ID': '2024-08655', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on a generic clearance to collect information to support social and behavioral research used by FDA about drug products.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by June 24, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08655.pdf?1713789931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-23'}, {'ID': '2024-08657', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of May 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08657.pdf?1713789931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-23'}, {'ID': '2024-08649', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the Agency\\'s annual report entitled \"Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments.\" Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA is required to report annually on the status of postmarketing requirements (PMRs) and postmarketing commitments (PMCs) required of, or agreed upon by, application holders of approved drug and biological products. The report on the status of the studies and clinical trials that applicants are required to, or have agreed to, conduct is on the FDA\\'s website entitled \"Postmarketing Requirements and Commitments: Reports\" (https:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post- marketingPhaseIVCommitments/ucm064436.htm).', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08649.pdf?1713789929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-23'}, {'ID': '2024-08656', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or the Agency) announces a forthcoming public advisory committee meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.\", 'DATES': 'The meeting will take place virtually on May 23, 2024, from 9:30 a.m. to 5:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08656.pdf?1713789931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-23'}, {'ID': '2024-08628', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding requirements for official establishments to notify FSIS of adulterated or misbranded product, prepare and maintain written recall procedures, and document certain Hazard Analysis and Critical Control Point (HACCP) plan reassessments. There are no changes to the existing information collection. The approval for this information collection will expire on September 30, 2024.', 'DATES': 'Submit comments on or before June 24, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08628.pdf?1713789925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-23'}, {'ID': '2024-08369', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Interim final rule, extension of comment period.', 'SUMMARY': 'The USDA Food and Nutrition Service is extending for 120 days the public comment period on the interim final rule, \"Establishing the Summer EBT Program and Rural Non-Congregate Option in the Summer Meal Programs\", which published in the Federal Register on December 29, 2023. This action extends the public comment period from April 29, 2024, to August 27, 2024, to give the public additional time to prepare and submit comments.', 'DATES': 'The comment period of the interim final rule published December 29, 2023, at 88 FR 90230, is extended through August 27, 2024. To be assured of consideration, written comments on this interim final rule must be received on or before August 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08369.pdf?1713444344', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-19'}, {'ID': '2024-08276', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that LENMELDY (atidarsagene autotemcel), approved on March 18, 2024, manufactured by Orchard Therapeutics (Europe) Ltd., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08276.pdf?1713357931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-18'}, {'ID': '2024-08293', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by May 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08293.pdf?1713357934', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-18'}, {'ID': '2024-08274', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the availability of the final decision withdrawing approval of PEPAXTO (melphalan flufenamide), for injection, equivalent to 20 milligrams (mg) base/vial, once every 28 days, under the new drug application (NDA) 214383, held by Oncopeptides AB (Oncopeptides). The Commissioner of Food and Drugs' (the Commissioner's) designee issued the decision, and a summary of responses to public comments. The Commissioner's designee issued this decision following the Center for Drug Evaluation and Research's (CDER) proposal to withdraw approval of PEPAXTO, Oncopeptides' appeal of the proposed withdrawal, a meeting between the designee and Oncopeptides, a public comment period on the proposed withdrawal, and an advisory committee that CDER convened and consulted on issues related to the proposed withdrawal.\", 'DATES': 'Approval of PEPAXTO is withdrawn as of February 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-08274.pdf?1713357930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-18'}, {'ID': '2024-07437', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': \"This final rule considers public comments submitted in response to the proposed rule revising the WIC food packages published on November 21, 2022. It revises regulations to align the WIC food packages with the current Dietary Guidelines for Americans and to reflect recommendations from the National Academies of Science, Engineering, and Medicine while promoting nutrition security and equity and considering program administration. The changes are intended to provide WIC participants with a wider variety of foods that align with the latest nutritional science; provide WIC State agencies with greater flexibility to prescribe and tailor food packages that accommodate participants' special dietary needs and personal and cultural food preferences; and address key nutritional needs to support healthy dietary patterns. This rule provides foods in amounts that are more consistent with the supplemental nature of the Program; encourages fruit and vegetable consumption; and strengthens support for individual breastfeeding goals to help establish long-term breastfeeding.\", 'DATES': 'Effective date: This rule is effective June 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07437.pdf?1713357917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-18'}, {'ID': '2024-07996', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding requirements for animal disposition reporting in the Public Health Information System. There are no changes to the existing information collection. The approval for this information collection will expire on September 30, 2024.', 'DATES': 'Submit comments on or before June 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07996.pdf?1713185130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-16'}, {'ID': '2024-07998', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding its Consumer Complaint Monitoring System (CCMS) web portal. There are no changes to the existing information collection. The approval for this information collection will expire on September 30, 2024.', 'DATES': 'Submit comments on or before June 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07998.pdf?1713185130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-16'}, {'ID': '2024-07829', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is publishing this notice to announce the establishment of the Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI). C3TI aims to be a central hub within CDER that supports innovative approaches to clinical trials that are designed to improve the quality and efficiency of drug development and regulatory decision making. C3TI's mission is to promote existing and future CDER clinical trial innovation activities through enhanced communication and collaboration. Existing CDER clinical development innovation programs will continue to operate according to their established processes with C3TI serving to synthesize lessons learned across those programs. C3TI will also be providing additional opportunities for sponsors of innovative clinical trials in the project areas described below to interact with CDER staff with the goal of fostering knowledge sharing both internally and externally.\", 'DATES': 'The applicable date of this notice is April 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07829.pdf?1713185117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-16'}, {'ID': '2024-07661', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07661.pdf?1712753119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-11'}, {'ID': '2024-07707', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that VISTARIL (hydroxyzine pamoate) Oral Suspension, 25 milligrams (mg)/5 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for VISTARIL (hydroxyzine pamoate) Oral Suspension, 25 mg/5 mL, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07707.pdf?1712753127', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-11'}, {'ID': '2024-07657', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that DUVYZAT (givinostat), approved on March 21, 2024, manufactured by Italfarmaco S.p.A., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07657.pdf?1712753118', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-11'}, {'ID': '2024-07722', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that KEMSTRO (baclofen) orally disintegrating tablets, 10 milligrams (mg) and 20 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for baclofen orally disintegrating tablets, 10 mg and 20 mg, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07722.pdf?1712753130', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-11'}, {'ID': '2024-07663', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07663.pdf?1712753119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-11'}, {'ID': '2024-07493', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public meeting; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled \"Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.\" The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.', 'DATES': 'The public meeting will be held on June 6, 2024, from 9:30 a.m. to 10:40 a.m. via ZoomGov. Either electronic or written comments on this public meeting must be submitted by July 6, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07493.pdf?1712580325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-09'}, {'ID': '2024-07494', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07494.pdf?1712580326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-09'}, {'ID': '2024-07495', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; request for comments.', 'SUMMARY': \"The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of the Agency's annual compilation of notices of updates to the Agency's Susceptibility Test Interpretive Criteria web page. The Agency established the Susceptibility Test Interpretive Criteria web page on December 13, 2017, and since establishment has provided updates to both the format of the web pages and the susceptibility test interpretive criteria identified and recognized by FDA on the web pages. FDA is publishing this notice in accordance with procedures established by the 21st Century Cures Act (Cures Act).\", 'DATES': 'This notice is published in the Federal Register on April 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07495.pdf?1712580326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-09'}, {'ID': '2024-07377', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a new collection without an assigned OMB control number for the Supplemental Nutrition Assistance Program (SNAP). This information collection is for activities associated with SNAP demonstration projects and the SNAP State Options Report, respectively.', 'DATES': 'Written comments must be received on or before June 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07377.pdf?1712321132', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-08'}, {'ID': '2024-07271', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Robert Lance Shuffert for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Shuffert was convicted of one felony count under Federal law for, with the intent to defraud and mislead, causing a drug to be misbranded while it was held for sale after shipment in interstate commerce. The factual basis supporting Mr. Shuffert's conviction, as described below, is conduct relating to the importation into the United States of any drug or controlled substance. Mr. Shuffert was given notice of the proposed debarment and an opportunity to request a hearing to show why he should not be debarred. As of March 4, 2024 (30 days after receipt of the notice), Mr. Shuffert had not responded. Mr. Shuffert's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable April 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07271.pdf?1712234727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-05'}, {'ID': '2024-07261', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting that any industry organization interested in participating in the selection of a nonvoting industry representative to serve on the Device Good Manufacturing Practice Advisory Committee (DGMPAC) in the Center for Devices and Radiological Health notify FDA in writing. FDA is also requesting nominations for a nonvoting industry representative to fill an upcoming vacancy on DGMPAC. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for an upcoming vacancy effective with this notice.', 'DATES': 'Any industry organizations interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to FDA by May 6, 2024 (see sections I and III of this document for further details). Concurrently, nomination materials for prospective candidates should be sent to FDA by May 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07261.pdf?1712234725', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-05'}, {'ID': '2024-07273', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on May 22, 2024, from 10 a.m. to 3:45 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07273.pdf?1712234727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-05'}, {'ID': '2024-07254', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is requesting nominations for voting members, excluding consumer and industry representatives, to serve on the Patient Engagement Advisory Committee (the Committee) in the Center for Devices and Radiological Health. Nominations will be accepted for upcoming vacancies effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.', 'DATES': 'Nominations received on or before June 4, 2024, will be given first consideration for membership on the Committee. Nominations received after June 4, 2024, will be considered for nomination to the Committee as later vacancies occur.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07254.pdf?1712234723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-05'}, {'ID': '2024-07268', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that GLUCOTROL (glipizide) tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to these products as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07268.pdf?1712234726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-05'}, {'ID': '2024-07095', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a draft guidance for industry entitled \"New Dietary Ingredient Notification Master Files for Dietary Supplements.\" The draft guidance, when finalized, will provide recommendations to the dietary supplement industry on Master Files for new dietary ingredients. The purpose of this draft guidance, when finalized, will be to help industry comply more easily with the new dietary ingredient notification requirement by providing recommendations on the submission and use of Master Files that contain identity, manufacturing, or safety data that can be used to support a new dietary ingredient notification. New dietary ingredient Master Files are submitted solely at the discretion of the Master File owner and are not required by statute or regulation.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 3, 2024 to ensure that we consider your comment on the draft guidance before we begin work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07095.pdf?1712148315', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-04'}, {'ID': '2024-07164', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a new information collection for the contract of the study titled \"Evaluating the Interview Requirement for SNAP Certification.\" The purpose of this collection is to help FNS describe the effects of waiving the interview requirement, including SNAP agency processes and staff experiences with implementing the no-interview demonstration, analyzing the differences in outcomes for SNAP applicants and recipients, and identifying key lessons to inform future policy or implementation.', 'DATES': 'Written comments must be received on or before June 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07164.pdf?1712148326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-04'}, {'ID': '2024-07163', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This is a new collection for the study \"Assessment of Administrative Costs of Electronic Healthy Incentives Projects (eHIP).\" This study will calculate costs incurred by eHIP, which will provide incentives through EBT integration to increase purchase of healthy foods (e.g., fruits and vegetables) by Supplemental Nutrition Assistance Program (SNAP) participants.', 'DATES': 'Written comments must be received on or before June 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07163.pdf?1712148325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-04'}, {'ID': '2024-07127', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding voluntary recalls from commerce of meat, poultry, and egg products. There are no changes to the existing information collection. The approval for this information collection will expire on September 30, 2024.', 'DATES': 'Submit comments on or before June 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07127.pdf?1712148319', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-04'}, {'ID': '2024-07080', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Data Integrity for In Vivo Bioavailability and Bioequivalence Studies.\" The purpose of this guidance is to provide recommendations to applicants and testing site management on achieving and maintaining data integrity for the clinical and bioanalytical portions of bioavailability (BA) and bioequivalence (BE) studies submitted in support of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and the bioanalytical portion of clinical pharmacologic studies supporting Center for Drug Evaluation and Research-regulated biologic license applications (BLAs) as well as amendments and supplements to these applications. In addition, the recommendations in this guidance apply to the bioanalytical portion of nonclinical studies. FDA also encourages applicants and testing sites to consider these recommendations when conducting other studies, including in vitro and pharmacology and toxicology studies.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 3, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-07080.pdf?1712061931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-03'}, {'ID': '2024-06985', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Draft Guidance on Oxymetazoline Hydrochloride.\" The draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for oxymetazoline hydrochloride ophthalmic solution.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 3, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06985.pdf?1712061917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-03'}, {'ID': '2024-06726', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies.\" This guidance provides instructions for the electronic submission of expedited individual case safety reports (ICSRs) from investigational new drug (IND)-exempt bioavailability (BA)/bioequivalence (BE) studies to the FDA Adverse Event Reporting System (FAERS). This guidance finalizes the draft guidance entitled \"Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies\" issued on August 3, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on April 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06726.pdf?1711975513', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-02'}, {'ID': '2024-06837', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice of availability and request for comments.', 'SUMMARY': 'FSIS is announcing the availability of a guideline to assist meat (including Siluriformes fish and fish products) and poultry establishments in meeting the regulatory requirements for calculating the correct retained water percentage in raw livestock, poultry, and Siluriformes fish carcasses and parts resulting from post-evisceration processing, and the proper labeling of these products. FSIS is also announcing when the Agency will start verifying that establishments are correctly calculating retained water in applicable product. The guideline clarifies the methods an establishment may use to collect and use data to determine the amount of retained water in a product covered by its retained water protocol (RWP). In addition, it provides specific information on protocol development, process control, and air-chilled product claims.', 'DATES': 'Submit comments on or before May 31, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06837.pdf?1711716326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-01'}, {'ID': '2024-06736', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Providing Regulatory Submissions in Electronic Format: IND Safety Reports.\" This guidance finalizes the draft guidance of the same name published on October 30, 2019, and describes the electronic format sponsors will be required to use when they electronically submit investigational new drug application (IND) safety reports to the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER) for serious and unexpected suspected adverse reactions, as required by FDA regulations. FDA is establishing the electronic format requirements described in this guidance under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The requirements in the guidance will be effective 24 months after the date of publication (April 1, 2026). Certain sponsors will be required to submit the specified IND safety reports electronically to FDA using the FDA Adverse Event Reporting System (FAERS) as structured data elements, which will provide sponsors with a reporting format that is consistent with the International Council for Harmonisation (ICH) E2B format guidelines and reporting requirements to other regulatory agencies.', 'DATES': 'The announcement of the guidance is published in the Federal Register on April 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06736.pdf?1711716315', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-04-01'}, {'ID': '2024-06723', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the over-the-counter (OTC) monograph drug facility (MDF) fee rates under the OTC monograph drug user fee program (OMUFA) for fiscal year (FY) 2024. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to assess and collect user fees from qualifying manufacturers of OTC monograph drugs and submitters of OTC monograph order requests (OMORs). This notice publishes the OMUFA facility fee rates for FY 2024.', 'DATES': 'These facility fees are effective on October 1, 2023, and will remain in effect through September 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06723.pdf?1711629926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-29'}, {'ID': '2024-06734', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Animal Studies for Dental Bone Grafting Material Devices--Premarket Notification (510(k)) Submissions.\" This draft guidance document provides animal study design recommendations and animal study information to include to support a 510(k) submission for dental bone grafting material devices. This draft guidance may help manufacturers comply with some special controls for dental bone grafting material devices. The recommendations reflect current review practices and are intended to promote consistency and facilitate efficient review of these submissions. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 28, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06734.pdf?1711629928', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-29'}, {'ID': '2024-06730', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is withdrawing approval of 30 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of April 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06730.pdf?1711629927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-29'}, {'ID': '2024-06500', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled \"Handling and Retention of BA and BE Testing Samples.\" This guidance is intended to provide recommendations for applicants of new drug applications (NDAs) and abbreviated new drug applications (ANDAs), including supplemental applications, and contract research organizations (CROs), regarding the procedures for handling reserve samples from relevant bioavailability (BA) and bioequivalence (BE) studies, and recommendations regarding responsibilities of each party involved in the study pertaining to reserve samples. Additionally, this guidance describes the conditions under which the Agency generally does not intend to take enforcement action against an applicant or CRO that retains less than the quantity of reserve samples specified in the regulation.', 'DATES': 'Submit either electronic or written comments on the draft portion of this guidance by May 28, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Comments on the final portion of this guidance may be submitted at any time for Agency consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06500.pdf?1711457126', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-27'}, {'ID': '2024-06438', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by April 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06438.pdf?1711457116', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-27'}, {'ID': '2024-06298', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for LYNPARZA (olaparib) Capsules, 50 milligrams (mg) held by AstraZeneca Pharmaceuticals LP (AZ), 1800 Concord Pike, Wilmington, DE 19803. AZ has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.', 'DATES': 'Approval is withdrawn as of March 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06298.pdf?1711370722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06311', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) has determined that ISUPREL (isoproterenol hydrochloride) injection, 0.2 milligrams (mg)/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ISUPREL (isoproterenol hydrochloride) injection, 0.2 mg/mL, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06311.pdf?1711370724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06299', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that it is withdrawing approval of the indications for the treatment of adult patients with advanced ovarian cancer for poly (ADP-ribose) polymerase (PARP) inhibitors under three new drug applications (NDAs) from multiple applicants. The applicants Clovis Oncology, Inc. (Clovis), AstraZeneca Pharmaceuticals LP (AZ), and GlaxoSmithKline, LLC (GSK) have each voluntarily requested that the Agency withdraw approval of the indications for the treatment of adult patients with advanced ovarian cancer for their respective PARP inhibitors and waived their opportunities for hearings. Applicant and indication details are further discussed in SUPPLEMENTARY INFORMATION.', 'DATES': 'Approval is withdrawn as of March 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06299.pdf?1711370722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06287', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Phillip Leonowens for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Leonowens was convicted of one felony count under Federal law for conspiracy to smuggle goods into the United States. The factual basis supporting Mr. Leonowens' conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Leonowens was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of December 31, 2023 (30 days after receipt of the notice), Mr. Leonowens had not responded. Mr. Leonowens's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable March 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06287.pdf?1711370721', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06316', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection requirements for a voluntary survey for the Department of Health and Human Services (HHS), the U.S. Department of Agriculture (USDA), and the Department of Homeland Security (DHS), which will inform the FDA Food Safety Modernization Act (FSMA), National Agriculture and Food Defense Strategy (NAFDS) Report to Congress. The proposed survey will be used to determine what food defense activities, if any, State, local, territorial, and/or tribal (SLTT) agencies have completed to date. The information will be compared to the initial baseline data previously collected by State(s).', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06316.pdf?1711370725', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06395', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled \"Reporting and Recordkeeping Requirements for Human Food and Cosmetics Manufactured From, Processed With, or Otherwise Containing, Material From Cattle\" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06395.pdf?1711370738', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06294', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA or Agency) Center for Biologics Evaluation and Research (CBER) is announcing support for the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data Implementation Guide--Animal Rule Version 1.0 (SENDIG-AR v1.0) on March 26, 2024, and this standard will be required in submissions to CBER for studies that start after March 15, 2027. The Agency will update the FDA Data Standards Catalog (Catalog) to reflect this change.\", 'DATES': 'Support for version CDISC SENDIG-AR v1.0 begins March 26, 2024. The requirement for electronic submissions using CDISC SENDIG-AR v1.0 begins for studies that start after March 15, 2027, for new drug applications (NDAs), abbreviated new drug applications (ANDAs), certain biologics license applications (BLAs), and certain investigational new drug applications (INDs). Submit either electronic or written comments at any time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06294.pdf?1711370722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06314', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on April 12, 2024, from 9 a.m. to 4 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06314.pdf?1711370725', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06265', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06265.pdf?1711370717', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06037', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is proposing to ban electrical stimulation devices (ESDs) intended for self-injurious behavior (SIB) or aggressive behavior (AB). FDA has determined these devices present an unreasonable and substantial risk of illness or injury that cannot be corrected or eliminated by labeling. This proposal follows a court decision vacating a prior ban and amendment to the Federal Food, Drug, and Cosmetic Act clarifying our authority to ban a device for one or more intended uses. This action, if finalized, will mean ESDs for SIB and AB are adulterated and not legally marketed.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by May 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06037.pdf?1711370716', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-26'}, {'ID': '2024-06242', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Martin Valdes, M.D., from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Dr. Valdes was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product under the FD&C Act. Dr. Valdes was given notice of the proposed permanent debarment and an opportunity to request a hearing to show why he should not be debarred. As of January 7, 2023 (30 days after receipt of the notice), Dr. Valdes had not responded. Dr. Valdes's failure to respond and request a hearing within the prescribed timeframe constitutes a waiver of his right to a hearing concerning this action.\", 'DATES': 'This order is applicable March 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06242.pdf?1711111530', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-25'}, {'ID': '2024-05802', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': \"The Food and Drug Administration (FDA or we) is amending its regulations relating to the procedures for determining that a premarket notification for a food contact substance (FCN) is no longer effective. The final rule provides additional reasons that could form the basis for FDA to determine that an FCN is no longer effective. The final rule also ensures that manufacturers or suppliers have the opportunity to provide input before we determine that an FCN is no longer effective. We are making these changes to allow FDA to respond better to new information on the safety and use of food contact substances (FCSs), as well as manufacturers' business decisions, and also improve the efficiency of the premarket notification program.\", 'DATES': 'This rule is effective May 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05802.pdf?1711025115', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-22'}, {'ID': '2024-05981', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Willis Reed from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Reed was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Mr. Reed was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of February 10, 2024 (30 days after receipt of the notice), Mr. Reed has not responded. Mr. Reed's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable March 21, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05981.pdf?1710938722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-05969', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products.\" FDA is issuing this draft guidance as part of a series of guidance documents under its Real-World Evidence (RWE) Program and to satisfy, in part, a mandate under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to issue guidance about the use of RWE in regulatory decision-making. The draft guidance provides recommendations to sponsors who are considering submitting a non- interventional study, also referred to as an observational study, to FDA to contribute to a demonstration of substantial evidence of effectiveness and/or evidence of safety of a drug. This draft guidance was developed in response to stakeholders\\' growing interest in the potential use of non-interventional studies to contribute to a demonstration of the effectiveness or safety of a drug.', 'DATES': 'Submit either electronic or written comments on the draft guidance by June 18, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05969.pdf?1710938720', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-05980', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Life Technologies Corp. (a legal entity of Thermo Fisher Scientific, Inc.), for the TaqPath COVID-19 Pooling Kit; Bio-Rad Laboratories, Inc., for the Reliance SARS-CoV-2 RT-PCR Assay Kit; Revvity, Inc., (on behalf of Revvity Omics (a Revvity, Inc. company that was a rebranding of PerkinElmer Genomics)), for the PerkinElmer SARS-CoV-2 RT-qPCR Reagent Kit; bioM[eacute]rieux SA for the VIDAS SARS-CoV-2 IgM kit; bioM[eacute]rieux SA for the VIDAS SARS- CoV-2 IgG kit; and Luminex Corp. for the xMAP SARS-CoV-2 Multi-Antigen IgG Assay. FDA revoked the Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.', 'DATES': \"The Authorization for the Life Technologies Corp.'s (a legal entity of Thermo Fisher Scientific, Inc.) TaqPath COVID-19 Pooling Kit is revoked as of January 16, 2024. The Authorization for the Bio-Rad Laboratories, Inc.'s Reliance SARS-CoV-2 RT-PCR Assay Kit is revoked as of January 16, 2024. The Authorization for the Revvity, Inc.'s (on behalf of Revvity Omics (a Revvity, Inc. company that was a rebranding of PerkinElmer Genomics)) PerkinElmer SARS-CoV-2 RT-qPCR Reagent Kit is revoked as of January 30, 2024. The Authorization for the bioM[eacute]rieux SA's VIDAS SARS-CoV-2 IgM kit is revoked as of January 31, 2024. The Authorization for the bioM[eacute]rieux SA's VIDAS SARS-CoV-2 IgG kit is revoked as of January 31, 2024. The Authorization for the Luminex Corp.'s xMAP SARS-CoV-2 Multi-Antigen IgG Assay is revoked as of February 22, 2024.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05980.pdf?1710938722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-05982', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of SARAFEM (fluoxetine hydrochloride (HCl)) capsules, equivalent to (EQ) 10 milligrams (mg) base and EQ 20 mg base, including the premenstrual dysphoric disorder (PMDD) indication, approved under new drug application (NDA) 018936. This NDA is held by Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285 (Lilly). Lilly notified the Agency in writing that SARAFEM (fluoxetine HCl) capsules, EQ 10 mg base and EQ 20 mg base, indicated for the treatment of PMDD, was no longer marketed and requested that the approval of SARAFEM (fluoxetine HCl) capsules, including the PMDD indication, be withdrawn.', 'DATES': 'Approval is withdrawn as of April 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05982.pdf?1710938722', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-05986', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the reporting, recordkeeping, and third-party disclosure burden associated with the veterinary feed directive regulations.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05986.pdf?1710938723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-05970', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collections associated with Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05970.pdf?1710938720', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-06028', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the reporting and recordkeeping requirements of our regulations implementing the Federal Import Milk Act (FIMA).', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-06028.pdf?1710938729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-21'}, {'ID': '2024-05801', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present demonstrable difficulties for compounding (Demonstrable Difficulties for Compounding Lists or DDC Lists) under certain sections of the Federal Food, Drug, and Cosmetic Act. Additionally, the Agency is proposing to identify the first three categories of drug products on both DDC Lists. Drug products or categories of drug products that appear on the DDC Lists cannot qualify for certain statutory exemptions, and therefore may not be compounded under, either section 503A or section 503B, respectively.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by June 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05801.pdf?1710852315', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-20'}, {'ID': '2024-05742', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) 205864 and the new animal drug application (NADA) 141-395 for the designated medical gas Helium, USP held by Air Products and Chemicals, Inc., 1940 Air Products Blvd., Allentown, PA 18106-5500 (Air Products). Air Products notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.', 'DATES': 'Approval is withdrawn as of April 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05742.pdf?1710765917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-19'}, {'ID': '2024-05683', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Pharmacokinetics in Patients with Impaired Renal Function--Study Design, Data Analysis, and Impact on Dosing.\" In general, drug development programs should be conducted so that when products are approved, the labeling provides appropriate dosing recommendations for patients with renal impairment. This guidance is intended to assist sponsors in the design and analysis of studies that assess the influence of impaired renal function on the pharmacokinetics (PK) and/ or pharmacodynamics (PD) of an investigational drug and addresses how such information can inform the labeling. This guidance finalizes the draft guidance \"Pharmacokinetics in Patients with Impaired Renal Function--Study Design, Data Analysis, and Impact on Dosing\" issued on September 4, 2020.', 'DATES': 'The announcement of the guidance is published in the Federal Register on March 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05683.pdf?1710506727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-18'}, {'ID': '2024-05686', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #285 entitled \"Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs.\" This draft guidance is intended to provide recommendations for the primary batches of drug product manufactured to support the approval or conditional approval of new animal drug products. This guidance is applicable to all original new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs), and their associated investigational new animal drug files (INADs) and generic investigational new animal drug files, respectively, as well as applications for conditional approval of new animal drugs (CNADAs).', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 17, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05686.pdf?1710506727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-18'}, {'ID': '2024-05619', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for ALIQOPA (copanlisib) for injection, 60 milligrams (mg)/vial, held by Bayer HealthCare Pharmaceuticals Inc., 100 Bayer Blvd., Whippany, NJ 07981- 0915. Bayer HealthCare Pharmaceuticals Inc. (Bayer) has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.', 'DATES': 'Approval is withdrawn as of March 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05619.pdf?1710506717', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-18'}, {'ID': '2024-05687', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Controlled Correspondence Related to Generic Drug Development.\" This guidance provides information regarding the process by which generic drug manufacturers and related industry can submit controlled correspondence to FDA requesting information related to generic drug development and the Agency\\'s process for providing communications related to such correspondence. This guidance also describes the process by which generic drug manufacturers and related industry can submit requests to clarify ambiguities in FDA\\'s controlled correspondence response and the Agency\\'s process for responding to those requests. This guidance finalizes the draft guidance of the same title issued on December 22, 2022. This guidance replaces the guidance \"Controlled Correspondence Related to Generic Drug Development\" issued on December 17, 2020.', 'DATES': 'The announcement of the guidance is published in the Federal Register on March 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05687.pdf?1710506727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-18'}, {'ID': '2024-05479', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Final rule.', 'SUMMARY': 'FSIS is amending its regulations to define the conditions under which the labeling of meat, poultry, and egg products under mandatory inspection, as well as voluntarily inspected products, may bear voluntary label claims indicating that the product is of United States origin. As of the compliance date of this final rule, establishments will not need to include these claims on the label, but if they choose to include them, they will need to meet the requirements in this rule.', 'DATES': 'Effective date: May 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05479.pdf?1710506714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-18'}, {'ID': '2024-05584', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Evaluation of Thermal Effects of Medical Devices That Produce Tissue Heating and/or Cooling.\" FDA is issuing this draft guidance document to describe relevant information that should be provided in premarket submissions to support the evaluation of thermal effects of medical devices that produce local, regional, and/or systemic changes in tissue temperature (i.e., heating and/or cooling) due to their use. The recommendations in this draft guidance reflect current review practices and are intended to promote consistency and facilitate efficient review of thermal effects data in premarket submissions for these devices. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 14, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05584.pdf?1710420335', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-15'}, {'ID': '2024-05473', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendments.', 'SUMMARY': \"The Food and Drug Administration (FDA, the Agency, or we) is amending certain medical device regulations to update a citation for information collection and conform the regulatory provisions to the Federal Food, Drug, and Cosmetics Act (FD&C Act). The rule does not impose any new requirements on affected parties. This action is editorial in nature to correct errors and to ensure accuracy and clarity in the Agency's regulations.\", 'DATES': 'This rule is March 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05473.pdf?1710420320', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-15'}, {'ID': '2024-05580', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program.\" This draft guidance document provides an overview of the mechanisms available to submitters through which they can request interactions with FDA related to medical device submissions. This draft guidance, when finalized, is intended to supersede the document entitled \"Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program\" issued on June 2, 2023, and provides clarification and additional information on the scope of Q- Submission (Q-Sub) types, better delineation of how to obtain feedback for different types of questions (i.e., informal communication vs. Pre- Submission or other Q-Submission types), and improved examples. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 14, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05580.pdf?1710420335', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-15'}, {'ID': '2024-05582', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that NUCYNTA (tapentadol hydrochloride) solution, equivalent (eq) 20 milligrams (mg) base/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for tapentadol hydrochloride solution, eq 20 mg base/mL, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05582.pdf?1710420335', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-15'}, {'ID': '2024-05578', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that DUEXIS (ibuprofen and famotidine) tablet, 800 milligrams (mg) ibuprofen and 26.6 mg famotidine, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05578.pdf?1710420334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-15'}, {'ID': '2024-04598', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': \"The Food and Drug Administration (FDA or we) is revoking the standard of identity and the standard of quality for frozen cherry pie. This action, in part, responds to a citizen petition submitted by the American Bakers Association (ABA). We conclude that these standards are no longer necessary to promote honesty and fair dealing in the interest of consumers. Revocation of the standards of identity and quality for frozen cherry pie will provide greater flexibility in the product's manufacture, consistent with comparable, nonstandardized foods available in the marketplace.\", 'DATES': 'This rule is effective April 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04598.pdf?1710420315', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-15'}, {'ID': '2024-05408', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VTAMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by May 13, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 10, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05408.pdf?1710333924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-14'}, {'ID': '2024-05421', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CIBINQO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by May 13, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 10, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05421.pdf?1710333927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-14'}, {'ID': '2024-05426', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on December 18, 2023. The document announced the withdrawal of approval of two new drug applications (NDA), withdrawn as of January 17, 2024. The document indicated that FDA was withdrawing approval of NDA 022424, FLOWTUSS (guaifenesin 200 milligrams (mg)/5 milliliters (mL) and hydrocodone bitartrate 2.5 mg/5 mL) Oral Solution held by Chartwell RX Sciences, LLC, 77 Brenner Dr., Congers, NY 10920. Before FDA withdrew the approval of this NDA, Chartwell RX Sciences, LLC informed FDA that it did not want the approval of the NDA withdrawn. Because Chartwell RX Sciences, LLC timely requested that approval of NDA 022424 not be withdrawn, the approval is still in effect. This notice corrects that error.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05426.pdf?1710333927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-14'}, {'ID': '2024-05407', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PYRUKYND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by May 13, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 10, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05407.pdf?1710333924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-14'}, {'ID': '2024-05381', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports.\" The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance updates the existing E2D guidance entitled \"E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting,\" published in 2003. The draft guidance is intended is to clarify the use of new or increasingly used data sources (e.g., social media, market research programs, patient support programs) and update terminology and standards for postmarket adverse event reporting.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 13, 2024, to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05381.pdf?1710333920', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-14'}, {'ID': '2024-05436', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a revision of a currently approved collection.', 'DATES': 'Written comments must be received on or before May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05436.pdf?1710333929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-14'}, {'ID': '2024-05293', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Annual Reportable Labeling Changes for NDAs and ANDAs for Nonprescription Drug Products.\" This draft guidance provides recommendations to applicants of approved new drug applications (NDAs) and abbreviated new drug applications (ANDAs) for nonprescription drug products on documenting minor labeling changes in the next annual report and provides examples of minor labeling changes that may be submitted in an annual report. The recommendations in this draft guidance address the types of minor labeling changes that may be appropriate to submit in an annual report to ensure that consumers have timely access to the most current labeling for a nonprescription drug product to ensure the product\\'s safe and effective use. We anticipate that these recommendations may assist industry in understanding the circumstances in which it would be appropriate to document minor changes in the applicant\\'s next annual report rather than submitting a prior approval supplement or \"changes being effected\" supplement, thereby reducing burden on industry and FDA.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 13, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05293.pdf?1710247520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-13'}, {'ID': '2024-05298', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that Romidepsin Injection, 10 milligrams (mg)/2 milliliters (mL) (5 mg/mL) and 27.5 mg/5.5 mL (5 mg/mL), were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for romidepsin solution, 10 mg/2 mL (5 mg/mL) and 27.5 mg/5.5 mL (5 mg/mL), that refer to these drugs as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05298.pdf?1710247521', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-13'}, {'ID': '2024-05295', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act.\" This draft guidance proposes select updates to the final guidance \"Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions.\" This draft guidance, when finalized, will identify the information FDA generally considers to be necessary for cyber devices to support obligations under the new amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) for ensuring cybersecurity of devices. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 13, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05295.pdf?1710247520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-13'}, {'ID': '2024-05305', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAURISMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by May 13, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 9, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05305.pdf?1710247522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-13'}, {'ID': '2024-05294', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Proposed Small Dispensers Assessment under the Drug Supply Chain Security Act (DSCSA).', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05294.pdf?1710247520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-13'}, {'ID': '2024-05178', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled \"Early Alzheimer\\'s Disease: Developing Drugs for Treatment.\" This draft guidance is intended to assist sponsors in the clinical development of drugs for the treatment of the stages of sporadic Alzheimer\\'s disease (AD) that occur before the onset of overt dementia. This draft guidance revises the previous draft guidance for industry of the same name issued on February 16, 2018.', 'DATES': 'Submit either electronic or written comments on the draft guidance by May 13, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05178.pdf?1710161120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-05215', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection requirements in the Agency's regulations relating to establishment registration and product listing for manufacturers of human blood and blood products and licensed devices.\", 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05215.pdf?1710161232', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-05222', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by April 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05222.pdf?1710161290', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-05219', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's procedures for early food safety evaluation and consultations for new plant varieties intended for food use, including biotechnology-derived food plants.\", 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05219.pdf?1710161125', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-05213', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LIGHT ADJUSTABLE LENS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by May 13, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 9, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05213.pdf?1710161124', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-05218', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pharmaceutical Science and Clinical Pharmacology Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the January 22, 2026, expiration date.', 'DATES': 'Authority for the Pharmaceutical Science and Clinical Pharmacology Advisory Committee will expire on January 22, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05218.pdf?1710161125', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-04840', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA) is proposing to revise the requirements for the content and format of labeling for approved or conditionally approved new animal drugs to provide for a more comprehensive set of requirements in one location in the Code of the Federal Register (CFR). As part of this revision, certain current requirements would be updated and moved, and certain obsolete requirements would be removed. The proposed requirements would apply to the labeling of prescription and over-the-counter (OTC) new animal drugs, as well as new animal drugs for use in animal feeds.', 'DATES': 'Either electronic or written comments on the proposed rule must be submitted by June 10, 2024. Submit written comments (including recommendations) on information collection issues under the Paperwork Reduction Act of 1995 by April 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04840.pdf?1709905524', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-12'}, {'ID': '2024-05074', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of meeting; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Blood Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues regarding blood and blood products. At this meeting the Committee will consider strategies to reduce the risk of transfusion-transmitted malaria by testing blood donations from donors at risk of malaria exposure. The meeting will be open to the public. FDA is establishing a docket for public comment on this topic.', 'DATES': 'The meeting will be held on May 9, 2024, from 9:30 a.m. to 3:10 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05074.pdf?1709905537', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-11'}, {'ID': '2024-05085', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Eli Lilly and Co. (Lilly), for bamlanivimab and etesevimab administered together. FDA revoked the Authorization on December 14, 2023, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.', 'DATES': 'The Authorization is revoked as of December 14, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-05085.pdf?1709905540', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-11'}, {'ID': '2024-04845', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Gastrointestinal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Gastrointestinal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 3, 2026, expiration date.', 'DATES': 'Authority for the Gastrointestinal Drugs Advisory Committee will expire on March 3, 2026, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04845.pdf?1709732724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-07'}, {'ID': '2024-04834', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of final guidances for industry entitled \"Q2(R2) Validation of Analytical Procedures\" and \"Q14 Analytical Procedure Development.\" The guidances were prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance entitled \"Q2(R2) Validation of Analytical Procedures\" provides a general framework for the principles of analytical procedure validation, including validation principles that cover the analytical use of spectroscopic data. The guidance entitled \"Q14 Analytical Procedure Development\" provides harmonized guidance on scientific approaches for analytical procedure development and describes principles to facilitate more efficient, science-based, and risk-based postapproval change management. The guidances are intended to facilitate regulatory evaluations and potential flexibility in postapproval change management of analytical procedures when scientifically justified. The guidances replace the draft guidances \"Q2(R2) Validation of Analytical Procedures\" and\" Q14 Analytical Procedure Development\" issued on August 29, 2022.', 'DATES': 'The announcement of the guidances is published in the Federal Register on March 7, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04834.pdf?1709732723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-07'}, {'ID': '2024-04735', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the availability of the decision to deny a request for a hearing regarding the proposal of the Center for Drug Evaluation and Research (CDER) to refuse to approve the supplemental new drug application (sNDA) 205677-004, submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), for the treatment of jet lag disorder. The decision, which also refuses approval of sNDA 205677-004, is available in the docket identified by the number in the heading of this document.', 'DATES': 'The decision was published in the docket on March 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04735.pdf?1709646332', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-06'}, {'ID': '2024-04718', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled \"Dietary Supplements: New Dietary Ingredient Notification Procedures and Timeframes: Guidance for Industry.\" The guidance focuses on frequently asked questions about the new dietary ingredient notification submission and review process. The guidance is intended to help manufacturers and distributors of new dietary ingredients and dietary supplements prepare and submit new dietary ingredient notifications to FDA.', 'DATES': 'The announcement of the guidance is published in the Federal Register on March 6, 2024', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04718.pdf?1709646329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-06'}, {'ID': '2024-04716', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by April 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04716.pdf?1709646329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-06'}, {'ID': '2024-04722', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on \"Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Restaurant and Retail Foodservice Facility Types.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by May 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04722.pdf?1709646330', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-06'}, {'ID': '2024-04751', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is amending the standing advisory committee regulations to add the establishment of the Genetic Metabolic Diseases Advisory Committee (GeMDAC or the Committee) to the list of standing committees.', 'DATES': 'This rule is effective March 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04751.pdf?1709646334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-06'}, {'ID': '2024-04715', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by April 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04715.pdf?1709646328', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-06'}, {'ID': '2024-04526', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by April 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04526.pdf?1709559914', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-05'}, {'ID': '2024-04523', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. On May 16, 2024, the Committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held virtually on May 16, 2024, from 8:30 a.m. to 4:30 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04523.pdf?1709300744', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04481', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FYARRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by May 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 3, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04481.pdf?1709300736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04480', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RELYVRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by May 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 3, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04480.pdf?1709300736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04483', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOTYKTU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by May 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 3, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04483.pdf?1709300737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04478', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by May 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 3, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04478.pdf?1709300736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04479', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOXZOGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by May 3, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by September 3, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04479.pdf?1709300736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04492', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': \"The Chef Ann Foundation (CAF) is a cooperative argreement recipient from the United States Department of Agriculture's (USDA's) Food and Nutrition Service (FNS). CAF plans to collect additional information from sub-grantees, based on an assessment and data report, which is beyond the information already approved under OMB Control Number: 0584-0512 (Expiration Date: July 31, 2025). FNS already has OMB approval for collection of information associated with these grants under the Uniform Grant Application for Non-Entitlement Discretionary Grants, as approved under OMB Control Number: 0584-0512. This notice solicits public comment on the additional information proposed for collection.\", 'DATES': 'July 31, 2025). FNS already has OMB approval for collection of information associated with these grants under the Uniform Grant Application for Non-Entitlement Discretionary Grants, as approved under OMB Control Number: 0584-0512. This notice solicits public comment on the additional information proposed for collection.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04492.pdf?1709300738', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-04'}, {'ID': '2024-04375', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Clinical Pharmacology Considerations for Antibody-Drug Conjugates,\" which provides recommendations for the development of antibody-drug conjugates (ADCs). Specifically, this guidance addresses the FDA\\'s current thinking regarding clinical pharmacology considerations and recommendations for ADC development programs, including bioanalytical methods, dose selection and adjustment, dose- and exposure-response analysis, intrinsic factors, QTc assessments, immunogenicity, and drug- drug interactions (DDIs) for ADCs with a cytotoxic small-molecule drug or payload. Currently, there are no final FDA guidances outlining the clinical pharmacology considerations for ADCs. This guidance finalizes the draft guidance of the same title issued on February 8, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on March 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04375.pdf?1709214330', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-01'}, {'ID': '2024-04376', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled \"Modifications to the List of Recognized Standards, Recognition List Number: 061\" (Recognition List Number: 061), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.', 'DATES': 'Submit either electronic or written comments on the notice at any time. These modifications to the list of recognized standards are applicable March 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04376.pdf?1709214330', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-03-01'}, {'ID': '2024-04232', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KLISYRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04232.pdf?1709127930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04166', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) announcing that the debarment of Timothy Baxter will terminate on October 26, 2025.', 'DATES': 'This order is applicable February 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04166.pdf?1709127919', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04205', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEMBEXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04205.pdf?1709127925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04203', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPHNELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04203.pdf?1709127924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04207', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVKEEZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04207.pdf?1709127925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04162', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VONJO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04162.pdf?1709127918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04230', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LEQVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04230.pdf?1709127929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04214', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADUHELM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04214.pdf?1709127926', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04156', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECORLEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04156.pdf?1709127917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04233', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ONGENTYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04233.pdf?1709127930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04224', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VEKLURY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04224.pdf?1709127928', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04217', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVRYSDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04217.pdf?1709127927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04150', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BREXAFEMME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04150.pdf?1709127916', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04204', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EPI-SENSE GUIDED COAGULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04204.pdf?1709127925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04165', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAMZYOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04165.pdf?1709127919', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04155', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by April 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04155.pdf?1709127917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04221', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GEMTESA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04221.pdf?1709127927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04206', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AMPLATZER AMULET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04206.pdf?1709127925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04227', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XERAVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04227.pdf?1709127929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04234', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INQOVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04234.pdf?1709127930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04163', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the extension of this information collection.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by April 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04163.pdf?1709127918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04218', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAMCEVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04218.pdf?1709127927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04229', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PREVNAR-20 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04229.pdf?1709127929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04226', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NULIBRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04226.pdf?1709127929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04231', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ISTURISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04231.pdf?1709127930', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04219', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OPDUALAG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04219.pdf?1709127927', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04157', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOUNJARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04157.pdf?1709127917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04208', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOGROYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 27, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04208.pdf?1709127925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-29'}, {'ID': '2024-04064', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': \"In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a revision of a currently approved collection to provide FNS and WIC State agencies with an ongoing/annual data set that can be used to assess State agencies' compliance with WIC vendor management requirements and estimate State agencies' progress in eliminating fraud, waste, and abuse.\", 'DATES': 'Written comments must be received on or before April 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-04064.pdf?1709041522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-28'}, {'ID': '2024-03765', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during October, November, and December 2023. The animal drug regulations are also being amended to improve their accuracy and readability.', 'DATES': 'This rule is effective February 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03765.pdf?1708955113', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-27'}, {'ID': '2024-03961', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Rybrevant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 26, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03961.pdf?1708955126', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-27'}, {'ID': '2024-03777', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendment.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is amending its regulations to update a link regarding user fee disputes. This technical amendment is non-substantive.', 'DATES': 'This rule is effective February 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03777.pdf?1708695917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-26'}, {'ID': '2024-03650', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Taylor McLaren for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. McLaren was convicted of one felony count under Federal law for conspiracy to smuggle goods into the United States. The factual basis supporting Mr. McLaren's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. McLaren was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of January 8, 2024 (30 days after receipt of the notice), Mr. McLaren had not responded. Mr. McLaren's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable February 23, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03650.pdf?1708609520', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-23'}, {'ID': '2024-03618', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is amending the standing advisory committees regulations to add the establishment of the Digital Health Advisory Committee (the Committee) to the list of standing advisory committees.', 'DATES': 'This rule is effective February 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03618.pdf?1708523125', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-22'}, {'ID': '2024-03619', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled \"Select Updates for the Medical Device User Fee Small Business Qualification and Certification Guidance.\" The guidance includes select updates to the guidance \"Medical Device User Fee Small Business Qualification and Certification\" which describe how FDA plans to determine if a small business is experiencing \"financial hardship\" which makes them eligible for a waiver of their registration fee. The guidance will detail what information FDA will review and consider in making this determination. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 22, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by April 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03619.pdf?1708523126', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-22'}, {'ID': '2024-03622', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment.\" Although the public health emergency declared by the Department of Health and Human Services under section 319 of the Public Health Services Act has ended, COVID-19 remains an ongoing public health problem with continued prevention and treatment efforts. FDA is issuing this guidance to provide sponsors and investigators with considerations for approaches on how common COVID- 19-related symptoms can be measured and analyzed in clinical trials evaluating drugs or biological products for the prevention or treatment of COVID-19 in outpatient adult and adolescent subjects. This guidance supersedes the guidance of the same name issued on September 29, 2020.', 'DATES': 'The announcement of the guidance is published in the Federal Register on February 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03622.pdf?1708523126', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-22'}, {'ID': '2024-02108', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Proposed rule.', 'SUMMARY': 'This rulemaking proposes important modifications to make the application of serious deficiency procedures in the Child and Adult Care Food Program and Summer Food Service Program consistent, effective, and in line with current requirements under the Richard B. Russell National School Lunch Act. The serious deficiency process provides a systematic way for State agencies and sponsoring organizations to correct serious management problems, and when that effort fails, protect Child Nutrition Program integrity through due process. In response to public comments received on a prior rulemaking, the Food and Nutrition Service (FNS) proposes improvements to ensure that application of the serious deficiency process is fair and fully implemented. FNS proposes to add clarity to the serious deficiency process by defining key terms, establishing a timeline for full correction, and establishing criteria for determining when the serious deficiency process must be implemented. This rulemaking will also address termination for cause and disqualification, implementation of legal requirements for records maintained on individuals on the National Disqualified List, and participation of multi-State sponsoring organizations.', 'DATES': 'Written comments must be received on or before May 21, 2024 to be assured of consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02108.pdf?1708436713', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-21'}, {'ID': '2024-03355', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': \"This notice announces the Department's annual adjustments to the Income Eligibility Guidelines to be used in determining eligibility for free and reduced price meals, free milk, and Summer Electronic Benefit Transfer benefits for the period from July 1, 2024 through June 30, 2025. These guidelines are used by schools, institutions, and facilities participating in the National School Lunch Program (and Commodity School Program), School Breakfast Program, Special Milk Program for Children, Child and Adult Care Food Program, and Summer Food Service Program. Beginning in 2024, they will also be used by States and Indian Tribal Organizations that administer the Summer Electronic Benefits Transfer for Children Program. The annual adjustments are required by section 9 of the Richard B. Russell National School Lunch Act. The guidelines are intended to direct benefits to those children most in need and are revised annually to account for changes in the Consumer Price Index.\", 'DATES': 'Applicable July 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03355.pdf?1708091118', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-20'}, {'ID': '2024-03343', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Final rule.', 'SUMMARY': 'FSIS is amending its regulations to exempt certain records maintained by its AssuranceNet (ANet) system of records from the notification and access provisions of the Privacy Act of 1974 (Privacy Act). FSIS is taking this action because ANet contains information directly associated with investigations conducted by FSIS for law enforcement purposes.', 'DATES': 'Effective date: April 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03343.pdf?1708091116', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-20'}, {'ID': '2024-03296', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability that published in the Federal Register of December 22, 2023. In that notice, FDA requested comments on the draft guidance for industry entitled, \"Master Protocols for Drug and Biological Product Development.\" The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the draft guidance published December 22, 2023 (88 FR 88623). Submit either electronic or written comments by March 21, 2024, to ensure that the Agency considers your comments on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03296.pdf?1708004734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-16'}, {'ID': '2024-03302', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing an amendment to the notice of the request for nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee (the Committee) in the Center for Drug Evaluation and Research. This request for nominations was announced in the Federal Register of December 13, 2023. The amendment is being made to reflect a change in the DATES portion of the document. There are no other changes.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03302.pdf?1708004735', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-16'}, {'ID': '2024-03300', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" that explained the process that would be used to make product-specific guidances available to the public on FDA\\'s website. The guidances identified in this notice were developed using the process described in that guidance.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 16, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03300.pdf?1708004735', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-16'}, {'ID': '2024-03186', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Charging for Investigational Drugs Under an IND: Questions and Answers.\" This guidance addresses frequently asked questions related to the implementation of FDA\\'s regulation on charging for investigational drugs under an investigational new drug application (IND) for the purpose of either clinical trials or expanded access for treatment use. This guidance finalizes the revised draft guidance of the same title issued on August 23, 2022, and replaces the final guidance issued on June 3, 2016.', 'DATES': 'The announcement of the guidance is published in the Federal Register on February 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03186.pdf?1707918337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-15'}, {'ID': '2024-02603', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Office of the Commissioner (OC), Office of Digital Transformation (ODT) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on December 21, 2023.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02603.pdf?1707918315', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-15'}, {'ID': '2024-03185', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice of intent to renew the Committee and its charter.', 'SUMMARY': 'In accordance with the Federal Advisory Committee Act, this notice is announcing the intention of the USDA to renew the committee for the National Advisory Committee on Microbiological Criteria for Foods (NACMCF) and its charter.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03185.pdf?1707918337', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-15'}, {'ID': '2024-03024', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SIMPLIFY CERVICAL ARTIFICIAL DISC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03024.pdf?1707831922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03030', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ERVEBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03030.pdf?1707831923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03026', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REACTIV8 SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03026.pdf?1707831923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03032', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS (MM)) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03032.pdf?1707831924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03029', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the PORTICO TRANSCATHETER AORTIC VALVE IMPLANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03029.pdf?1707831923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03025', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIVISTIM SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03025.pdf?1707831923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03036', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Kalpen D. Patel from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Patel was convicted of a felony under Federal law for conduct that relates to the regulation of any drug product under the FD&C Act. Mr. Patel was given notice of the proposed permanent debarment and was given an opportunity to request a hearing to show why he should not be debarred within the timeframe prescribed by regulation. Mr. Patel responded to the notice by submitting correspondence to FDA, but he did not request a hearing. Mr. Patel's failure to request a hearing within the prescribed timeframe constitutes a waiver of his right to a hearing concerning this action.\", 'DATES': 'This order is applicable February 14, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03036.pdf?1707831925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03020', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Ross Lucien for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Lucien was convicted of one felony count under Federal law for conspiracy to smuggle goods into the United States. The factual basis supporting Mr. Lucien's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Lucien was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of December 20, 2023 (30 days after receipt of the notice), Mr. Lucien had not responded. Mr. Lucien's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable February 14, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03020.pdf?1707831922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03022', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WINLEVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03022.pdf?1707831922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03028', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORGAN CARE SYSTEM HEART (OCS HEART SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03028.pdf?1707831923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03039', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA or the Agency) Center for Drug Evaluation and Research (CDER) is announcing the continuation of the Regulatory Project Management Site Tours and Regulatory Interaction Program (the Site Tours Program). The purpose of this document is to invite pharmaceutical companies interested in participating in this program to contact CDER.\", 'DATES': 'Pharmaceutical companies may send proposed agendas to the Agency by April 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03039.pdf?1707831925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03034', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORGAN CARE SYSTEM LIVER (OCS LIVER) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03034.pdf?1707831924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03031', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKYTROFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03031.pdf?1707831924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-03019', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QULIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by April 15, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by August 12, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-03019.pdf?1707831921', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-14'}, {'ID': '2024-02849', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Use of Data Monitoring Committees in Clinical Trials.\" This guidance is intended to assist sponsors of clinical trials in determining when a data monitoring committee (DMC) (also known as a data and safety monitoring board (DSMB), a data and safety monitoring committee (DSMC), or an independent data monitoring committee (IDMC)) would be useful for trial monitoring and what procedures and practices should be considered to guide their operation. When finalized, this guidance will supersede the final guidance for clinical trial sponsors entitled \"Establishment and Operation of Clinical Trial Data Monitoring Committees,\" issued in March 2006. This draft guidance is not final nor is it in effect at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 15, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by April 15, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02849.pdf?1707745521', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-13'}, {'ID': '2024-02922', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'The U.S. Department of Agriculture (\"Department\") announces adjusted income eligibility guidelines to be used by State agencies in determining the income eligibility of persons applying to participate in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). These income eligibility guidelines are to be used in conjunction with the WIC Regulations.', 'DATES': 'Applicable date July 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02922.pdf?1707745531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-13'}, {'ID': '2024-02838', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a draft guidance for industry entitled \"Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer\\'s Goods from DWPE.\" The draft guidance, when finalized, will provide recommendations for collecting a representative sample for products subject to DWPE under an import alert due to the appearance of adulteration caused by pathogens, unlawful animal drugs, scombrotoxin (histamine), and/or decomposition. When finalized, the draft guidance will also help foreign manufacturers and other processors of fish and fishery products subject to DWPE introduce evidence to FDA to support a request to have products removed from DWPE.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 12, 2024 to ensure that we consider your comment on the draft guidance before we begin work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02838.pdf?1707486333', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-12'}, {'ID': '2024-02836', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability; extension of comment period.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability entitled \"Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request\" that appeared in the Federal Register of December 13, 2023. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.', 'DATES': 'FDA is extending the comment period on the document published on December 13, 2023 (88 FR 86333). Either electronic or written comments must be submitted by March 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02836.pdf?1707486333', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-12'}, {'ID': '2024-02841', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of public workshop; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled \"FY 2024 Generic Drug Science and Research Initiatives Workshop.\" The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives. FDA is seeking this input from a variety of stakeholders-- industry, academia, patient advocates, professional societies, and other interested parties--as it fulfills its commitment under the Generic Drug User Fee Amendments of 2022 (GDUFA III) to develop an annual list of science and research initiatives specific to generic drugs. FDA will take the information it obtains from the public workshop into account in developing its fiscal year (FY) 2025 Generic Drug User Fee Amendments (GDUFA) science and research initiatives.', 'DATES': 'The public workshop will be held on May 20 and 21, 2024. Either electronic or written comments on this public workshop must be submitted by June 21, 2024. See the SUPPLEMENTARY INFORMATION section for registration date and information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02841.pdf?1707486334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-12'}, {'ID': '2024-02741', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': \"The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to amend its regulations to address the use of master files by applications licensed under the Public Health Service Act (PHS Act). This final rule codifies FDA's existing approach that former approved applications for certain biological products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) that have been deemed to be licenses for the biological products under the PHS Act may continue to incorporate by reference drug substance, drug substance intermediate, or drug product (DS/DSI/DP) information contained in a drug master file (DMF) if such information was being referenced at the time the application was deemed to be a license. This final rule also codifies FDA's general practices regarding the referencing of information in master files by applications licensed under the PHS Act, including applications for combination products licensed under the PHS Act, and by investigational new drug applications (INDs) for products that would be subject to licensure under the PHS Act.\", 'DATES': 'This rule is effective March 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02741.pdf?1707486321', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-12'}, {'ID': '2024-02710', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that QMIIZ (meloxicam) Orally Disintegrating Tablets, 7.5 milligrams (mg) and 15 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for QMIIZ (meloxicam) Orally Disintegrating Tablets, 7.5 mg and 15 mg, if all other legal and regulatory requirements are met.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02710.pdf?1707399937', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-09'}, {'ID': '2024-02709', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. This meeting will be held to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2024 to 2025 influenza season. The meeting will be open to the public.', 'DATES': 'The meeting will be held virtually on March 5, 2024, from 9 a.m. to 3:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02709.pdf?1707399936', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-09'}, {'ID': '2024-02706', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Brendon Gagne for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Gagne was convicted of one felony count under Federal law for conspiracy to smuggle goods into the United States. The factual basis supporting Mr. Gagne's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Gagne was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of January 5, 2024 (30 days after receipt of the notice), Mr. Gagne had not responded. Mr. Gagne's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is effective February 9, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02706.pdf?1707399936', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-09'}, {'ID': '2024-02579', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02579.pdf?1707313526', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-08'}, {'ID': '2024-02573', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is providing interested persons with the opportunity to submit written comments concerning recommendations by the World Health Organization (WHO) to impose international manufacturing and distributing restrictions, under international treaties, on certain drug substances. The comments received in response to this notice will be considered in preparing the United States' position on these proposals for a meeting of the United Nations Commission on Narcotic Drugs (CND) in Vienna, Austria, in March 2024. This notice is issued under the Controlled Substances Act (CSA).\", 'DATES': 'Submit either electronic or written comments by February 27, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02573.pdf?1707313525', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-08'}, {'ID': '2024-02417', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to renew an approved information collection regarding the labeling requirements for mechanically tenderized beef products. There are no changes to the existing information collection. The approval for this information collection will expire on June 30, 2024.', 'DATES': 'Submit comments on or before April 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02417.pdf?1707227115', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-07'}, {'ID': '2024-02361', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or the Agency) announces a forthcoming public advisory committee meeting of the Ophthalmic Devices Panel of the Medical Devices Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.\", 'DATES': 'The meeting will take place virtually on March 21, 2024, from 9 a.m. to 6 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02361.pdf?1707140731', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-06'}, {'ID': '2024-02356', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUAs) (the Authorizations) issued to Southern California Permanente Medical Group, for the Kaiser Permanente High Throughput SARS-CoV-2 Assay, that includes the Kaiser Permanente Saliva Home Collection Kit, and Drexel University College of Medicine, for the SARS-CoV-2 DUCoM-PDL Modified Tetracore Assay. FDA revoked the Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.', 'DATES': \"The revocation of the Authorization for the Southern California Permanente Medical Group's Kaiser Permanente High Throughput SARS-CoV-2 Assay, that includes the Kaiser Permanente Saliva Home Collection Kit, is effective as of September 29, 2023. The revocation of the Authorization for the Drexel University College of Medicine for the SARS-CoV-2 DUCoM-PDL Modified Tetracore Assay is effective as of October 5, 2023.\", 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02356.pdf?1707140730', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-06'}, {'ID': '2024-02369', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability.\" This guidance addresses the process through which registrants of drug establishments should submit reports to FDA on the amount of each listed drug manufactured, prepared, propagated, compounded, or processed for commercial distribution, as required by the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance finalizes the draft guidance of the same title published on November 1, 2021. To allow for the transition of technical updates to the NextGen Portal, FDA will delay implementation of the final guidance until February 26, 2024. The draft guidance will remain available until that date.', 'DATES': 'The announcement of the guidance is published in the Federal Register on February 6, 2024. Implementation of this guidance will be delayed until February 26, 2024, to allow for the transition of technical updates to the NextGen Portal.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02369.pdf?1707140732', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-06'}, {'ID': '2024-02229', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on March 15, 2024, from 8:30 a.m. to 5:30 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02229.pdf?1706881527', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-05'}, {'ID': '2024-02064', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed revision to the currently approved information collection for the Supplemental Nutrition Assistance Program (SNAP) FNS-885, \"SNAP Education (SNAP-Ed) Intervention Scoring Tool\" and the FNS-886, \"SNAP Education (SNAP-Ed) Intervention Submission Form.\" This revision to forms FNS-885 and FNS-886 will provide an improved user experience by simplifying scoring criteria and clarifying the information requested for certain fields. These updates will also align with the new SNAP-Ed National Program Evaluation and Reporting System (N-PEARS), to ensure consistency with SNAP-Ed specific terms. More information on changes to these forms is in the Supplementary Information section of this notice.', 'DATES': 'Comments on this notice must be received on or before April 2, 2024 to be assured of consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-02064.pdf?1706795119', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-02'}, {'ID': '2024-01709', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to amend the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) regulation to harmonize and modernize the regulation. We are harmonizing to align more closely with the international consensus standard for devices by converging with the quality management system (QMS) requirements used by other regulatory authorities from other jurisdictions (i.e., other countries). We are doing so by incorporating by reference an international standard specific for device quality management systems. Through this rulemaking we also establish additional requirements and make conforming edits to clarify the device CGMP requirements for such products. This action will continue our efforts to align our regulatory framework with that used by regulatory authorities in other jurisdictions to promote consistency in the regulation of devices and provide timelier introduction of safe, effective, high-quality devices for patients.', 'DATES': 'This rule is effective February 2, 2026. The incorporation by reference of certain material listed in this rule is approved by the Director of the Federal Register February 2, 2026.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01709.pdf?1706708714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-02-02'}, {'ID': '2024-01796', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium propionate as a source of chromium in turkey feed. This action is in response to a food additive petition filed by Kemin Industries, Inc.', 'DATES': 'This rule is effective January 30, 2024. See section V for further information on the filing of objections. Either electronic or written objections and requests for a hearing on the final rule must be submitted by February 29, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01796.pdf?1706535924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-30'}, {'ID': '2024-01789', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Guidance for Industry.\" The guidance is intended to assist sponsors, including industry and academic sponsors, developing ex vivo- manufactured CAR T cell products. The guidance provides CAR T cell specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and design of clinical studies for oncology indications (including hematologic malignancies and solid tumors). The guidance announced in this notice finalizes the draft guidance of the same title dated March 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01789.pdf?1706535923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-30'}, {'ID': '2024-01782', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products.\" The purpose of this guidance is to provide FDA\\'s expectations for, and recommendations on, use of a standardized approach for collecting and reporting race and ethnicity data in submissions including information collected and reported from clinical studies and clinical trials for FDA-regulated medical products. Using standard terminology for race and ethnicity helps ensure that data are collected and reported consistently in submissions to FDA. This draft guidance revises the final guidance for industry and FDA staff entitled \"Collection of Race and Ethnicity Data in Clinical Trials\" issued on October 26, 2016.', 'DATES': 'Submit either electronic or written comments on the draft guidance by April 29, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01782.pdf?1706535922', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-30'}, {'ID': '2024-01788', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry.\" The guidance document provides recommendations to sponsors developing human gene therapy products incorporating genome editing (GE) of human somatic cells. Specifically, the guidance provides recommendations regarding information that should be provided in an investigational new drug (IND) application to assess the safety and quality of the investigational GE product, including information on product design, product manufacturing and testing, nonclinical safety assessment, and clinical trial design. The guidance announced in this notice finalizes the draft guidance of the same title dated March 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 30, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01788.pdf?1706535923', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-30'}, {'ID': '2024-01797', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on March 14, 2024, from 9:30 a.m. to 3 p.m. eastern time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01797.pdf?1706535924', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-30'}, {'ID': '2024-01613', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality (OPQ) has modified its organizational structure. This new structure was approved by the Secretary of Health and Human Services on August 10, 2023.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01613.pdf?1706276714', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-29'}, {'ID': '2024-01584', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final document entitled \"Best Practices for FDA Staff in the Postmarketing Safety Surveillance of Human Drug and Biological Products.\" The 21st Century Cures Act (Cures Act), enacted on December 13, 2016, requires that FDA make publicly available on its internet website best practices for certain postmarketing drug safety surveillance activities. This final document sets forth risk-based principles for FDA\\'s conduct of ongoing postmarketing safety surveillance for human drug products and human biological products, in part, to address the Cures Act requirements. This document finalizes the draft document entitled \"Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff\" that was issued on November 7, 2019.', 'DATES': 'The announcement of the final document is published in the Federal Register on January 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01584.pdf?1706190328', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-26'}, {'ID': '2024-01586', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by February 26, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01586.pdf?1706190329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-26'}, {'ID': '2024-01585', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; renewal of Federal advisory committee.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Vaccines and Related Biological Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Vaccines and Related Biological Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the December 31, 2025, expiration date.', 'DATES': 'Authority for the Vaccines and Related Biological Products Advisory Committee will expire on December 31, 2025, unless the Commissioner formally determines that renewal is in the public interest.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01585.pdf?1706190328', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-26'}, {'ID': '2024-01589', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability for comment of a revised draft guidance for industry entitled \"Conducting Remote Regulatory Assessments--Question and Answers.\" FDA has revised and is reissuing the draft guidance in response to public comments and recent amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act). When finalized, this guidance will describe FDA\\'s current thinking regarding its use of remote regulatory assessments (RRAs). FDA has used RRAs to conduct oversight, mitigate risk, meet critical public health needs, and help maximize compliance of FDA-regulated products. This revised draft guidance provides answers to frequently asked questions regarding RRAs.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 26, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01589.pdf?1706190329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-26'}, {'ID': '2024-01423', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for a limited number of establishments to participate in a voluntary Quality Management Maturity Prototype Assessment Protocol Evaluation Program involving the use of a prototype assessment protocol to evaluate quality management maturity (QMM). The Center for Drug Evaluation and Research (CDER) is implementing this voluntary program for manufacturers of CDER-regulated drug products to gain experience with the prototype assessment protocol and to evaluate whether use of the protocol, as designed, will enable a meaningful assessment of the establishment's quality management practices while providing useful feedback for the establishment. This notice outlines the types of establishments FDA is seeking for participation and the process for submitting a request to participate in the program.\", 'DATES': 'FDA intends to accept requests to participate in the voluntary QMM Prototype Assessment Protocol Evaluation Program through March 25, 2024. See the \"Participation\" section of this document for instructions on submitting a request to participate and the selection process.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01423.pdf?1706103929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-25'}, {'ID': '2024-01426', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) is announcing the issuance of Emergency Use Authorizations (EUAs) (the Authorizations) for certain medical devices related to Coronavirus Disease 2019 (COVID-19). FDA has issued the Authorizations listed in this document under the Federal Food, Drug, and Cosmetic Act (FD&C Act). These Authorizations contain, among other things, conditions on the emergency use of the authorized products. The Authorization follows the February 4, 2020, determination by the Secretary of Health and Human Services (HHS), as amended on March 15, 2023, that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad and that involves the virus that causes COVID-19, and the subsequent declarations on February 4, 2020, March 2, 2020, and March 24, 2020, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19, personal respiratory protective devices, and medical devices, including alternative products used as medical devices, respectively, subject to the terms of any authorization issued under the FD&C Act. These Authorizations, which include an explanation of the reasons for issuance, are listed in this document, and can be accessed on FDA's website from the links indicated.\", 'DATES': 'These Authorizations are effective on their date of issuance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01426.pdf?1706103929', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-25'}, {'ID': '2024-01439', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CABENUVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by March 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by July 23, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01439.pdf?1706103931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-25'}, {'ID': '2024-01441', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #286 (VICH GL60) entitled \"Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products.\" This draft guidance has been developed for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). The objective of this draft guidance is to provide recommendations regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 25, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01441.pdf?1706103932', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-25'}, {'ID': '2024-01442', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Revising ANDA Labeling Following Revision of the RLD Labeling.\" This guidance provides recommendations for updating labeling for abbreviated new drug applications (ANDAs) following revisions to the labeling of a reference listed drug (RLD), including information on how to identify RLD labeling updates and how to submit labeling updates to both unapproved and approved ANDAs to conform to RLD labeling updates. This guidance finalizes the draft guidance for industry of the same title issued on January 27, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01442.pdf?1706103932', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-25'}, {'ID': '2024-01438', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOCABRIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by March 25, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by July 23, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01438.pdf?1706103931', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-25'}, {'ID': '2024-01106', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; confirmation of effective date.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is confirming the effective date of December 4, 2023, for the final rule that appeared in the Federal Register of November 3, 2023, and that amended the color additive regulations to provide for the safe use of jagua (genipin- glycine) blue as a color additive in various food categories at levels consistent with good manufacturing practice.', 'DATES': 'The effective date of December 4, 2023, for the final rule published in the Federal Register of November 3, 2023 (88 FR 75490) is confirmed.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01106.pdf?1705931116', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01164', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application (Supplement-35) for COSENTYX (secukinumab), approved June 16, 2020, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01164.pdf?1705931122', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01158', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Characterization of Metallic Coatings and/or Calcium Phosphate Coatings on Orthopedic Devices.\" This draft guidance document provides recommendations for premarket submissions for orthopedic devices that contain metallic coatings and/or calcium phosphate coatings on the surface. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 25, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01158.pdf?1705931121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01160', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application (Supplement-1) for ZEPOSIA (ozanimod), approved May 27, 2021, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01160.pdf?1705931121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01239', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the record retention requirements for the soy protein/coronary heart disease (CHD) health claim.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by March 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01239.pdf?1705931127', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01240', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, us, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of our requirements for food irradiation processors.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by March 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01240.pdf?1705931127', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01153', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01153.pdf?1705931120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01237', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by February 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01237.pdf?1705931127', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01156', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that XYWAV (calcium, magnesium, potassium, and sodium oxybates), approved July 21, 2020, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01156.pdf?1705931120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01238', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on reporting requirements contained in existing FDA regulations governing State enforcement notifications.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by March 25, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01238.pdf?1705931127', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01154', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting that any industry organizations interested in participating in the selection of a nonvoting industry representative to serve on the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) for the Center for Biologics Evaluation and Research notify FDA in writing. FDA is also requesting nominations for a nonvoting industry representative(s) to serve on the CTGTAC. A nominee may either be self- nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for current vacancies effective with this notice.', 'DATES': 'Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to FDA by February 22, 2024 (see sections I and II of this document for further details). Concurrently, nomination materials for prospective candidates should be sent to FDA by February 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01154.pdf?1705931120', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01163', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that VEOZAH (fezolinetant), approved May 12, 2023, meets the criteria for redeeming a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01163.pdf?1705931121', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-23'}, {'ID': '2024-01108', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a material threat medical countermeasure (MCM) priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the issuance of material threat MCM priority review vouchers as well as the approval of products redeeming a voucher. FDA has determined that QULIPTA (atogepant) tablets, approved September 28, 2021, meets the redemption criteria.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01108.pdf?1705671925', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-22'}, {'ID': '2024-01079', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with Agency regulations that govern prescription drug marketing.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by March 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01079.pdf?1705671921', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-22'}, {'ID': '2024-01082', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.\", 'DATES': 'The meeting will take place virtually on February 13, 2024, from 9 a.m. to 6 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01082.pdf?1705671921', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-22'}, {'ID': '2024-01009', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'This notice informs the public of the annual adjustments to the reimbursement rates for meals served in the Summer Food Service Program. These adjustments address changes in the Consumer Price Index, as required under the Richard B. Russell National School Lunch Act. The 2024 reimbursement rates are presented as a combined set of rates to highlight simplified cost accounting procedures. The 2024 rates are also presented individually, as separate operating and administrative rates of reimbursement, to show the effect of the Consumer Price Index adjustment on each rate. On average, the 2024 rates adjustment represents a 5.3 percent increase in the rates from last year.', 'DATES': 'This adjustment is applicable January 1, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01009.pdf?1705585529', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-19'}, {'ID': '2024-00997', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': \"The U.S. Department of Agriculture's (USDA) Food and Nutrition Service (FNS) requests comments from the public--including the food industry and research community--to help inform future policy and decisions about potentially updating Thrifty Food Plan (TFP) cost estimates for the State of Hawaii. Specifically, FNS invites comments and ideas about food price data for the State of Hawaii--including communities in the State outside of the County of Honolulu--that may be available, potentially accessible to FNS, and of sufficient quality, format, sample size, and recent period to be used potentially by FNS to make cost adjustments for the State of Hawaii to the TFP pursuant to section 3(u)(2) of the Food and Nutrition Act of 2008, as amended. Comments must be received on or before March 4, 2024.\", 'DATES': 'Written comments must be received on or before March 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00997.pdf?1705585527', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-19'}, {'ID': '2024-01016', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; establishment of a public docket; request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Medical Imaging Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.', 'DATES': 'The meeting will be held on March 5, 2024, from 9 a.m. to 5:30 p.m. Eastern Time.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-01016.pdf?1705585531', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-19'}, {'ID': '2024-00886', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled \"Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations\" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00886.pdf?1705499128', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-18'}, {'ID': '2024-00732', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by February 16, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00732.pdf?1705412721', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-17'}, {'ID': '2024-00688', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the approval of a product redeeming a material threat medical countermeasure (MCM) priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the issuance of material threat MCM priority review vouchers as well as the approval of products redeeming a voucher. FDA has determined that FABHALTA (iptacopan) capsules, approved December 5, 2023, meets the redemption criteria.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00688.pdf?1705067129', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-16'}, {'ID': '2024-00406', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by February 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00406.pdf?1704894326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-11'}, {'ID': '2024-00403', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Requests for Reconsideration at the Division Level Under GDUFA.\" This draft guidance provides recommendations on the procedures for applicants of abbreviated new drug applications (ANDAs) that wish to pursue a request for reconsideration within the review discipline at the division level or original signatory authority. This draft guidance revises the draft guidance of the same title issued in October 2017. This revision is being issued to reflect the most recent reauthorization of the Generic Drug User Fee Amendments (GDUFA) and to clarify what matters are appropriate for requests for reconsideration.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 11, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by March 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00403.pdf?1704894326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-11'}, {'ID': '2024-00400', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that FILSUVEZ (birch triterpenes), manufactured by Amryt Pharmaceuticals, meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00400.pdf?1704894325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-11'}, {'ID': '2024-00401', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ADZYNMA (ADAMTS13, recombinant-krhn), manufactured by Takeda Pharmaceuticals U.S.A., Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00401.pdf?1704894325', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-11'}, {'ID': '2024-00407', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.\" The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance is intended to describe risk-based principles and mitigation strategies to assure the viral safety of biotechnology products, including the data necessary to submit in a marketing application. The guidance also finalizes the updates based on advances in scientific knowledge and regulatory expectations to the first version of the ICH guidance for industry \"Q5A Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin,\" issued in September 1998. Lastly, the guidance replaces the draft guidance \"Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin\" issued on November 14, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on January 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00407.pdf?1704894326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-11'}, {'ID': '2024-00263', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that CASGEVY (exagamglogene autotemcel), manufactured by Vertex Pharmaceuticals, Inc., meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00263.pdf?1704721529', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-09'}, {'ID': '2024-00221', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the collection of qualitative data on tobacco products and communications.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by March 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00221.pdf?1704721522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-09'}, {'ID': '2024-00219', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by February 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00219.pdf?1704721522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-09'}, {'ID': '2024-00220', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': 'Submit written comments (including recommendations) on the collection of information by February 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00220.pdf?1704721522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-09'}, {'ID': '2024-00217', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection pertaining to \"Expedited Programs for Serious Conditions--Drugs and Biologics.\"', 'DATES': 'Submit either electronic or written comments on the collection of information by March 11, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2024-00217.pdf?1704721522', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-09'}, {'ID': '2023-28872', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability, request for comments.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled \"Food and Drug Administration\\'s Draft Report and Plan on Best Practices for Guidance.\" This draft report responds to the Consolidated Appropriations Act of 2023, which directs FDA to issue a report identifying best practices for the efficient prioritization, development, issuance, and use of guidance documents and a plan for implementation of such best practices. It also directs FDA to publish a draft report and plan no later than 1 year after enactment of the Consolidated Appropriations Act and to consult with stakeholders in developing the report and implementation plan.', 'DATES': 'Submit either electronic or written comments on the draft report and plan by March 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28872.pdf?1704203118', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2024-01-03'}, {'ID': '2023-28488', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Interim final rule.', 'SUMMARY': \"The Consolidated Appropriations Act, 2023 requires the Secretary of Agriculture to make available an option to States to provide summer meals for non-congregate meal service in rural areas with no congregate meal service and to establish a permanent summer electronic benefits transfer for children program (Summer EBT) for the purpose of ensuring continued access to food when school is not in session for the summer. This interim final rule amends the Summer Food Service Program (SFSP) and the National School Lunch Program's Seamless Summer Option (SSO) regulations to codify the flexibility for rural program operators to provide non-congregate meal service in the SFSP and SSO, collectively referred to as the summer meal programs. This rule also establishes regulations and codifies the Summer EBT Program in the Code of Federal Regulations.\", 'DATES': 'Effective date: This rule is effective December 29, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28488.pdf?1703771114', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-29'}, {'ID': '2023-28675', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Reformulating Drug Products That Contain Carbomers Manufactured With Benzene.\" The purpose of this guidance is to provide recommendations to applicants and manufacturers on what tests should be performed and what documentation should be submitted or available to support the reformulation of drug products that use carbomers manufactured with benzene. Certain United States Pharmacopeia (USP) carbomer monographs currently allow for unacceptable levels of benzene, which raises safety concerns. FDA has requested that the USP omit (or remove) these monographs, and applicants and manufacturers may need to reformulate their drug products to avoid use of these carbomers. This guidance provides recommendations for tests and documentation related to reformulation based on various routes of administration and dosage forms of affected drug products, and provides recommendations for application holders on the appropriate submission types to notify the Agency of reformulation changes. The intended effect of this guidance is to, as appropriate, provide a less burdensome risk-based approach to reformulation submissions relative to existing guidances on scale-up and post-approval changes (SUPAC), and address the immediate public health need to expedite the discontinuation of the use of carbomers manufactured with high levels of benzene in drug products.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 28, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28675.pdf?1703684737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-28'}, {'ID': '2023-28594', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) Center for Biologics Evaluation and Research (CBER) is announcing the availability of version 2.3 of the Specifications for Preparing and Submitting Postmarket Individual Case Safety Reports (ICSRS) for Vaccines (Specifications). The version update is not applicable to CBER- regulated drug products marketed for human use with approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs); CBER-regulated therapeutic biological products marketed for human use with approved Biologic License Applications (BLAs); Whole Blood or blood components; and human cells, tissues, and cellular and tissue- based products (HCT/Ps) regulated solely under the Public Health Service Act.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28594.pdf?1703684723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-28'}, {'ID': '2023-28595', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled \"Quality Considerations for Topical Ophthalmic Drug Products.\" This revised draft guidance discusses certain quality considerations for ophthalmic drug products (i.e., gels, ointments, creams, and liquid formulations such as solutions, suspensions, and emulsions) intended for topical delivery in and around the eye. Specifically, this revised draft guidance discusses microbiological considerations; approaches to evaluating visible particulate matter, extractables and leachables, and impurities and degradation products; use of in vitro drug release/ dissolution testing as an optional quality control strategy for certain ophthalmic dosage forms; recommendations for design and delivery and dispensing features of container closure systems; and recommendations for stability studies. The revised draft guidance applies to marketed products including ophthalmic drug products approved under new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics license applications (BLAs), as well as to over-the-counter (OTC) monograph drugs, drugs compounded by outsourcing facilities, and the drug or biological product constituent part of a combination product. This guidance revises the draft guidance for industry of the same name issued in October 2023.', 'DATES': 'Submit either electronic or written comments on the revised draft guidance by February 26, 2024 to ensure that the Agency considers your comment on this revised draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28595.pdf?1703684723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-28'}, {'ID': '2023-28596', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance entitled \"Potency Assurance for Cellular and Gene Therapy Products.\" FDA is issuing this draft guidance to provide recommendations to help assure the potency of human cellular therapy or gene therapy (CGT) products at all stages of the product lifecycle. FDA is recommending a comprehensive approach to potency assurance of CGT products that is grounded in quality risk management. For investigational products, we describe how to progressively implement a strategy for potency assurance during product development and provide additional considerations to help assure the potency of products that are undergoing rapid clinical development. For licensed products, we describe requirements for potency assurance, including testing required for lot release.', 'DATES': 'Submit either electronic or written comments on the draft guidance by March 27, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28596.pdf?1703684723', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-28'}, {'ID': '2023-28511', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZOKINVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 26, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 24, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28511.pdf?1703598328', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-27'}, {'ID': '2023-28509', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PONVORY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 26, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 24, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28509.pdf?1703598327', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-27'}, {'ID': '2023-28519', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCEMBLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 26, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 24, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28519.pdf?1703598329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-27'}, {'ID': '2023-28507', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CYTALUX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 26, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 24, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28507.pdf?1703598327', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-27'}, {'ID': '2023-28310', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Rare Diseases: Considerations for the Development of Drugs and Biological Products.\" This guidance is intended to assist sponsors of drugs and biological products for treatment of rare diseases in conducting efficient and successful drug development programs through a discussion of selected issues commonly encountered in rare disease drug development. This guidance finalizes the draft guidance entitled \"Rare Diseases: Common Issues in Drug Development\" issued on February 1, 2019.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 26, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28310.pdf?1703252721', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-26'}, {'ID': '2023-28231', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice.', 'SUMMARY': \"FSIS is announcing the 2024 rates it will charge meat, poultry, and egg products establishments, and importers and exporters for providing voluntary, overtime, and holiday inspection and identification, certification, and laboratory services. Additionally, FSIS is announcing that there will be no changes to the fee FSIS assesses to exporters that choose to apply for export certificates electronically through the export component of the Agency's Public Health Information System. The 2024 basetime, overtime, holiday, and laboratory services rates will be applied on January 14, 2024.\", 'DATES': 'FSIS will charge the rates announced in this notice beginning January 14, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28231.pdf?1703166329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28210', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Master Protocols for Drug and Biological Product Development.\" The draft guidance addresses the design and analysis of trials conducted under a master protocol as well as the submission of documentation to support regulatory review. The primary focus is on randomized umbrella and platform trials that are intended to contribute to a demonstration of safety and substantial evidence of effectiveness. The considerations in this guidance apply to a range of therapeutic areas. The draft guidance is intended to clarify the Agency\\'s thinking on the use of master protocols in drug and biological product development, which was previously addressed in FDA\\'s guidance entitled \"COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention.\" FDA is also announcing the withdrawal of the guidance entitled \"COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention.\"', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 20, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28210.pdf?1703166326', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28233', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Emgality and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 20, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28233.pdf?1703166329', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28244', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Copiktra and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 20, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28244.pdf?1703166331', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28262', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry, investigators, and other stakeholders entitled \"Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.\" This guidance provides recommendations on the use of digital health technologies (DHTs) to acquire data remotely from participants in clinical investigations that evaluate medical products. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. Use of DHTs as recommended in this guidance may improve the efficiency of clinical trials for sponsors, investigators, and other stakeholders and may increase the opportunities for individuals to participate in research and make participation more convenient. This guidance finalizes the draft guidance of the same title issued on December 23, 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 22, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28262.pdf?1703166334', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28289', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products.\" This guidance provides considerations for sponsors proposing to design a registry or to use an existing registry to support regulatory decision-making about a drug\\'s effectiveness or safety. FDA is issuing this guidance as part of its Real-World Evidence (RWE) Program and to satisfy, in part, the mandate under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to issue guidance on the use of RWE in regulatory decision-making. This guidance finalizes the draft guidance of the same title issued on November 30, 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 22, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28289.pdf?1703166338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28291', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Data Standards for Drug and Biological Product Submissions Containing Real- World Data.\" This guidance provides recommendations to sponsors to help support compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act) when submitting study data derived from real-world data (RWD) sources in applicable regulatory submissions using standards specified in the Data Standards Catalog. FDA is publishing this guidance as part of a series of guidance documents under its program to evaluate the use of real-world evidence (RWE) in regulatory decision making. This guidance finalizes the draft guidance of the same title issued on October 22, 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 22, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28291.pdf?1703166339', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28287', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry (GFI) #61 entitled \"Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species.\" This guidance is intended to assist those interested in pursuing FDA approval of new animal drugs intended for minor uses in major species or for use in minor species (MUMS drugs). It outlines the basic statutory and regulatory requirements and special considerations for these approvals and describes the incentives available to encourage the development of MUMS drugs.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 22, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28287.pdf?1703166338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28290', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28290.pdf?1703166338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-22'}, {'ID': '2023-28095', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review.\" This draft guidance provides FDA\\'s current thinking regarding the 510(k) Third Party (3P510k) Review Program and review of Emergency Use Authorizations (EUA) requests by a third party review organizations (3PEUA review). The 3P510k Review Program and 3PEUA review create an alternative process for manufacturers to seek review of 510(k) submissions and EUA requests to assist FDA in reviewing in a timely manner. This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 20, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28095.pdf?1703079935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-21'}, {'ID': '2023-28094', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYBALVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 20, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 18, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28094.pdf?1703079935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-21'}, {'ID': '2023-28093', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled \"Examination of Implied Claims in Direct-to-Consumer Prescription Drug Promotion.\"', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by February 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28093.pdf?1703079935', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-21'}, {'ID': '2023-28092', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization.\" This guidance provides recommendations to sponsors on the development of monoclonal antibody products targeting SARS-CoV-2 intended for the prevention or treatment of COVID- 19, including addressing the impact of emerging variants. The recommendations focus on the data and information that may be used to support a request for emergency use authorization (EUA) under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance supersedes the guidance entitled \"Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency\" issued on February 22, 2021.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 21, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-28092.pdf?1703079934', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-21'}, {'ID': '2023-27935', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to amend its regulations to implement a provision of the 21st Century Cures Act (Cures Act). This final rule allows an exception from the requirement to obtain informed consent when a clinical investigation poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of human subjects. The final rule permits an institutional review board (IRB) to waive or alter certain informed consent elements or to waive the requirement to obtain informed consent, under limited conditions, for certain FDA-regulated minimal risk clinical investigations.', 'DATES': 'This rule is effective January 22, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27935.pdf?1703079919', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-21'}, {'ID': '2023-27967', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing the website location where the Agency will post a list of possible topics for future guidance document development or revision by the Office of the Chief Scientist (OCS) during the next year. In addition, FDA has established a docket where interested persons may provide comments that could benefit the OCS guidance program and its engagement with stakeholders, including comments on the priority of topics for guidance. This feedback is critical to the OCS guidance program as we consider feedback from stakeholders along with Agency resources and priorities.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27967.pdf?1702993538', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-20'}, {'ID': '2023-27857', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of calcium formate as a feed acidifying agent, to lower the pH, in complete swine and poultry feeds at levels not to exceed 1.2 percent of the complete feed. This action is in response to a food additive petition filed by LANXESS Corp.', 'DATES': 'This rule is effective December 19, 2023. See section V for further information on the filing of objections. Either electronic or written objections and requests for a hearing on the final rule must be submitted by January 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27857.pdf?1702907133', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27763', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a new collection that combines the School Nutrition and Meal Cost Study-II (SNMCS-II), School Food Purchase Study-IV (SFPS-IV), and a second Fresh Fruit and Vegetable Program Evaluation (FFVP-II) into one coordinated effort named the 2024-2025 National School Foods Study. The purpose of this combined effort is to reduce overall burden for respondents across the three studies and provide a comprehensive picture of the school- based child nutrition (CN) programs in the 2024-2025 school year.', 'DATES': 'Written comments must be received on or before February 20, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27763.pdf?1702907117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27649', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled \"Registration and Listing of Cosmetic Product Facilities and Products.\" The guidance will assist persons submitting cosmetic product facility registrations and product listing submissions to FDA under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This guidance also includes a new draft section, Appendix B, for comment purposes only, that describes frequently asked questions and answers about cosmetic product facility registrations and product listing submissions. Aside from that section, this guidance finalizes the draft guidance that was published on August 8, 2023.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 19, 2023. However, the portion of this guidance that describes frequently asked questions and answers, is being distributed for comment purposes only. To ensure that the Agency considers your comment on this draft section before it begins work on the final version of this section of the guidance, submit either electronic or written comments on this section by January 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27649.pdf?1702907116', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27858', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) has determined that MEPHYTON (phytonadione) tablets, 5 milligrams (mg), were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27858.pdf?1702907133', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27852', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices.\" FDA is issuing this draft guidance to clarify how FDA evaluates real- world data (RWD) to determine whether they are of sufficient quality for generating real-world evidence (RWE) that can be used in FDA regulatory decision-making for medical devices. This draft guidance proposes expanded recommendations to the 2017 guidance entitled \"Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices.\" This draft guidance is not final nor is it for implementation at this time.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 20, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27852.pdf?1702907132', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27854', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring James Funaro for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Funaro was convicted of one felony count under Federal law for conspiracy to launder money. The factual basis supporting Mr. Funaro's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Funaro was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of October 11, 2023 (30 days after receipt of the notice), Mr. Funaro had not responded. Mr. Funaro's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is applicable December 19, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27854.pdf?1702907132', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27855', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Jeremy Walenty for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Walenty was convicted of one felony count under Federal law for conspiracy to smuggle goods into the United States. The factual basis supporting Mr. Walenty's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Walenty was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of October 15, 2023 (30 days after receipt of the notice), Mr. Walenty had not responded. Mr. Walenty's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is effective December 19, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27855.pdf?1702907132', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27853', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is withdrawing approval of eight abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of January 18, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27853.pdf?1702907132', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27859', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': 'The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 11, 2009. The document announced the withdrawal of approval of 103 new drug applications and 35 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of March 13, 2009. The document erroneously included ANDA 75-108. The correct ANDA is ANDA 76-108 for Amiodarone hydrochloride (HCl) injection, 50 milligrams (mg)/milliliter (mL), held by Hospira, Inc., 275 North Field Dr., Lake Forest, IL 60045-5046. This document corrects that error.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27859.pdf?1702907133', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27821', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Proposed rule; reopening of comment period.', 'SUMMARY': \"The U.S. Department of Agriculture proposed to make changes to the Supplemental Nutrition Assistance Program's Quality Control (SNAP QC) system to strengthen and improve the integrity and accuracy of the system and to better align SNAP QC with requirements in the Payment Integrity Information Act of 2019 (PIIA). When published, the proposed rule included an incorrect email address for comments; the reopening of the comment period is intended to allow additional time for the public to submit comments in the event the original comment submission was returned as undeliverable due to the incorrect email address.\", 'DATES': 'The comment period for the proposed rule published September 19, 2023, at 88 FR 64756, is reopened. Written comments must be received on or before January 2, 2024 to ensure their consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27821.pdf?1702907127', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-19'}, {'ID': '2023-27652', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27652.pdf?1702647916', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-18'}, {'ID': '2023-27661', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is withdrawing approval of two new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.', 'DATES': 'Approval is withdrawn as of January 17, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27661.pdf?1702647918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-18'}, {'ID': '2023-27655', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #283 entitled \"Priority Zoonotic Animal Drug Designation and Review Process.\" This draft guidance is intended to assist sponsors pursuing priority zoonotic animal drug (PZAD) designation for a new animal drug. This draft guidance is intended to provide the eligibility criteria for PZAD designation, the process for requesting PZAD designation, and enhancements in the FDA review process for PZADs.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 16, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27655.pdf?1702647917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-18'}, {'ID': '2023-27662', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing that it is withdrawing approval of the indications for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) for IMBRUVICA (ibrutinib) Capsules and Tablets approved, respectively, under new drug applications (NDAs) 205552 and 210563. These NDAs are held by Pharmacyclics LLC, 1000 Gateway Blvd., South San Francisco, CA 94080 (Pharmacyclics). Pharmacyclics voluntarily requested that the Agency withdraw approval of these indications and waived its opportunity for a hearing.', 'DATES': 'Approval is withdrawn as of December 18, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27662.pdf?1702647918', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-18'}, {'ID': '2023-27602', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food Safety and Inspection Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995 and Office of Management and Budget (OMB) regulations, FSIS is announcing its intention to collect information using web surveys to test new labels for safe handling of raw and partially cooked meat and poultry products. This is a new information collection with 3,550 hours.', 'DATES': 'Submit comments on or before February 13, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27602.pdf?1702561535', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-15'}, {'ID': '2023-27557', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Adam Michael Nagy for a period of 15 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Nagy was convicted of three relevant felony counts under Federal law. The factual basis supporting Mr. Nagy's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Nagy was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of October 22, 2023 (30 days after receipt of the notice), Mr. Nagy had not responded. Mr. Nagy's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.\", 'DATES': 'This order is effective December 15, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27557.pdf?1702561527', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-15'}, {'ID': '2023-26641', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule with request for comment.', 'SUMMARY': \"This rulemaking serves to amend the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) Program regulations by incorporating provisions of the Access to Baby Formula Act of 2022 and making related amendments. ABFA establishes waiver authority for the Secretary of Agriculture to address certain emergencies, disasters, and supply chain disruptions impacting WIC, and adds requirements to State agency infant formula cost containment contracts to protect against disruptions to the Program in the event of a recall. The provisions focus on improving State agencies' ability to ensure continuity of Program operations during emergency periods (i.e., emergencies, disasters, and public health emergencies) and supply chain disruptions, while ensuring access to Program benefits among low-income pregnant and postpartum participants, infants, and children up to 5 years of age who are at nutritional risk.\", 'DATES': 'This rule is effective February 12, 2024. Written comments must be received on or before February 12, 2024 to be assured of consideration. Online comments submitted through the Federal eRulemaking Portal on this rule must be received on or before February 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26641.pdf?1702475114', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-14'}, {'ID': '2023-27351', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Final rule.', 'SUMMARY': 'This rule finalizes provisions of a proposed rule published on June 27, 2022. With this final rule, the Food and Nutrition Service (FNS) is revising Supplemental Nutrition Assistance Program (SNAP) regulations that cover collecting and reporting race and ethnicity data by State agencies on persons receiving benefits from SNAP. This rule removes regulatory language that provides an example that State agencies might collect race and ethnicity data by observation (also referred to as \"visual observation\") when participants do not voluntarily provide the information on the application form. In addition, based on feedback from the commenters, this rule prohibits using visual observation as a data collection method for race and ethnicity. Through this rulemaking, FNS intends to improve the quality of data collected for purposes of Federal civil rights law and policy including title VI of the Civil Rights Act of 1964. USDA\\'s Food and Nutrition Service is committed to promoting equity and inclusion through its Federal nutrition assistance programs. This regulatory change is consistent with this Administration\\'s priorities and furthers FNS\\' commitment to building equitable and inclusive systems for nutrition access.', 'DATES': 'This rule is effective February 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27351.pdf?1702475117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-14'}, {'ID': '2023-27506', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Direct final rule; confirmation of effective date.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is confirming the effective date of December 22, 2023, for the final rule that appeared in the Federal Register of August 9, 2023. The direct final rule amends our regulations to no longer provide for the use of partially hydrogenated oils (PHOs) in food given our determination that PHOs are no longer generally recognized as safe (GRAS). The rule also revokes prior sanctions (i.e., pre-1958 authorization of certain uses) for the use of PHOs in margarine, shortening, and bread, rolls, and buns based on our conclusion that these uses of PHOs may be injurious to health. This document confirms the effective date of the direct final rule.', 'DATES': 'The effective date of December 22, 2023, for the direct final rule published in the Federal Register of August 9, 2023 (88 FR 53764) is confirmed.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27506.pdf?1702475136', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-14'}, {'ID': '2023-27309', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Advanced Manufacturing Technologies Designation Program.\" FDA encourages the early adoption of advanced manufacturing technologies (AMTs) that have the potential to benefit patients by improving manufacturing and supply dependability and optimizing development time of drug and biological products. These technologies can be integral to ensuring quality and supporting a robust supply of drugs that are life-supporting, life-sustaining, of critical importance to providing healthcare, or in shortage. AMTs can directly improve product quality through higher capability manufacturing designs and enhanced controls (e.g., leading to fewer human errors). This draft guidance provides recommendations to persons and organizations interested in participating in FDA\\'s Advanced Manufacturing Technologies Designation Program, which is intended to facilitate the development of drugs, including biological products, manufactured using an AMT that has been designated as such under the program.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 12, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit electronic or written comments on the proposed collection of information in the draft guidance by February 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27309.pdf?1702388726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27310', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration\\'s (FDA or Agency) Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) are announcing that support begins for version 2.0 of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTMv2.0), version 3.4 of the CDISC Study Data Tabulation Model Implementation Guide (SDTMIGv3.4), and version 1.0 of the Standard for Exchange of Nonclinical Data Implementation Guide-- Genetox (SENDIG-Genetoxv1.0) and announcing the date that these version updates are required in certain submissions. CBER and CDER are also announcing the date that requirement ends for version 3.2 of the CDISC SDTMIG (SDTMIGv3.2). The Agency will update the FDA Data Standards Catalog (Catalog) to reflect these changes. The Agency will publish in the technical specifications document entitled \"Study Data Technical Conformance Guide\" additional details on how to implement new variables.', 'DATES': 'Support for version CDISC SDTMv2.0, SDTMIGv3.4, and SENDIG- Genetoxv1.0 begins December 13, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27310.pdf?1702388726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27301', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee (the Committee) in the Center for Drug Evaluation and Research. Nominations will be accepted for current vacancies effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore encourages nominations of appropriately qualified candidates from these groups.', 'DATES': 'Nominations received on or before February 12, 2024 will be given first consideration for membership on the Committee. Nominations received after February 12, 2024 will be considered for nomination to the committee as later vacancies occur.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27301.pdf?1702388724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27308', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of individuals on its advisory committee regardless of their gender identification, religious affiliation, racial and ethnic identification, or disability status and, therefore, encourages nominations of appropriately qualified candidates from all groups.', 'DATES': 'Any consumer organization interested in participating in the selection of an appropriate voting or nonvoting member to represent consumer interests on an FDA advisory committee or panel may send a letter or email stating that interest to FDA (see ADDRESSES) by January 29, 2024, for vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see ADDRESSES) by January 29, 2024. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27308.pdf?1702388726', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27302', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting nominations for a voting consumer representative to serve on the Genetic Metabolic Diseases Advisory Committee. FDA is also requesting that any consumer organizations interested in participating in the selection of a voting consumer representative to serve on the Genetic Metabolic Diseases Advisory Committee notify FDA in writing. Nominees recommended to serve as a voting consumer representative may either be self-nominated or may be nominated by a consumer organization. Nominations will be accepted for the current vacancy effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.', 'DATES': 'Any consumer organization interested in participating in the selection of an appropriate voting member to represent consumer interests on the Genetic Metabolic Diseases Advisory Committee may send a letter or email stating that interest to FDA (see ADDRESSES) by February 12, 2024 for vacancy listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA (see ADDRESSES) by February 12, 2024. Nominations will be accepted for current vacancy.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27302.pdf?1702388724', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27312', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the availability of a summary on the comments received for the \"Methodological Challenges Related to Patient Experience Data; Request for Information and Comments\" notice published on May 2, 2023. The input received in response to the Request for Information will help FDA plan two public workshops focused on methodological challenges and will help FDA identify priorities for future work.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27312.pdf?1702388727', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27304', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of establishment.', 'SUMMARY': 'Under the Federal Advisory Committee Act, the Food and Drug Administration (FDA) is announcing the establishment of the Genetic Metabolic Diseases Advisory Committee. The Commissioner of Food and Drugs (Commissioner) has determined that it is in the public interest to establish such a committee. Duration of this committee is 2 years from the date the Charter is filed, unless the Commissioner formally determines that renewal is in the public interest.', 'DATES': 'Either electronic or written comments on the notice must be submitted by February 12, 2024. FDA is establishing a docket for public comment on this document. The docket number is FDA-2023-N-4917. The docket will close on February 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27304.pdf?1702388725', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27303', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is requesting that industry organizations interested in participating in the selection of a nonvoting industry representative to serve on the Genetic Metabolic Diseases Advisory Committee (the Committee) in the Center for Drug Evaluation and Research notify FDA in writing. FDA is also requesting nominations for a nonvoting industry representative to serve on the Committee. Nominees recommended to serve as a nonvoting industry representative may either be self-nominated or nominated by an industry organization. Nominations will be accepted for the current vacancy effective with this notice.', 'DATES': 'Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interest, must send a letter stating that interest to the FDA by February 12, 2024, (see sections I and II of this document for details). Concurrently, nomination materials for prospective candidates should be sent to FDA by February 12, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27303.pdf?1702388725', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-13'}, {'ID': '2023-27044', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WELIREG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 9, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 10, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27044.pdf?1702043117', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-11'}, {'ID': '2023-26962', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice and request for comments.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed revision to the currently approved information collection for the Supplemental Nutrition Assistance Program (SNAP) form FNS-889, \"SNAP Education (SNAP-Ed) Connection Resource Sharing Form.\" This revision to the information collection will improve the submission process by clarifying the information requested for certain fields, thus providing data that is accurate and beneficial to stakeholders using the resource. These updates will also align with the new SNAP-Ed National Program Evaluation and Reporting System (N-PEARS) (OMB Control #0584-0683, expiration 4/30/2026), to ensure consistency with SNAP-Ed specific terms. With this update to form FNS-889, FNS has determined that nutrition and physical activity interventions (i.e., educational materials, curricula, etc.), will no longer be accepted through this information collection.', 'DATES': 'Comments on this notice must be received on or before February 6, 2024 to be assured of consideration.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26962.pdf?1701956729', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26992', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tivdak and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26992.pdf?1701956736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26996', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Pemazyre and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26996.pdf?1701956737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26994', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice; correction.', 'SUMMARY': \"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on October 4, 2023. The document announced the withdrawal of approval of 11 abbreviated new drug applications (ANDAs) from Dr. Reddy's Laboratories, Inc., withdrawn as of November 3, 2023. The document indicated that FDA was withdrawing approval of ANDA 203807, clozapine tablets, 25 milligrams (mg), 50 mg, 100 mg, and 200 mg, held by Dr. Reddy's Laboratories, Inc., U.S. Agent for Dr. Reddy's Laboratories SA, 107 College Rd. East, Princeton, NJ 08540. Before FDA withdrew the approval of this ANDA, Dr. Reddy's Laboratories, Inc., informed FDA that it did not want the approval of the ANDA withdrawn. Because Dr. Reddy's Laboratories, Inc., timely requested that approval of ANDA 203807 not be withdrawn, the approval is still in effect. This notice corrects that error.\", 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26994.pdf?1701956736', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-27004', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXKIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27004.pdf?1701956738', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26997', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Fotivda and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26997.pdf?1701956737', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26988', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Nextstellis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26988.pdf?1701956734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26982', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYNLONTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26982.pdf?1701956733', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-27003', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEYSARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27003.pdf?1701956738', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-27015', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is withdrawing the approval of CIPRO (ciprofloxacin hydrochloride (HCl)) oral tablet, equivalent to (EQ) 100 milligrams (mg) base under new drug application (NDA) 019537 and five generic ciprofloxacin HCl, oral tablet, EQ 100 mg base products which referenced it as their basis of submission. The holders of the applications requested withdrawal of the 100 mg strength products and waived their opportunity for a hearing.', 'DATES': 'Approval is withdrawn as of December 8, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27015.pdf?1701956740', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-27013', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VILTEPSO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27013.pdf?1701956740', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-27018', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with statutory provisions applicable to ingredients derived from major food allergens.', 'DATES': 'Either electronic or written comments on the collection of information must be submitted by February 6, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27018.pdf?1701956741', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26985', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 8, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26985.pdf?1701956734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26989', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Tablets (new drug application (NDA) 209816) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26989.pdf?1701956734', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-27012', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIZIMPRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 6, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 5, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-27012.pdf?1701956739', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-08'}, {'ID': '2023-26885', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Truseltiq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by February 5, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by June 4, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26885.pdf?1701870338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-07'}, {'ID': '2023-26845', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Interim Policy on Compounding Using Bulk Drug Substances Under section 503B of the Federal Food, Drug, and Cosmetic Act\" (draft guidance or 2023 503B Interim Policy Draft Guidance) to describe FDA\\'s interim policy regarding the use of bulk drug substances in compounding by outsourcing facilities while FDA develops the list of bulk drug substances that outsourcing facilities can use in compounding under the applicable section of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This draft guidance, when finalized, will replace the guidance for industry entitled, \"Interim Policy on Compounding Using Bulk Drug Substances Under section 503B of the Federal Food, Drug, and Cosmetic Act\" issued in January 2017 (2017 503B Interim Policy Guidance).', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 8, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26845.pdf?1701870331', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-07'}, {'ID': '2023-26846', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs.\" The guidance addresses the verification systems that manufacturers, repackagers, wholesale distributors, and dispensers must have in place to comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Supply Chain Security Act (DSCSA). Specifically, the guidance covers the statutory verification systems requirements that include the quarantine and investigation of a product determined to be suspect and the quarantine and disposition of a product determined to be illegitimate. The guidance also addresses the statutory requirement for notification to the Agency of a product that has been cleared by a manufacturer, repackager, wholesale distributor, or dispenser (also referred to as \"trading partners\") after a suspect product investigation because it is determined that the product is not an illegitimate product. Finally, the guidance addresses the statutory requirement for responding to requests for verification and processing saleable returns. The guidance finalizes the revised draft guidance \"Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs,\" issued on March 10, 2022.', 'DATES': 'The announcement of the guidance is published in the Federal Register on December 7, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26846.pdf?1701870331', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-07'}, {'ID': '2023-26886', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Interim Policy on Compounding Using Bulk Drug Substances Under section 503A of the Federal Food, Drug, and Cosmetic Act\" (draft guidance or 2023 503A Interim Policy Draft Guidance) to describe FDA\\'s interim policy regarding the use of bulk drug substances by human drug compounders that are not registered with FDA as outsourcing facilities while FDA develops the list of bulk drug substances that can be used in compounding under the applicable section of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This draft guidance, when finalized, will replace the guidance for industry entitled, \"Interim Policy on Compounding Using Bulk Drug Substances under section 503A of the Federal Food, Drug, and Cosmetic Act\" issued in January 2017 (2017 503A Interim Policy Guidance).', 'DATES': 'Submit either electronic or written comments on the draft guidance by January 8, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26886.pdf?1701870338', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-07'}, {'ID': '2023-26545', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Final rule; technical amendments.', 'SUMMARY': 'The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during July, August, and September 2023. The animal drug regulations are also being amended to improve their accuracy and readability.', 'DATES': 'This rule is effective December 6, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26545.pdf?1701783917', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-06'}, {'ID': '2023-26659', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': \"In accordance with the Paperwork Reduction Act of 1995 (PRA), this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is a revision of a currently approved collection for the reporting and recordkeeping burden associated with the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) Farmers' Market Nutrition Program (FMNP) regulations.\", 'DATES': 'Written comments must be received on or before February 5, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26659.pdf?1701697534', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-05'}, {'ID': '2023-26512', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': \"The Food and Drug Administration's (FDA), Center for Biologics Evaluation and Research (CBER), Office of Blood Research and Review (OBRR) and the Office of Vaccines Research and Review (OVRR) have modified organizational structures.\", 'DATES': 'These new organizational structures were approved by the Secretary of Health and Human Services on June 27, 2023.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26512.pdf?1701697518', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-05'}, {'ID': '2023-26652', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of priority review voucher. FDA has determined that XENPOZYME (olipudase alfa-rpcp), manufactured by Genzyme Corporation, meets the criteria for a priority review voucher.', 'DATES': None, 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26652.pdf?1701697533', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-05'}, {'ID': '2023-26653', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 4, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26653.pdf?1701697533', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-05'}, {'ID': '2023-26561', 'AGENCY': 'DEPARTMENT OF AGRICULTURE', 'SUB_AGENCY': 'Food and Nutrition Service', 'ACTION': 'Notice.', 'SUMMARY': 'In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on this proposed information collection. This collection is an extension of a currently approved collection. This information collection addresses the recordkeeping burden associated with forms FNS-292A (Report of Commodity Distribution for Disaster Relief) and FNS-292B (Report of Disaster Supplemental Nutrition Assistance Benefit Issuance).', 'DATES': 'Written comments must be received on or before February 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26561.pdf?1701438384', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-04'}, {'ID': '2023-26564', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26564.pdf?1701438389', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-04'}, {'ID': '2023-26544', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 3, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26544.pdf?1701438366', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-04'}, {'ID': '2023-26498', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA or Agency) is announcing an opportunity to provide public comment on modified risk tobacco product applications (MRTPAs). The applications are for renewal of existing modified risk tobacco product (MRTP) orders for General Snus smokeless tobacco products submitted by Swedish Match U.S.A., Inc.', 'DATES': 'Electronic or written comments on the application may be submitted beginning December 1, 2023. FDA will establish a closing date for the comment period as described in section I.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26498.pdf?1701352084', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-01'}, {'ID': '2023-26445', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26445.pdf?1701352017', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-12-01'}, {'ID': '2023-26299', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Amondys 45 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26299.pdf?1701265581', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26260', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEGALOGUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26260.pdf?1701265528', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26301', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Qelbree and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26301.pdf?1701265584', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26363', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Injection (new drug application (NDA) 209817) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26363.pdf?1701265655', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26300', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26300.pdf?1701265584', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26306', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice of availability.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry #284 entitled \"Using Relative Supersaturation to Support \"Urinary Tract Health\" Claims for Adult Maintenance Cat Food.\" FDA\\'s Center for Veterinary Medicine (CVM) has evaluated the use of relative supersaturation (RSS) methodology to support urinary tract health claims for certain adult maintenance cat food. RSS is a measurement that estimates the potential for crystal formation and bladder stone growth, which is a common affliction in cats. This draft guidance provides recommendations for how pet food manufacturers can use RSS methodology to substantiate general structure or function claims that an adult maintenance cat food supports urinary tract health by promoting a healthy mineral content in the urinary tract.', 'DATES': 'Submit either electronic or written comments on the draft guidance by February 28, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26306.pdf?1701265591', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26262', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.', 'DATES': 'Submit written comments (including recommendations) on the collection of information by January 2, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26262.pdf?1701265533', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26303', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Ukoniq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26303.pdf?1701265586', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26324', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Koselugo and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26324.pdf?1701265616', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26358', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Notice.', 'SUMMARY': 'The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Rezurock and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.', 'DATES': 'Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect may submit either electronic or written comments and ask for a redetermination by January 29, 2024. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by May 28, 2024. See \"Petitions\" in the SUPPLEMENTARY INFORMATION section for more information.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26358.pdf?1701265650', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}, {'ID': '2023-26209', 'AGENCY': 'DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'SUB_AGENCY': 'Food and Drug Administration', 'ACTION': 'Proposed rule.', 'SUMMARY': 'The Food and Drug Administration (FDA, Agency, or we) are proposing to classify certain types of wound dressings and liquid wound washes containing antimicrobials and/or other chemicals (unclassified, preamendments devices) as solid wound dressings; wound dressings formulated as a gel, cream, or ointment; and liquid wound washes. FDA currently regulates these unclassified devices as devices requiring premarket notification (510(k) requirements), with the product codes FRO, GER, MGP, MGQ, and EFQ, but FDA intends to create new product codes for these proposed classifications upon finalization of this classification action. FDA is proposing to classify certain wound dressings and liquid wound washes containing antimicrobials with a high level of antimicrobial resistance (AMR) concern (i.e., medically important antimicrobials) into class III. In addition, FDA is proposing to classify certain wound dressings and liquid wound washes containing antimicrobials with a medium or low level of AMR concern and/or other chemicals, into class II (subject to special controls and 510(k) requirements).', 'DATES': 'Either electronic or written comments on the proposed rule must be submit by February 28, 2024.', 'PUBLIC_INSPECTION_PDF_URL': 'https://public-inspection.federalregister.gov/2023-26209.pdf?1701265528', 'LAST_UPDATED': '2025-02-23 04:15:03 -0500', 'PUBLICATION_DATE': '2023-11-30'}]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "909"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(li)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "import snowflake.connector\n",
    "import configparser\n",
    "import pandas as pd\n",
    "import tempfile\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import snowflake.connector\n",
    "import configparser\n",
    "\n",
    "config = configparser.ConfigParser()\n",
    "config.read('configuration.properties')\n",
    "\n",
    "def snowflake_connection():\n",
    "    try:\n",
    "        user = config['SNOWFLAKE']['user']\n",
    "        password = config['SNOWFLAKE']['password']\n",
    "        account = config['SNOWFLAKE']['account']\n",
    "        role = config['SNOWFLAKE']['role']\n",
    "        warehouse = config['SNOWFLAKE']['warehouse']\n",
    "        database = config['SNOWFLAKE']['database']\n",
    "        schema = config['SNOWFLAKE']['schema']\n",
    "        table = config['SNOWFLAKE']['table']\n",
    "        stage = config['SNOWFLAKE']['stage']\n",
    "        file_format = config['SNOWFLAKE']['file_format']\n",
    "\n",
    "        conn = snowflake.connector.connect(\n",
    "            user=user,\n",
    "            password=password,\n",
    "            account=account,\n",
    "            warehouse=warehouse,\n",
    "            database=database,\n",
    "            schema=schema,\n",
    "            role=role\n",
    "        )\n",
    "\n",
    "        return conn, table, stage, file_format\n",
    "    except Exception as e:\n",
    "        print(\"Exception in snowflake_connection function: \",e)\n",
    "        return  \"\", \"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def stage_csv(df, conn, stage):\n",
    "    \"\"\"Save a Pandas DataFrame to a temporary CSV file and stage it to Snowflake.\"\"\"\n",
    "    try:\n",
    "        cursor = conn.cursor()\n",
    "\n",
    "        # Create a temporary CSV file\n",
    "        with tempfile.NamedTemporaryFile(delete=False, suffix=\".csv\") as temp_file:\n",
    "            temp_path = temp_file.name\n",
    "\n",
    "        # Save DataFrame to CSV (without index)\n",
    "        df.to_csv(temp_path, index=False, sep=\"|\")\n",
    "\n",
    "        # Extract file name from path\n",
    "        csv_name = os.path.basename(temp_path)\n",
    "\n",
    "        # Execute PUT command to stage file in Snowflake\n",
    "        put_query = f\"PUT file://{temp_path} @{stage} AUTO_COMPRESS=TRUE OVERWRITE=TRUE\"\n",
    "        cursor.execute(put_query)\n",
    "\n",
    "        print(f\" Staging data...\")\n",
    "        print(f\" File {csv_name} staged successfully at {stage}.\")\n",
    "\n",
    "        # Clean up: Delete temporary file\n",
    "        os.remove(temp_path)\n",
    "\n",
    "        cursor.close()\n",
    "        return csv_name  # Return the staged CSV file name\n",
    "\n",
    "    except Exception as e:\n",
    "        print(\" Exception in stage_csv function:\", e)\n",
    "        return None\n",
    "\n",
    "\n",
    "def load_to_snowflake(df):\n",
    "    \"\"\"Load DataFrame into Snowflake using staging and MERGE command.\"\"\"\n",
    "    try:\n",
    "        conn, table, stage, file_format = snowflake_connection()\n",
    "        if not conn:\n",
    "            raise ValueError(\" Failed to establish Snowflake connection.\")\n",
    "\n",
    "        cur = conn.cursor()\n",
    "\n",
    "        # Stage CSV file\n",
    "        csv_name = stage_csv(df, conn, stage)\n",
    "        if not csv_name:\n",
    "            raise ValueError(\" Failed to stage CSV file.\")\n",
    "\n",
    "        # Define the MERGE SQL Query\n",
    "        merge_query = f\"\"\"\n",
    "            MERGE INTO {table} AS t\n",
    "            USING (\n",
    "                SELECT \n",
    "                    $1 AS ID, \n",
    "                    $2 AS AGENCY, \n",
    "                    $3 AS SUB_AGENCY, \n",
    "                    $4 AS ACTION_TYPE, \n",
    "                    $5 AS SUMMARY, \n",
    "                    $6 AS IMPORTANT_DATES, \n",
    "                    $7 AS PUBLIC_INSPECTION_PDF_URL, \n",
    "                    $8 AS LAST_UPDATED_DATE, \n",
    "                    $9 AS PUBLICATION_DATE\n",
    "                FROM @{stage}/{csv_name} (FILE_FORMAT => {file_format})\n",
    "            ) AS s\n",
    "            ON t.ID = s.ID \n",
    "            WHEN MATCHED THEN\n",
    "                UPDATE SET  \n",
    "                    t.AGENCY = s.AGENCY,\n",
    "                    t.SUB_AGENCY = s.SUB_AGENCY,\n",
    "                    t.ACTION_TYPE = s.ACTION_TYPE,\n",
    "                    t.SUMMARY = s.SUMMARY,\n",
    "                    t.IMPORTANT_DATES = s.IMPORTANT_DATES,\n",
    "                    t.PUBLIC_INSPECTION_PDF_URL = s.PUBLIC_INSPECTION_PDF_URL,\n",
    "                    t.LAST_UPDATED_DATE = s.LAST_UPDATED_DATE,\n",
    "                    t.PUBLICATION_DATE = s.PUBLICATION_DATE\n",
    "            WHEN NOT MATCHED THEN\n",
    "                INSERT (ID, AGENCY, SUB_AGENCY, ACTION_TYPE, SUMMARY, IMPORTANT_DATES, PUBLIC_INSPECTION_PDF_URL, LAST_UPDATED_DATE, PUBLICATION_DATE, DI_LOAD_DT)\n",
    "                VALUES (s.ID, s.AGENCY, s.SUB_AGENCY, s.ACTION_TYPE, s.SUMMARY, s.IMPORTANT_DATES, s.PUBLIC_INSPECTION_PDF_URL, s.LAST_UPDATED_DATE, s.PUBLICATION_DATE, CURRENT_TIMESTAMP);\n",
    "        \"\"\"\n",
    "\n",
    "        print(\" Merging data into Snowflake...\")\n",
    "\n",
    "        # Execute the merge query\n",
    "        cur.execute(merge_query)\n",
    "\n",
    "        print(\" Data merged successfully!\")\n",
    "\n",
    "        # Close resources\n",
    "        cur.close()\n",
    "        conn.close()\n",
    "\n",
    "    except Exception as e:\n",
    "        print(\" Exception in load_to_snowflake function:\", e)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame(li)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "d:\\Projects\\hackathon\\civic_ai\\venv\\Lib\\site-packages\\snowflake\\connector\\config_manager.py:351: UserWarning: Bad owner or permissions on C:\\Users\\anshu\\.snowflake\\connections.toml\n",
      "  warn(f\"Bad owner or permissions on {str(filep)}{chmod_message}\")\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Staging data...\n",
      " File tmp7tvsxklz.csv staged successfully at notice_rule_stage.\n",
      " Merging data into Snowflake...\n",
      " Data merged successfully!\n"
     ]
    }
   ],
   "source": [
    "load_to_snowflake(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
